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ABSTRACT
Schwabe, Anna Louise. A Multifaceted Approach to Address Variation in Cannabis
sativa. Published Doctor of Philosophy Dissertation, University of Northern
Colorado, 2019.

For thousands of years, humans have cultivated and dispersed Cannabis sativa L.
across the globe. Although Cannabis has been largely illegal worldwide for decades,
public perceptions and attitudes are changing. Increasing interest in potential Cannabis
usage worldwide and nationwide is leading to less restrictions to make way for an
expanding and lucrative industry with numerous applications. Although only one species
is formally recognized in the Cannabis genus, thousands of years of artificial selection
for diverse phenotypes and uses have resulted in two major usage groups; hemp-types
which are defined worldwide as having very low levels of THC (< 1.0%), and drug-types
which exceed a specified level of THC that varies among nations. The drug-type category
includes three commonly used subcategories including Sativa, Indica and Hybrid types,
and newly developed high CBD varieties that have more THC than hemp-types but are
not bred for high THC. The quality of federally produced Cannabis for medical studies in
the U.S. has recently been brought into question, and we included samples to determine
the genetic relationship to these groups.
Phenotypic variation in Cannabis gives rise to commonly referenced categories,
but sources of variation are unclear and understudied. Phenotypes are observable
characteristics that results from a combination of both genotype and the environment.

iii

The preferred method of propagation for Cannabis is cloning, and therefore variation
within varietals should be from differences in environmental factors. Ten microsatellite
markers were developed de-novo to investigate four aims: (1) genetic variation within
strains, (2) genetic relationships among the common categories, (3) if genetic variation is
detectable through olfactory sensation, and (4) how genetic variation is reflected in
phytochemical levels. This dissertation includes four manuscript chapters representing
each aim and uses a genetic basis for a multifaceted approach to investigate variation in
Cannabis sativa. Substantial genetic variation was found within strains from obtained
from different facilities. Genetic divergence between hemp and drug-types was
genetically supported, but the Sativa, Indica, and Hybrid subcategories were not
genetically well defined. The high CBD strains appear to bridge the genetic gap between
hemp and drug-types, and federally grown research grade marijuana was genetically
more similar to hemp than Cannabis available through the legal cannabis market. Genetic
imposters within a strain had measurable aromatic differences, but there was considerable
variation in aromas among samples with identical genetic identity. Analyses of both
terpene and cannabinoid profiles among individuals with identical genotypes acquired
from different sources varied considerably indicating environmental variation has a
substantial impact on phenotype in Cannabis.
Together these results show a need for the Cannabis industry to implement
regulatory checks in the form of genetic testing in order to provide consistency,
especially for medical applications. These results demonstrate the need for genotyping in
order for phenotypic consistency to be achieved if standard growing conditions can be
established. When genetic verification and standard protocols are established, deviations
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in phenotypic changes can be identified and disclosed to consumers so they are aware
that there may be abnormal effects. This investigation highlights the need for additional
research to provide consistent products, which is especially important for medical
marijuana flower products. In order to provide consumers consistent products, it is
imperative to understand sources of variation. Consumers deserve to be provided with
quality consistent products as the industry continues to grow on a global scale.
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CHAPTER I
INTRODUCTION AND REVIEW OF THE LITERATURE
Introduction
Cannabis sativa L. is one of the most interesting and useful plants with evidence
of human cultivation dating back as far as 10,000 years (Abel 2013; Clarke and Merlin
2013; Okazaki et al. 2011; Small 2015a). As humans moved across the globe to various
continents, they took Cannabis with them for utilitarian purposes such as fiber, food,
fuel, and also for the plants medicinal and psychoactive properties (Clarke and Merlin
2013; Small 2015a). Human driven dispersal across the globe may have led to local
adaptation, contributing to morphological variants. However, cultivation and selective
breeding over thousands of years has arguably been the driving force behind the wide
variation of phenotypes observed in modern Cannabis. Generally, two broad categories
of Cannabis are recognized: hemp-types and drug-types. Hemp-types are grown for fiber,
seeds, and non-psychoactive phytochemicals produced mainly by the flowers. Drug-types
produce more of the psychoactive phytochemical precursor Δ9-tetrahydrocannabinolic
acid (THCA) and are labeled as such when THCA exceeds a predefined threshold of
percent of dry weight, which varies by country. However, they are labeled as “THC”
content which is the analyte measured due to decarboxylation during the analysis. While
the level of THCA produced in the flower is the main distinction between hemp and drug
types, usage, morphology, and cultivation methods differ between the two types. There is
a third elusive type, C. ruderalis, which is smaller and flowers as a function of age rather
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than photoperiod (Clarke and Merlin 2013; Small 2015b) but has been suggested that this
type may be an escapee from hemp cultivation that has adapted to a weedy lifecycle
(Clarke and Merlin 2013; Emboden 1974; Schultes et al. 1974). Cultivation and selective
breeding over several millennia are thought to have altered the evolutionary trajectory of
Cannabis to such an extent that natural, unaltered ancestral populations no longer exist
(Small 2017). Cannabis cultivators have successfully bred thousands of varietals, and
extensive genetic variation has been observed throughout the species (Clarke and Merlin
2016; Lynch et al. 2016; Pisupati et al. 2018; Soler et al. 2017). Recent legalization for
medical and recreational consumption has increased access to Cannabis and information
about Cannabis, leading to changes in the demographics of consumers (Han and Palamar
2018). The goal of this work is to bring additional awareness and information about the
products consumers have access to and give more context to the information they are
provided.
The Cannabis samples used in this study were collected from dispensaries,
herbaria, and cultivators. Retail samples were legally purchased from dispensaries located
in Colorado, Washington, and California. It was important to purchase samples
anonymously since I wanted flowers that were representative of product supplied to
customers without bias. Disclosing that the samples would be used in a research study
could introduce the potential for producers to differentially select samples. The primary
purpose of this investigation was to examine variation in Cannabis and to determine how
genetic variation manifests as differences in phenotypic characters. The chapters herein
address (1) genetic variation within strains, (2) genetic variation among categories, (3) if
genetic variation is detectable through olfactory sensation, and (4) how genetic variation
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is reflected in phytochemical levels. Variation in Cannabis can come from multiple
sources, some of which are explored here to expose and highlight the need for additional
research to provide consistent products, which is especially important for medical
marijuana.
Overview of Cannabis sativa
Cannabis sativa L. is a member of the Cannabaceae with about 170 species in ten
small genera including Cannabis, Humulus, and Celtis (McPartland 2018), although
sources have conflicting information about the current taxonomy (Clarke and Merlin
2013; Integrated Taxonomic Information System 2014; The Plant List 2013). Although
the Flora of North America recognizes only Cannabis sativa L. (Small 1997), many
breeders and botanists support the polytypic taxonomy of Cannabis (Anderson 1980;
Clarke and Merlin 2013; de Lamarck 1785; Emboden 1974). Whether the genus is
comprised of one (C. sativa), two (C. sativa and C. indica) or three species (C. sativa, C.
indica and C. ruderalis) remains a topic of debate. Monotypic Cannabis sativa includes
narrow and broad leaf drug types, non-drug hemp types, and C. ruderalis, which is
smaller and flowers as a function of age rather that photoperiod. Drug types are defined
as any Cannabis sativa plant with total THC (THCA + THC) concentrations above a
stated limit. Plants of broad and narrow leaf drug types, as well as hybrid variants, are
commonly referred to as marijuana. Low total THCA defines hemp types with the legal
limit varying among countries: for example 0.3% by dry weight in the U.S., 0.2% in the
U.K., and 1.0% in Western Australia (European Monitoring Centre for Drugs and Drug
Addiction 2018; Parliament of Western Australia 2004; United States Department of
Agriculture and 113th United States Congress 2018). However, drug types generally have
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much higher levels of THC compared to hemp, often reported as 12-25% THC in retail
strains (Jikomes and Zoorob 2018; Potter et al. 2008; Vergara et al. 2017). There are also
some varieties with relatively low THC that are nonetheless ranked as a drug type due to
the THC limits defining hemp. Hemp and marijuana are genetically distinct (e.g. Lynch
et al. 2016; Sawler et al. 2015; Schwabe and McGlaughlin 2018; Soler et al. 2017) and
are distinguished further by levels of chemical constituents, particularly THC, as well as
the products that will be made from the plant (Datwyler and Weiblen 2006; de Meijer et
al. 1992; Lynch et al. 2016; Rustichelli et al. 1998).
Terminology to describe Cannabis is convoluted and conflicted among scientists,
horticulturalists, taxonomists, enthusiasts and consumers. For the purposes of the work
here, Cannabis and cannabis refer to any variety of Cannabis sativa. Drug-type and
marijuana refer to varieties with > 0.3% THC. Hemp-type and hemp refer to varieties
with low THC (< 0.3% in the U.S.). Sativa is used in the colloquial context to describe
narrow-leafed strains with uplifting or energizing psychoactivity. Indica is used in the
colloquial context to describe broad-leafed strains with relaxing and sedating
psychoactive effects. Hybrid is used to describe varieties with a combination of
morphologies and/or reported effects from both Sativa and Indica types. Variety is a
group with distinct and uniform characters (physical, chemical, genetic) that are exhibited
in all members of the group (Cervantes 2006). The term cultivar refers to a cultivated
variety that is developed by a plant breeder through cross breeding, which can also be
called a hybrid (Griess 2016). Plants grown from the seeds of a cultivar often will not
display characteristics of a single parent since they were produced by crossing two
distinct varieties (Griess 2016). True-to-type plants have the same genetics as the parent
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(Griess 2016), and in Cannabis this is most commonly achieved through cloning.
Although the term “strain” is botanically incorrect when applied to varieties of plants, the
term is widely used in the cannabis industry to describe selections of cultivars of
varieties, in part because many strains of Cannabis are not true varieties in that they are
not genetically stable and do not breed true (Cervantes 2006). According to Cervantes
(2006), strains in many cases do not have described defining characters and are merely
hybrids of hybrids that have been given a unique name. Given the recency and
exponential growth of the number of available strains, it is likely that many strains lack
genetic stability and are unlikely to be produced consistently.
Cannabis Breeding System
Cannabis is predominantly dioecious with separate sex chromosomes, which is
rare for plants. Male and female flowers develop on separate plants, although
occasionally hermaphrodites are observed (Moliterni et al. 2004). Male and female plants
are virtually indistinguishable prior to flowering, although genetic tests for
Deoxyribonucleic acid (DNA) polymorphisms and sex chromosomes may assist in early
developmental sexing of Cannabis plants (Mandolino et al. 1999). Hemp types are
commonly grown for their fibrous stem and seeds that are highly nutritious and rich in
omega-3 and omega-6 fatty acids (Callaway 2004; Small 2016). Therefore, male and
female hemp plants are grown together because when female flowers are fertilized, they
produce large quantities of seed. Drug types are commonly grown for the female
inflorescence, as it is mainly the female flowers that produce the glandular trichomes
where the manufacturing of cannabinoids and aromatic terpenes occurs. Specific
cannabinoid molecules bind to receptors in animals (McPartland et al. 2001) and elicit
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various effects. Terpenes are produced in many different plants and are the primary
constituents of essential oils, which are also thought to have therapeutic properties
(Paduch et al. 2007). The dioecious breeding system is problematic for drug type
Cannabis breeders because they seek to forego seed production and maximize
inflorescence growth. Producers of drug type Cannabis remove pollen producing male
plants from the population to prevent fertilization and seed production (Meier and
Mediavilla 1998). The preference for production of unfertilized female flowers has led to
the widely practiced artificial vegetative propagation via cloning of popular Cannabis
drug type strains.
In order to produce novel Cannabis varieties, plants are cross- pollinated to
produce seeds that have characteristics of both the parents (Cervantes 2006). Plants
grown from seeds of the parental cross are called the first filial (F1) generation and are
genetic hybrids of the parents (Cervantes 2006). Offspring resulting from the F1
generation seeds are assessed, and individual plants are selected based on desirable
phenotypic traits (Cervantes 2006). In order to remove unwanted genetic traits from the
lineage, it is necessary to continue crossing offspring of each subsequent generation until
the offspring reliably and consistently exhibit the desired phenotype, and at this point the
new variety is said to have stable genetics. Other crop and ornamental plants are often
subjected to inbreeding for several generations to remove genetic variation, but as this is
time consuming and because breeders are often limited by space, this important technique
to developing a genetically stable variety may be cursory.
The legal medical and recreational Cannabis industries aim to produce consistent
products for consumption and maximum yield, which is generally achieved through
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vegetative cloning techniques. Female plants are selected based on desirable characters
and can be used as mother plants for the cloning process. Cloning methods are used to
reproduce desirable strains that are genetically identical. Some Cannabis strains
reportedly have stable seed genetics (discussed in Chapter II) and should have little
variability observed in the phenotype of the offspring. In either case, the genotypes of
clonal plants or plants from stable seed should be highly similar. Cloning in Cannabis is
widely practiced in order to produce consistent products from the F1 generations and can
produce hundreds of genetically identical plants. Therefore, breeders may not be invested
in creating stable varieties because not only is cloning relatively easy, but also they are
not provided protection for their novel varieties. This creates a situation where strains
may be marketed with a specific name, but the genetics of plants with the same strain
name but from a different source could be quite different.
Intellectual Property Protection for Plant Varieties
In the U.S., intellectual property and commercial exploitation protection for new
plant cultivars is afforded under the Plant Variety Protection Act (PVPA) of 1970 (United
States Department of Agriculture 1970). Plant growers and breeders can register
proprietary varietals with the United States Department of Agriculture (United States
Department of Agriculture 1970, 2015). In order to obtain a certificate for a novel variety
from the Plant Variety Protection Office, the cultivar must be “new, distinct, uniform,
and stable” (United States Department of Agriculture 1970, 2015). The new varietal must
have a name that does not conflict with existing names of that crop. The distinctness of a
novel variety may be based on one or more identifiable morphological, physiological,
genetic, or other characteristics (e.g. baking characteristic for wheat) (United States
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Department of Agriculture 1970, 2015). However, the ability to describe, distinguish and
certify new cultivars in crop species does not apply to Cannabis sativa. The USDA lists
‘Hemp’ as an ineligible commodity (United States Department of Agriculture 1970;
United States Department of Agriculture 2015) for protection under the PVPA, therefore,
all Cannabis varietals are excluded from protection.
There are thousands of described Cannabis varieties, and probably thousands
more that remain as “backyard” creations. For example, the online database Leafly
describes more than 2500 strains, but it is far from a comprehensive list (Leafly 2018b).
Moreover, many of these strains have not been stabilized and will only exist as long as
there are healthy mothers to produce clones. Because the USDA Plant Variety Protection
Office lists ‘Hemp’ (Cannabis sativa) as an ineligible commodity (United States
Department of Agriculture 2015), there is no official or standardized database describing
the different strains and the characteristics defining each strain. As a result, the cannabis
industry has no way to verify varieties. Additionally, suppliers are not required to provide
confirmation that the strain marked for sale as “Blue Dream”, for example, is in fact
“Blue Dream”. The lack of a verification system for Cannabis strains is more than likely
contributing to the high potential for misidentification and mislabeling. Consumers report
that acquiring strains, such as “Blue Dream”, does not always result in the same effects
each time (Prichard 2014), which reinforces the likelihood that Cannabis strain names are
not a reliable identifier for plants and flower material at the present time.
Cannabis Consistency
Public, scientific, and economic interest in Cannabis and Cannabis products is
increasing worldwide. Consumers want to have confidence that the products they buy are
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consistent. Consistency is an issue that researchers and industry are beginning to address.
Teasing apart some of the elements that could contribute to variation is vital to the
Cannabis industry, for both recreational and medical consumers. Determining variation
within and among Cannabis types and how those genetic differences might be reflected
in physical characteristics such as phytochemical constituents and aromatic profile,
requires examining genetic differences. The phenotype of any organism is a product of
genotype and environment. However, environmental variation such as growing
conditions, harvesting time, soil, nutrient regimes and water levels are examples of
confounding variables that could contribute to phenotypic differences observed in clonal
organisms such as commercial Cannabis. Where variation is unexpected, examining the
genotype to rule out genetic variation, rather than some other variable, is required.
Unknown genetic differences leading to variation cannot be remedied by standardizing
growing, harvesting, and storage procedures. However, if a grower has a certified and
verified variety, any variation among plants can be narrowed down to differences in
treatment following germination, and presumably be addressed. Occasional recreational
users may not be concerned with variation in products; however, the growing number of
medical marijuana patients who seek specific effects from their Cannabis need to be
provided consistent products. Expecting one set of effects and experiencing another set of
effects is unacceptable when it comes to medicine.
Cannabinoids and Terpenes
Cannabis sativa is a chemically complex plant with numerous natural
constituents. To date, 565 constituents have been identified (ElSohly et al. 2016) that are
classified as cannabinoids or non-cannabinoids (alkaloids, flavonoids, terpenoids, amino
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acids and others). Varying levels and combinations of the chemical constituents results in
unique chemical profiles, referred to as a chemotype. Constituents include 120
phytocannabinoids, which are a group of C21 terpenophenolic molecules with a ring
structure derived from geranyl pyrophosphate (ElSohly et al. 2017). The main
psychoactive cannabinoid, and the main reason for Cannabis prohibition, is 9tetrahydrocannabinol (THC). Besides being a psychoactive substance, THC has other
known effects, such as analgesic properties (Rahn and Hohmann 2009). Cannabidiol
(CBD), the second most abundant cannabinoid, has recently received attention as an
antiepileptic and is particularly promising for intractable pediatric epilepsy (United States
Food and Drug Administration 2018). However, the bioactive cannabinoids THC and
CBD are not produced by the plant. Rather, the acidic forms 9 -tetrahydrocannabinolic
acid (THCA) and cannabidiolic acid (CBDA) are produced in the plant and are converted
to their active forms through other mechanisms, such as the addition of heat. Other
cannabinoids gaining popularity for various reported effects include:
tetrahydrocannabivarin (THCV), which decreases appetite and increases metabolism
(Halford and Harrold 2008); cannabichromene (CBC) which has anti-inflammatory, antibacterial, and anti-fungal properties (ElSohly et al. 1982); cannabigerol (CBG), which
has anti-bacterial properties and reduces blood pressure (Banerjee et al. 1975); and
cannabinol (CBN), which is an analgesic (Zygmunt et al. 2002), appetite stimulant
(Farrimond et al. 2012), and an effective but mild sedative (Musty et al. 1976). Aromatic
terpenes produced in the glandular trichomes of the female flower are a second important
group of chemical constituents abundantly produced in Cannabis. Terpenes are
manufactured in varying combinations and levels and produce distinctive characteristic
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odors. Cannabis strain aroma descriptions include skunk, diesel, fruit, and cheese (see
Chapter IV). Aromatic profiles give rise to descriptive strain names such as “Island Sweet
Skunk”, “Sour Diesel”, “Banana Kush”, and “Blue Cheese”.
Cannabis types, such as hemp and drug types, are often defined by the level of
THCA (but reported as THC) produced in the plant, validated methods to measure
relative amounts of cannabinoids, as well as terpenes, have been developed. Gas
chromatography (GC) is widely used for detecting the major cannabinoids because it is
simple, fast and sensitive. However, GC cannot distinguish acidic cannabinoids from
their decarboxylated forms unless a derivatization is performed. Gas chromatography
uses high temperature and will decarboxylate the natural acidic forms of several
cannabinoids such as Δ9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid
(CBDA) (de Oliveira et al. 2008; ElSohly et al. 2016; Hazekamp et al. 2005; Hillig 2005;
Pellegrini et al. 2005). Several validated GC cannabinoid and terpene separation methods
are available (ElSohly et al. 2017; Mariotti et al. 2016; Raharjo and Verpoorte 2004).
High-performance liquid chromatography (HPLC) is another method to detect Cannabis
chemical components that does not heat the sample and therefore the natural acidic and
neutral cannabinoids are unaffected. The limitation of HPLC is that it may not resolve the
full array of cannabinoids due to the complex composition of the plant extracts. Several
validated HPLC methods for separation of cannabinoids and terpenes are available
(Aizpurua-Olaizola et al. 2014; Brighenti et al. 2017; De Backer et al. 2009; Giese et al.
2015; Gul et al. 2015; Rustichelli et al. 1996; Swift et al. 2013; Xiaoyan et al. 2016).
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History of Prohibition
Cannabis has been used for centuries and is notorious for the psychoactive
properties produced when THCA is activated through heating, for example when it is
smoked. The Single Convention on Narcotic Drugs of 1961 is an international treaty
listing specific drugs prohibited worldwide with the exception of medical and research
purposes (The United Nations 1961). In this treaty, Cannabis drug types, such as hashish
and marijuana, are listed as both Schedule I and IV drugs (The United Nations 1961).
Schedule I substances have the strictest controls and Schedule IV substances are
described as having “particularly dangerous properties” (The United Nations 1961). The
most dangerous drugs (includes opium, opioids, coca, cocaine, heroin, and fentanyl), are
listed as Schedule IV and are described as having extremely limited and therapeutic value
and are thereby subject to the strictest controls under Schedule I (The United Nations
1961). The treaty explicitly states that Cannabis used for hemp and fiber is not
considered controlled substances, but rather only the fruiting crowns of the plant and
derived products are included. The Single Convention requires countries in the treaty to
establish a government agency to control cultivation of scheduled drugs from plants such
as Cannabis and opium. In the U.S. the National Institute on Drug Abuse (NIDA) is that
agency. However, since the treaty was written, the discovery of the endocannabinoid
system suggests there are therapeutic applications, and mounting evidence suggests a
wide variety of medical applications for Cannabis.
The Single Convention united countries worldwide in the prohibition of a
multitude of substances, but Cannabis bans had been introduced long before 1961. One
of the first bans was by the Emir of the Joneima in Arabia in 1378 who declared
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Cannabis ingestion was punishable by removing all the offender’s teeth (Johnson et al.
2010). King Andrianampoinimerina of Madagascar imposed capital punishment for
Cannabis use in 1787 (Yates 2015). Napoleon banned Cannabis use and distribution in
1800 (Booth 2004). Singapore banned Cannabis in 1870 (De Padua et al. 1999). Greece
banned cultivating, importing, and use in 1890 (Abel 2013). The Ganja Law supported by
the Council of Evangelical Churches outlawed Cannabis in Jamaica in 1913 (Moyston
2013). Australia banned Cannabis in 1926 (Wodak and Owens 1996).
The United States participated in The Single Convention, but already had existing
legislation in the form of the Marihuana Tax Act of 1937 (75th Congress of the United
States 1937). The Act did not ban Cannabis outright, but rather placed a hefty sales tax
on Cannabis and Cannabis products, including hemp, thereby effectively making it
difficult to engage in Cannabis based business. Cannabis was formally criminalized in
the United States under the Controlled Substances Act, passed by the 91st United States
Congress, and signed into Law by President Richard Nixon (United States Congress
1970).
Current Status
The United States has seen significant changes over the past two decades
regarding the legal status of Cannabis use for both medical and recreational purposes.
State-level legislation has side-stepping the federal Cannabis ban, making allowances for
medical Cannabis use. While Cannabis remains federally illegal, national enforcement of
Cannabis restrictions has shifted to the responsibility of states. This disconnect between
federal and state laws creates logistical issues for federally regulated organizations, such
as research and financial institutions, as well as creating confusion for federal law
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enforcement agencies such as the United States Marshals Service (USMS), the Federal
Bureau of Investigation (FBI), and the Drug Enforcement Administration (DEA).
Moreover, it is impossible to visually distinguish different Cannabis types. Now that
hemp is legal in all 50 states (United States Department of Agriculture and 113th United
States Congress 2018), law enforcement has no way to tell if someone is hauling 17,000
lbs. of hemp flower for CBD, or if they are smuggling 17,000 lbs. of illicit drugs across
state lines (Konopasek 2019). Some states allow Cannabis treatment in the cases of
serious or debilitating conditions (ProCon 2016b). Other states are more lenient with
medical conditions that may appropriately be treated with Cannabis and allow medical
doctors and authorized healthcare professionals to recommended patients use medical
marijuana as treatment (National Conference of State Legislatures 2018). The initiation
of statewide changes began with California passing Proposition 215 in 1996, which
legalized medical marijuana (National Conference of State Legislatures 2018). From
1996 to 2012, sixteen states and the District of Columbia passed legislation allowing
medical marijuana use (Table 1.1). In 2012, Colorado was the first state to legalize
recreational marijuana use, followed by Washington later that year. Since then, ten more
states have legalized medical marijuana, and eight states plus the District of Columbia
legalized recreational use (National Conference of State Legislatures 2018). All in all, the
current standing in the U.S. is 33 states allow medical marijuana, and of those ten and the
District of Columbia, also allow recreational use (Table 1.1) (ProCon 2018b).
While the United States continues to relax legislation, other countries are
following suit (Table 1.1). Over the last two decades, a wave of decriminalization, reclassification, and legalization of Cannabis has surged worldwide. Paraguay was one of
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the first countries to decriminalize possession of small amounts (10 grams) of Cannabis
in 1988 (Mostyn et al. 2012). Uruguay was the first country in this modern era to fully
legalize Cannabis, although the legal purchase of Cannabis is limited to registered
Uruguayan citizens (Gerner 2015). Canada legalized medical use in 2001, and recently
became the second country to legalize recreational use and establish a nationwide
marijuana market. There are at least fifteen countries worldwide that have legalized
medical marijuana use, the majority of which have made changes in the last five years.
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Table 1.1. Worldwide and U.S. Legalization History. Legalization year of medical and
recreational Cannabis both worldwide and in the United States (by state).
Medical
Recreational
Year
Country
U.S. State
Country
U.S. State
Israel
1990
California
1996
Alaska
1998
Oregon
Washington
Maine
1999
Colorado
2000
Hawaii
Canada
2001
Chile
2004
Montana
2007
New Mexico
Rhode Island
Vermont
Michigan
2008
New Jersey
2009
Arizona
2010
District of Columbia
Delaware
2011
Massachusetts
Colorado
2012
Connecticut
Washington
Czech Republic
Illinois
Uruguay
2013
Uruguay
New Hampshire
Minnesota
Alaska
2014
New York
District of Columbia
Utah
Oregon
Maryland
Columbia
Georgia
2015
Croatia
Louisiana
Italy
Puerto Rico
Argentina
Florida
California
2016
Australia
North Dakota
Maine
Macedonia
Ohio
Massachusetts
Turkey
Pennsylvania
Nevada
Nevada
Arkansas
Germany
West Virginia
2017
Mexico
Philippines
Poland
Malta
Peru
Greece
Georgia
Oklahoma
Canada
Vermont
2018
New Zealand
Missouri
Georgia
Michigan
Luxembourg
South Africa
Portugal
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Medical Applications
Research on potential medical applications for the treatment of a wide array of
medical conditions is abundant and ongoing. However, the short and long-term health
effects of Cannabis consumption remain largely unknown. The National Academies of
Sciences, Engineering, and Medicine published a comprehensive review of medical
Cannabis and conclude that the effects of Cannabis are understudied, and limitations
need to be addressed and prioritized (Cousijn et al. 2018; National Academies of
Sciences 2017).
The recent surge of legalization of medical marijuana in the U.S. and worldwide
suggests there is enough evidence to support the claims that Cannabis is effective in
treating certain medical conditions. The U.S. had an estimated 2.2 million registered
medical marijuana patients in legal medical states in 2016 (Leafly 2018a), and there are a
wide range of conditions for which Cannabis treatment is being investigated, including
chronic pain, multiple sclerosis, cancer, and epilepsy. Chronic pain is persistent pain that
results from injury, disease, or can be a disease in itself (The American Academy of Pain
Medicine 2019). The American Academy of Pain Medicine estimates there are more than
100 million Americans suffering from chronic pain with associated costs > $600 billion
annually (The American Academy of Pain Medicine 2019). Reviews of research on
Cannabis treatment of chronic pain have found mixed results and suggest further largescale clinical trials are necessary (Baron 2018; Hill 2015; Jensen et al. 2015). Recently, a
large-scale clinical study in Israel administered four strains and reported 93.7% of the
2,736 elderly patients in the study reported significant pain reductions (Abuhasira et al.
2018). Cannabinoid agonists found in Cannabis, medicinal isolates such as Sativex,
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and synthetic cannabinoid receptor agonists such as nabilone, reduce pain by acting on
CB1 and CB2 receptors located in the central and peripheral nervous systems (Costa et
al. 2007; Guindon and Hohmann 2008; Pertwee 2001, 2005, 2009). Studies conducted in
the United Kingdom found convincing evidence that Sativex is an effective treatment
for tremors and spasticity (Alexander 2016) associated with multiple sclerosis, for
example. Sativex was also shown to be effective in reducing symptoms related to
chemotherapy and was well tolerated by patients and resulted in minimal adverse side
effects (Duran et al. 2010). Anti-tumoral actions are associated with several cannabinoids
including THC, but CBD has been found to be the most effective cannabinoid in reducing
tumor cell growth (Ligresti et al. 2006). Additionally, CBD induces apoptosis in human
myleoblastic cells but has no effect on healthy mononuclear cells (Gallily et al. 2003;
McKallip et al. 2006; Vaccani et al. 2005). The U.S. Food and Drug Administration
(FDA) has not approved Cannabis to treat medical conditions but has approved three
cannabinoids for medical use (United States Food and Drug Administration 2018; United
States Department of Health and Human Services et al. 2018). These are Epidiolex®
(CBD) for the treatment of two rare forms of epilepsy, dronabinol (synthetic THC) for
nausea and weight loss associated with cancer and AIDS, and nabilone (synthetic THC)
for nausea associated with cancer treatments (United States Food and Drug
Administration 2018; United States Department of Health and Human Services et al.
2018).
Genetic Research
Genetic research on Cannabis is complicated because it is primarily dioecious,
highly heterozygous, considerably variable, and extraordinarily plastic in response to
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varying environmental conditions (Onofri and Mandolino 2017). Genetic studies on
Cannabis have focused on evolutionary history (Booth 2004; Clarke and Merlin 2016;
Hillig 2005; Russo 2007; Small et al. 1976; Sytsma et al. 2002; Yang et al. 2013),
speciation (Emboden 1981; Hillig 2005; McPartland and Guy 2017; Sawler et al. 2015),
geographic origins (Alghanim and Almirall 2003; Coyle et al. 2003; Gao et al. 2014;
Gilmore et al. 2003), distribution (Hillig 2005; Piluzza et al. 2013; Piomelli and Russo
2016), identification of sex chromosomes (Faux et al. 2014; Faux et al. 2016; Mandolino
et al. 1999; Moliterni et al. 2004; Peil et al. 2003; Razumova et al. 2016; Techen et al.
2010), genetic contribution to the variation of chemotypes among varietals (AizpuruaOlaizola et al. 2016; de Meijer et al. 2009a; de Meijer et al. 2009b; Desjardins 2008;
Pacifico et al. 2006; Staginnus et al. 2014; Welling et al. 2016), and analyses to aid law
enforcement and forensic investigations (Dufresnes et al. 2017; Houston et al. 2016;
Kojoma et al. 2006; Onofri and Mandolino 2017).
Studies with accessions of both hemp and drug types have clearly and consistently
shown genetic distinction between the two types using clustering analyses such as PCA,
UPGMA, and STRUCTURE (Datwyler and Weiblen 2006; Gilmore and Peakall 2003;
Gilmore et al. 2003; Grassa et al. 2018; Hillig 2005; Kojoma et al. 2006; Lynch et al.
2016; Pacifico et al. 2006; Sawler et al. 2015). Genetic evidence using traditional genetic
techniques such as allozymes, Random Amplification of Polymorphic DNA (RAPD) and
Short Tandem Repeat (STR) markers give little support to the differentiation of Sativa
narrow-leaf drug type and the Indica broad-leaf drug type (Hillig 2005; Knight et al.
2010; Lynch et al. 2016; Sawler et al. 2015). However, new genetic tools using nextgeneration sequencing (NGS) techniques such as single nucleotide polymorphisms
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(SNPs), whole genome shotgun sequencing (WGS), and Restriction site Associated DNA
Sequencing (RAD-Seq) create datasets for large portions of the genome compared to
previous techniques. These tools may be able to better distinguish the genetic difference
driving the reported Sativa and Indica phenotypic differences. Recent studies using NGS
have had more success distinguishing the two types (Henry 2015; Lynch et al. 2016;
Sawler et al. 2015). With the information gathered thus far, it appears that the Sativa and
Indica types shared a common ancestor that likely diverged via natural selection when
populations established in regions of India (warm, low, wet) and Afghanistan (cool, high,
dry) leading to phenotypic and genotypic differences (McPartland 2017). However, the
human relationship with Cannabis, including cultivation, breeding and selection, has
blurred the line differentiating what were presumably two distinct species (McPartland
2017; McPartland and Guy 2017).
Entire genomic sequences allow researchers to not only explore relationships
among different Cannabis types, but also uncover information about genes controlling
characters of interest, such as cannabinoid and terpene synthesis, as well as flowering
time, and flower production. The nuclear (van Bakel et al. 2011; Vergara et al. 2016),
chloroplast (Oh et al. 2015; Vergara et al. 2015), and mitochondrial (White et al. 2016)
genomes, as well as transcriptomes for “Purple Kush” (drug type) and “Finola” (hemp
type) (van Bakel et al. 2011) have been published. Despite the full sequencing of the
nuclear genome, it is complex and highly repetitive, and has yet to be assembled in
entirety. However, there are several researchers focused on the complete assembly and
annotation of the entire genome. Of great interest are the genes responsible for
synthesizing cannabinoids (Grassa et al. 2018; Laverty et al. 2019). Recently the genes
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responsible for THCA and CBDA production were found to be located on chromosome
9, and analyses suggest these genes have been targets for selection by breeding for drug
type strains (Grassa et al. 2018). However, the genes responsible for controlling the
relative abundance of cannabinoids have not yet been discovered (Grassa et al. 2018).
Summary
Historical criminalization of Cannabis has severely hindered scientific research
on this prominent plant. Research on Cannabis’ phytochemicals including hundreds of
cannabinoids and terpenes is growing, but the details of the genetic contribution to the
abundance and combination of these compounds is in its research infancy. Relatively few
genetic studies have been conducted and the origins and genetic identities of most
Cannabis varieties are largely unknown. Additionally, there are few Cannabis studies
researching genetic and chemical aspects together. While a lack of research on such an
economically important plant is problematic for the Cannabis industry, it can be argued
that a larger problem is the lack of a regulation and verification system to accurately
identify or verify the thousands of strains that have been described. Chemical constituents
of strains are the dominant focus of the Cannabis industry (Hillig and Mahlberg 2004;
Pacifico et al. 2006; Fischedick et al. 2010; Hazekamp and Fischedick 2012; Elzinga et
al. 2015; Aizpurua-Olaizola et al. 2016). However, the cannabinoid and terpenes present
in the plant, as well as the levels of gene expression can vary widely. Cannabis
chemotypes are variable (plastic) and are therefore unreliable to identify strains. Research
on plastic traits such as chemical constituents needs to be juxtaposed with genetic data in
order to more accurately describe and verify Cannabis strains.
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The research herein addresses genetic variation in Cannabis and how genetic
variation relates to phenotype. This dissertation includes: (1) a genetic investigation to
determine if strains with the same name purchased from Cannabis dispensaries are
genetically similar (Chapter II), (2) an examination of the genetic relationship among
various types of Cannabis (Chapter III), (3) an investigation of human perception of
aromas in four Cannabis strains and if genetic anomalies are detectable through olfaction
(Chapter IV), and (4) an examination of cannabinoids and terpenes to determine if
chemical profiles of four Cannabis strains are similar within strains and if genetic
anomalies are reflected in different cannabinoid levels (Chapter V). Taken together, these
studies aim to provide valuable information about sources of variation in the recently
revived and globally expanding Cannabis industry.
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CHAPTER II
GENETIC VARIATION PART 1: GENETIC TOOLS
WEED OUT MISCONCEPTIONS OF STRAIN
RELIABILITY IN CANNABIS SATIVA:
IMPLICATIONS FOR A BUDDING
INDUSTRY
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Abstract
Unlike other plants, Cannabis sativa is excluded from regulation by the United
States Department of Agriculture (USDA). Distinctive Cannabis varieties are ostracized
from registration and therefore nearly impossible to verify. As Cannabis has become
legal for medical and recreational consumption in many states, consumers have been
exposed to a wave of novel Cannabis products with many distinctive names. Despite
more than 2000 named strains being available to consumers, questions about the
consistency of commercially available strains have not been investigated through
scientific methodologies. As Cannabis legalization and consumption increases, the need
to provide consumers with consistent products becomes more pressing. In this research,
we examined commercially available, drug-type Cannabis strains using genetic methods
to determine if the commonly referenced distinctions are supported and if samples with
the same strain name are consistent when obtained from different facilities. We
developed ten de-novo microsatellite markers using the “Purple Kush” genome to
investigate potential genetic variation within 30 strains obtained from dispensaries in
three states. Samples were examined to determine if there is any genetic distinction
separating the commonly referenced Sativa, Indica and Hybrid types and if there is
consistent genetic identity found within strain accessions obtained from different
facilities. Although there was strong statistical support dividing the samples into two
genetic groups, the groups did not correspond to commonly reported
Sativa/Hybrid/Indica types. The analyses revealed genetic inconsistencies within strains,
with most strains containing at least one genetic outlier. However, after the removal of
obvious outliers, many strains showed considerable genetic stability. We failed to find
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clear genetic support for common strain descriptions of Sativa, Indica and Hybrid types
as described in online databases. Significant genetic differences within samples of the
same strain were observed indicating that consumers could be provided inconsistent
products. These differences have the potential to lead to phenotypic differences and
unexpected effects, which could be surprising for the recreational user, but have more
serious implications for patients relying on strains that alleviate specific medical
symptoms.
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Introduction
Cultivation of Cannabis sativa L. dates back thousands of years (Abel 2013) but
has been largely illegal worldwide for the best part of the last century. The U.S. Drug
Enforcement Agency considers Cannabis a Schedule I drug with no “accepted medical
use in treatment in the United States” (United States Congress 1970), but laws allowing
Cannabis for use as hemp, medicine, and some adult recreational use are emerging
(ProCon 2018b). Global restrictions have limited Cannabis related research, and there are
relatively few genetic studies focused on strains (Lynch et al. 2016; Soler et al. 2017), but
studies with multiple accessions of a particular strain show variation (Lynch et al. 2016;
Sawler et al. 2015; Soler et al. 2017).
Currently, the Cannabis industry has no way to verify strains. Consequently,
suppliers are unable to provide confirmation of strains, and consumers have to trust the
printed name on a label matches the product inside the package. Reports of
inconsistencies, along with the history of underground trading and growing in the
absence of a verification system, reinforce the likelihood that strain names may be
unreliable identifiers for Cannabis products at the present time. Without verification
systems in place, there is the potential for misidentification and mislabeling of plants,
creating names for plants of unknown origin, and even re-naming or re-labeling plants
with prominent names for better sale. Cannabis taxonomy is complex (Clarke and Merlin
2013, 2015, 2016; Emboden 1974; Hillig 2005; Russo 2007; Schultes et al. 1974; Small
2015b; Small et al. 1976), but given the success of using genetic markers, such as
microsatellites, to determine varieties in other crops, we suggest that similar genetic
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based approaches should be used to identify Cannabis strains in medical and recreational
marketplaces.
There are an estimated ~3.5 million medical marijuana patients in the United
States (U.S.) (Leafly 2018a) and various levels of recent legalization in many states has
led to a surge of new strains (Leafly 2018b; Wikileaf 2018). Breeders are producing new
Cannabis strains with novel chemical profiles resulting in various psychotropic effects
and relief for an array of symptoms associated with medical conditions including (but not
limited to): glaucoma (Tomida et al. 2004), Chron’s Disease (Naftali et al. 2013),
epilepsy (United States Food and Drug Administration 2018; Maa and Figi 2014),
chronic pain, depression, anxiety, PTSD, autism, and fibromyalgia (Borgelt et al. 2013;
Cousijn et al. 2018; Naftali et al. 2013; Ogborne et al. 2000; ProCon 2016a).
There are primarily two Cannabis usage groups, which are well supported by
genetic analyses (Dufresnes et al. 2017; Lynch et al. 2016; Sawler et al. 2015; Soler et al.
2017): hemp defined by a limit of < 0.3% Δ9-tetrahydrocannabinol (THC) in the U.S.,
and marijuana or drug-types with moderate to high THC concentrations (always > 0.3%
THC). Within the two major groups Cannabis can be further divided into strains
(varietals), and particularly for the drug types, strains are assigned to one of three
categories: Sativa which reportedly has uplifting and more psychotropic effects, Indica
which reportedly has more relaxing and sedative effects, and Hybrid which is the result
of breeding Sativa and Indica types resulting in intermediate effects. The colloquial terms
Sativa, Hybrid, and Indica are used throughout this document even though these terms
do not align with the current formal botanical taxonomy for Cannabis sativa and
proposed Cannabis indica (McPartland 2017; Piomelli and Russo 2016). We feel the
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colloquial terminology is 8necessary here as the approach for this study was from a
consumer view, and these are the terms offered as common descriptors for the general
public (Leafly 2018b; NCSM 2018; PotGuide.com 2018; Seedfinder 2018; Wikileaf
2018; Marijuana strains database 2019). Genetic analyses have not provided a clear
consensus for higher taxonomic distinction among these commonly described Cannabis
types (Lynch et al. 2016; Sawler et al. 2015), and whether there is a verifiable difference
between Sativa and Indica type strains is debated. However, both the recreational and
medical Cannabis communities claim there are distinct differences in effects between
Sativa and Indica type strains (Smith 2012; Leaf Science 2016; Leafly 2018b; NCSM
2018; PotGuide.com 2018; Seedfinder 2018; Wikileaf 2018; Marijuana strains database
2019).
Female Cannabis plants are selected based on desirable characters (mother plants)
and are produced through cloning and, in some cases, self-fertilization to produce seeds
(Green 2005). Cloning allows Cannabis growers to replicate plants, ideally producing
consistent products. There are an overwhelming number of Cannabis strains that vary
widely in appearance, taste, smell and psychotropic effects (Leafly 2018b; NCSM 2018;
PotGuide.com 2018; Seedfinder 2018; Wikileaf 2018; Marijuana strains database 2019).
Online databases such as Leafly (Leafly 2018b) and Wikileaf (Wikileaf 2018), for
example, provide consumers with information about strains but lack scientific merit for
the Cannabis industry to regulate the consistency of strains. Other databases exist
(NCSM 2018; PotGuide.com 2018; Seedfinder 2018; Marijuana strains database 2019),
but the method of assignment to the three groups is often undisclosed, confounded, or
mysterious. Wikileaf reports a numeric percentage of assignment to Sativa and/or Indica
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(Wikileaf 2018), which is why we chose it as our scale reference scale of ancestry,
although there is some disagreement among online sources (Table 2.1). To our
knowledge, there have not been any published scientific studies specifically investigating
the genetic consistency of strains at multiple points of sale for Cannabis consumers.
Breeders and growers choose Cannabis plants with desirable characters
(phenotype) related to flowers, cannabinoid profile, and terpene production. Phenotype is
a product of genotype and environment. Cannabis is considerably variable and
extraordinarily plastic in response to varying environmental conditions (Onofri and
Mandolino 2017). Therefore, determining sources of variation, at the most basic level,
requires examining genetic differences. Strains propagated through cloning should have
minimal genetic variation. Eight of the strains examined in this study are reportedly clone
only strains indicating there should be little to no genetic variation within these strains.
That being said, it is possible for mutations to accumulate over multiple generations of
cloning (Gabriel et al. 1993; Hojsgaard and Horandl 2015), but these should not be
widespread. Self-fertilization and subsequent seed production may also be used to grow a
particular strain. With most commercial plant products growers go through multiple
generations of self-fertilization and backcrossing to remove genetic variability within a
strain and provide a consistent product (Riggs 1988). However, for many Cannabis
strains, the extent of genetic variability stabilization is uncertain. It has been observed
that novel Cannabis strains developed through crossing are often phenotypically variable
(Green 2005), which could be the result of seed producers growing seeds that are not
stabilized enough to produce a consistent phenotype. Soler et al. (Soler et al. 2017)
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examined the genetic diversity and structure of Cannabis cultivars grown from seed and
found considerable variation, suggesting that seed lots are not consistent.
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Table 2.1. Twelve popular strains and their described assignment of Sativa and Indica according to six online databases of Cannabis strain
information (Leafly 2018b).
%
Strain
Leafly
Strainfinder
NCSM
PotGuide
Seedfinder
Sativa
7 breeders: Pure Sativa (4), Mostly Sativa
Durban Poison*
100
Pure sativa
Sativa dominant
Pure Sativa
Sativa
(2), Sativa/Indica (1)
Sativa
Sativa dominant
Sativa Dominant
19 breeders: Mostly Sativa (12),
Sour Diesel*
90
Mostly Sativa
dominant
(70%)
Hybrid
Sativa/Indica (5), mostly Indica (2)
Sativa
Sativa
Sativa Dominant
3 breeders: Mostly Sativa (2),
Golden Goat*v
65
dominant
Not Found
Dominant
Hybrid
Sativa/Indica (1)
hybrid
Sativa
*Sativa
*Sativa
10 breeders: Mostly Sativa (6),
Bruce Banner*
60
Sativa effects
Dominant
Dominant
dominant (65%)
Sativa/Indica (1), mostly Indica (3)
(60%)
Hybrid
Sativa dominant
Flo*
60
Hybrid
Not Found
Not Found
1 breeder: Mostly Sativa
(60%)
Sativa
Sativa
6 breeders: Mostly Sativa (2),
Indica dominant
Pineapple Express*
60
dominant
Dominant
Not Found
Sativa/Indica (1), mostly Indica (1),
(70%)
hybrid
(60%)
Ruderalis/Sativa/Indica (2)
Indica dominant
Sativa Dominant 25 breeders: Pure Indica (3), mostly Sativa
v
OG Kush*
55
Hybrid
Not Found
(75%)
Hybrid
(1), mostly Indica (15), Sativa/Indica (6)
Sativa
Sativa
Sativa dominant
Sativa Dominant
10 breeders: Mostly Sativa (9), mostly
Blue Dream*v
50
dominant
Dominant
(70%)
Hybrid
Indica (1)
hybrid
(60%)
Indica dominant Indica dominant Sativa Dominant 2 breeders: Mostly Sativa (2) (Chem Dog
Chemdawg*
45
Hybrid
(60%)
(55%)
Hybrid
and Chemdawg)
Indica Dominant
3 breeders: Mostly Indica (1),
Banana Kush*
40
Hybrid
Not Found
Not Found
Hybrid
Sativa/Indica (2)
17 breeders: Mostly Sativa (2),
Indica dominant Indica dominant
Girl Scout Cookies*v
40
Hybrid
Hybrid
Sativa/Indica (7), mostly Indica (7),
(60%)
(60%)
Ruderalis/Sativa/Indica (1)
Indica dominant
Indica Dominant
v
Purple Kush*
0
Pure Indica
Pure Indica
5 breeders: Mostly Indica (5)
(75%)
Hybrid
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Given the uncertainties surrounding named Cannabis strains, genetic data provide an
ideal path to examine how widespread genetic inconsistencies might be.
In the U.S., protection against commercial exploitation, trademarking, and
recognition of intellectual property for developers of new plant cultivars is provided
through the United States Department of Agriculture (USDA) and The Plant Variety
Protection Act of 1970 (United States Department of Agriculture 1970). Traditionally,
morphological characters were used to define new varieties in crops such as grapes (Vitis
vinifera L.), olives (Olea europea L.) and apples (Malus domestica Borkh.). With the
rapid development of new varieties in these types of crops, morphological characters
have become increasingly difficult to distinguish. Currently, quantitative and/or
molecular characters are often used to demonstrate uniqueness among varieties.
Microsatellite genotyping enables growers and breeders of new cultivars to demonstrate
uniqueness through variable genetic profiles (Rongwen et al. 1995). Microsatellite
genotyping has been used to distinguish cultivars and hybrid varieties of multiple crop
varietals within species (Baldoni et al. 2009; Belaj et al. 2004; Cipriani et al. 2002;
Costantini et al. 2005; Guilford et al. 1997; Hokanson et al. 1998; Muzzalupo et al. 2009;
Pellerone et al. 2001; Poljuha et al. 2008; Rongwen et al. 1995; Sarri et al. 2006; Stajner
et al. 2011). Generally, 3-12 microsatellite loci are sufficient to accurately identify
varietals and detect misidentified individuals (Baldoni et al. 2009; Belaj et al. 2004;
Cipriani et al. 2002; Muzzalupo et al. 2009; Poljuha et al. 2008; Sarri et al. 2006).
Cannabis varieties however, are not afforded any legal protections, as the USDA
considers it an “ineligible commodity” (United States Department of Agriculture 2014)
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but genetic variety identification systems provide a model by which Cannabis strains
could be developed, identified, registered, and protected.
We used a well-established genetic technique to compare commercially available
C. sativa strains to determine if products with the same name purchased from different
sources have genetic congruence. This study is highly unique in that we approached
sample acquisition as a common retail consumer by purchasing flower samples from
dispensaries based on what was available at the time of purchase. All strains were
purchased as-is, with no additional information provided by the facility, other than the
identifying label. This study aimed to determine if: (1) any genetic distinction separates
the common perception of Sativa, Indica and Hybrid types; (2) consistent genetic identity
is found within a variety of different strain accessions obtained from different facilities;
(3) there is evidence of misidentification or mislabeling.
Methods
Genetic Material
Cannabis samples for 30 strains were acquired from 20 dispensaries or donors in three
states (Table 2.2). All samples used in this study were obtained legally from either retail
(Colorado and Washington), medical (California) dispensaries, or as a donation from
legally obtained samples (Greeley 1). DNA was extracted using a modified CTAB
extraction protocol (Doyle 1987) with 0.035-0.100 grams of dried flower tissue per
extraction. Although several databases exist with various descriptive Sativa and Indica
assignments for thousands of strains (Table 2.1 & 2.2), proportions of Sativa and Indica
phenotypes from Wikileaf (Wikileaf 2018) were used for this study. Analyses were
performed on the full 122-sample data set (Table 2.2). The 30 strains were assigned a
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proportion of Sativa according to online information (Table 2.2). Twelve of the 30 strains
were designated as ‘popular’ due to higher availability among the dispensaries as well as
online information reporting the most popular strains (Table 2.3) (Escondido 2014; Rahn
2016a; Rahn 2016b; Rahn et al. 2016). Results from popular strains are highlighted to
show levels of variation in strains that are more widely available or that are in higher
demand.
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Table 2.2. Cannabis samples (122) from 30 strains. Reported proportion of Sativa from Wikileaf
(Wikileaf 2018) and the city location and state where each sample was acquired are included. (SLO:
San Luis Obispo).
Name

Sativa

City

State

Name

Sativa

City

State

Durban Poison
Durban Poison
Durban Poison
Durban Poison
Durban Poison
Durban Poison
Durban Poison
Durban Poison
Durban Poison
Hawaiian
Hawaiian
Sour Diesel
Sour Diesel
Sour Diesel
Sour Diesel
Sour Diesel
Sour Diesel
Sour Diesel
Trainwreck
Trainwreck
Island Sweet Skunk
Island Sweet Skunk
Island Sweet Skunk
AK-47
AK-47
AK-47
Golden Goat
Golden Goat
Golden Goat
Golden Goat
Golden Goat
Golden Goat
Golden Goat
Green Crack
Green Crack
Green Crack
Bruce Banner
Bruce Banner
Bruce Banner
Bruce Banner
Bruce Banner
Bruce Banner
Flo
Flo
Flo
Flo
Jillybean
Jillybean

100
100
100
100
100
100
100
100
100
90
90
90
90
90
90
90
90
90
90
90
80
80
80
65
65
65
65
65
65
65
65
65
65
65
65
65
60
60
60
60
60
60
60
60
60
60
60
60

Boulder 1
Boulder 3
Denver 1
Denver 2
Fort Collins 3
Fort Collins 4
Garden City 1
Garden City 2
Union Gap 1
Boulder 1
Fort Collins 2
Boulder 1
Boulder 3
Greeley 1
Denver 4
Fort Collins 3
Garden City 1
Garden City 2
Denver 1
Garden City 1
Boulder 1
Garden City 1
Garden City 2
Boulder 1
Denver 3
SLO 2
Boulder 1
Boulder 2
Boulder 3
Denver 1
Garden City 1
Garden City 1
Garden City 2
Fort Collins 2
Garden City 1
SLO 2
Boulder 1
Denver 1
Denver 4
Fort Collins 3
Fort Collins 4
Garden City 1
Boulder 1
Denver 1
Fort Collins 2
Garden City 1
Garden City 1
Garden City 2

CO
CO
CO
CO
CO
CO
CO
CO
WA
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CA
CO
CO
CO
CO
CO
CO
CO
CO
CO
CA
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO

55
55
55
55
50
50
50
50
50
50
50
50
50
50
50
50
50
40
45
45
40
40
40
45
45
45
40
40
40
40
40
40
40
40
40
40
40
40
55
55
40
40
40
30
30
30
30
30

Denver 3
Fort Collins 3
Garden City 2
SLO 1
Boulder 1
Boulder 2
Boulder 3
Denver 1
Garden City 4
Garden City 4
SLO 2
SLO 3
SLO 4
Boulder 1
Denver 1
Fort Collins 4
SLO 3
Boulder 1
Boulder 2
Boulder 3
Denver 1
Denver 5
Garden City 1
Garden City 2
Garden City 1
Greeley 1
Denver 1
Garden City 1
Garden City 2
Greeley 1
Boulder 1
Denver 1
Fort Collins 2
Garden City 2
Garden City 3
SLO 3
SLO 4
Union Gap 1
Boulder 1
Denver 3
Boulder 1
Denver 4
SLO 3
Boulder 3
Fort Collins 3
Garden City 2
Boulder 1
Garden City 2

CO
CO
CO
CA
CO
CO
CO
CO
CO
CO
CA
CA
CA
CO
CO
CO
CA
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CA
CA
WA
CO
CO
CO
CO
CA
CO
CO
CO
CO
CO

Pineapple Express

60

Boulder 1

CO

OG Kush
OG Kush
OG Kush
OG Kush
Blue Dream
Blue Dream
Blue Dream
Blue Dream
Blue Dream
Blue Dream
Blue Dream
Blue Dream
Blue Dream
Tahoe OG
Tahoe OG
Tahoe OG
Tahoe OG
ChemdawgD*
ChemDawg
ChemDawg
ChemdawgD*
Chemdawg 91
Chemdog 1*
ChemDawg
Headband
Headband
Banana Kush
Banana Kush
Banana Kush
Banana Kush
Girl Scout Cookies
Girl Scout Cookies
Girl Scout Cookies
Girl Scout Cookies
Girl Scout Cookies
Girl Scout Cookies
Girl Scout Cookies
Girl Scout Cookies
Jack Flash
Jack Flash
Larry OG
Larry OG
Larry OG
G-13
G-13
G-13
Lemon Diesel
Lemon Diesel
Hash Plant
(Australian)

20

Garden City 1

CO
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Table 2.2. continued
Name

Sativa

City

State

Name

Sativa

City

State

Pineapple Express
Pineapple Express
Pineapple Express
Pineapple Express
Purple Haze
Purple Haze
Purple Haze
Tangerine
Tangerine
Jack Herer
Jack Herer
Jack Herer

60
60
60
60
60
60
60
60
60
55
55
55

Denver 1
Garden City 2
Longmont 1
Union Gap
Denver 4
Greeley 1
Fort Collins 1
Denver 1
Garden City 1
Garden City 3
SLO 1
Union Gap 1

CO
CO
CO
WA
CO
CO
CO
CO
CO
CO
CA
WA

Hash Plant
Hash Plant
Bubba Kush 98
Pre-98 Bubba Kush
Grape Ape
Grape Ape
Purple Kush
Purple Kush
Purple Kush

20
20
20
15
0
0
0
0
0

Garden City 1
Garden City 2
Denver 1
Fort Collins 3
Boulder 1
Union Gap 1
Denver 1
Garden City 3
Garden City 4

CO
CO
CO
CO
CO
WA
CO
CO
CO

* Strain proportion of “Chemdawg” variants not listed on Wikileaf
 Strain
proportion of “Tangerine” not listed on Wikileaf; proportion listed is of “Tangerine Dream”
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Table 2.3. Summary of Cannabis samples (122) from 30 strains. The reported proportion of Sativa
retrieved from Wikileaf (Wikileaf 2018). Abbreviations used for Lynch & Ritland (Lynch and Ritland
1999) relatedness statistics are included, and the proportions of membership for genotype 1 and genotype 2
from the STRUCTURE (Fig. 2.1) expressed as a percentage.
#
Genotype 1
Genotype 2
Standard
Strain
Abbr
Sativa %
Samples
(% average)
(% average) Deviation
DuPo
Durban Poison*
9
100
86
14
9.9
Hawaiian

Hawa

2

90

61

39

27.58

Sour Diesel*

SoDi

7

90

14

86

53.74

Trainwreck

TrWr

2

90

59

41

21.92

ISS

3

80

93

7

9.19

AK47

3

65

55

45

7.07

Golden Goat*

GoGo

7

65

68

32

2.12

Green Crack

GrCr

3

65

60

40

3.54

Bruce Banner*

BrBa

6

60

19

81

28.99

Flo*

Flo

4

60

38

62

15.56

Jillybean

JiBe

3

60

73

27

9.19

Pineapple Express*

PiEx

5

60

62

38

1.41

Purple Haze

PuHa

3

60

77

23

12.02

Tangerine

Tang

2

60

53

47

4.95

Jack Herer

JaHe

3

55

66

34

7.78

OG Kush*

OGKu

4

55

28

72

19.09

Blue Dream*

BlDr

9

50

80

20

21.21

Tahoe OG

TaOG

4

50

26

74

16.97

Chemdawg*

ChDa

7

45

9

91

25.46

Headband

HeBa

2

45

57

43

8.49

BaKu

4

40

52

48

8.49

Girl Scout Cookies*

GSC

8

40

25

75

10.61

Jack Flash

JaFl

2

40

96

4

39.6

Larry OG

LaOG

3

40

7

93

23.33

G13

3

30

50

50

14.14

LeDi

2

30

85

15

38.89

Hash Plant

HaPl

4

20

37

63

12.02

Pre98-Bubba Kush

PBK

2

15

7

93

5.66

Grape Ape

GrAp

2

0

55

45

38.89

PuKu
Purple Kush*
4
* Twelve popular strains

Clone only strains (SeedFinder 2018)

0

29

71

20.51

Island Sweet Skunk
AK-47


Banana Kush*


G-13
Lemon Diesel
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Microsatellite Development
The Cannabis draft genome from “Purple Kush” (GenBank accession
AGQN00000000.1) was scanned for microsatellite repeat regions using
MSATCOMMANDER-1.0.8-beta (Faircloth 2008). Primers were developed de-novo
flanking microsatellites with 3-6 nucleotide repeat units (Table 2.4). Seven of the
microsatellites were trinucleotide motifs with >10 repeating units. There was two
hexanucleotide motifs with 20 and 30 repeating units. Finally, one tetranucleotide motif
with 10 repeating units was included (Table 2.4). One primer in each pair was tagged
with a 5’ universal sequence (M13 or T7) so that a matching sequence with a
fluorochrome tag could be incorporated via Polymerase Chain Reaction (PCR) (Schwabe
et al. 2015). Ten primer pairs produced consistent peaks within the predicted size range
and were used for the genetic analyses herein (Table 2.4).

Table 2.4. Primer information. Includes the multiplex assignment, primer name, microsatellite repeat and number of units repeated in the "Purple Kush" draft genome (National Center for
Biotechnology Information, accession AGQN00000000.1), forward and reverse sequences (asterisk denotes the sequence to which the tag is attached), the universal tag (sequence revealed at the
bottom of the table), dye (VIC, FAM, PET), optimized annealing temperature, MgCl uL volume, amplified fragment size range, and the number of alleles in the data set.
Multiplex

Primer

Repeat Unit

Forward Sequence

Reverse Sequence

Tag

Dye

Anneal Temp

Magnesium

Fragment Size

Na

1

Casa_002

(GGAATT)20

GTTAGACAATGCTGCCGGTG

*TTCCGATCCAATCCGCAC

M13

FAM

57.4

MgCl 2uL

270-324

8

1

Casa_022

(AGAT)10

TCCACAGCCAGAGGAGAATC

*GGATCATTGGACAGCCATTC

T7

VIC

63.0

MgCl 2uL

190-208

6

1

Casa_027

(GTT)20

CATCTCCCAGCCCTTTCATA

*GCTAGGGTTTTTGCCAAC

M13

FAM

57.4

MgCl 2uL

184-196

9

1

Casa_028

(AAT)13

*TGCACATTGCTCTCCTTTTG

GAATGTGGTCCAATAAACACTCC

M13

PET

55.1

MgCl 2uL

173-190

8

1

Casa_030

(CAA)19

CAATCCACACAACAGCTCCT

*TGCAGCAAGTTTAGGTGGTC

M13

VIC

55.1

MgCl 6uL

271-300

8

2

Casa_006

(TTTCTC)30

*TTCTTCTCTCGACAGAACCC

TAGAACCAAGCAAGAAGGGC

M13

FAM

55.1

MgCl 1uL

410-422

6

2

Casa_014

(TAG)13

*ATCGTGTTGCATGTTTGTGG

TGTGCTCCCTCTTGTATGATTC

M13

FAM

63.0

MgCl 2uL

270-290

8

2

Casa_018

(ATT)28

*TCATAACCCCAAAAGCAAAG

GGGTAAATATAGCTGGCAAAGC

T7

VIC

55.1

MgCl 3uL

182-221

10

2

Casa_026

(CTT)13

*CCATTTCGACCCTTGTAGGT

CTGGGGAAGATGAACGAAAG

M13

FAM

57.4

MgCl 1uL

201-206

9

CCCTCTCAGTCCCAAATTCA

*GATGGTGATGAGGAGGAGGA

M13

PET

55.1

MgCl 2uL

183-192

5

Casa_029
(ACC)11
2
M13: AGGAAACAGCTATGACCAT
T7: GCTAGTTATTGCTCAGCGG
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Polymerase Chain Reaction
and Data Scoring
Microsatellite loci (Table 2.4) were amplified in 12 µL reactions using 1.0 μL
DNA (10-20 ng/ μL), 0.6 μL fluorescent tag (5 μM; FAM, VIC, or PET), 0.6 μL nontagged primer (5 μM), 0.6 μL tagged primer (0.5 μM), 0.7 μL dNTP mix (2.5mM), 2.4
μL GoTaq Flexi Buffer (Promega, Madison, WI, USA), 0.06 μL GoFlexi taq polymerase
(Promega), 0.06 μL BSA (Bovine Serum Albumin 100X), 0.5 - 6.0 μL MgCl or MgSO4,
and 0.48 - 4.98 μL dH2O. An initial 5-minute denaturing step was followed by thirty-five
amplification cycles with a 1-minute denaturing at 95º C, 1-minute annealing at primerspecific temperatures and 1-minute extension at 72ºC. Two multiplexes (Table 2.4) based
on fragment size and fluorescent tag were assembled and 2 μL of each PCR product were
combined into multiplexes up to a total volume of 10 μL. From the multiplexed product,
2 μL was added to Hi-Di formamide and LIZ 500 size standard (Applied Biosystems,
Foster City, CA, USA) for electrophoresis on a 3730 Genetic Analyzer (Applied
Biosystems) at the Arizona State University DNA Lab. Fragments were sized using
GENEIOUS 8.1.8 (Biomatters Ltd).
Genetic Statistical Analyses
GENALEX ver. 6.4.1 (Peakall and Smouse 2006; Peakall and Smouse 2012) was
used to calculate deviation from Hardy–Weinberg equilibrium (HWE) and number of
alleles for each locus (Table 2.4). Linkage disequilibrium was tested using GENEPOP
ver. 4.0.10 (Raymond and Rousset 1995; Rousset 2008). Presence of null alleles was
assessed using MICRO-CHECKER (Van Oosterhout et al. 2004). Genotypes were
analyzed using the Bayesian cluster analysis program STRUCTURE ver. 2.4.2 (Pritchard
et al. 2000). Burn-in and run-lengths of 50,000 generations were used with ten
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independent replicates for each STRUCTURE analysis. STRUCTURE HARVESTER
(Earl and vonHoldt 2012) was used to determine the K value to best describe the likely
number of genetic groups for the data set. GENALEX produced a Principal Coordinate
Analysis (PCoA) to examine variation in the data set. Lynch & Ritland (Lynch and
Ritland 1999) mean pairwise relatedness (r) statistics were calculated between all 122
samples resulting in 7381 pairwise r-values showing degrees of relatedness. For all
strains the r-mean and standard deviation (SD) was calculated averaging among all
samples. Obvious outliers were determined by calculating the lowest r-mean and
iteratively removing those samples to determine the relatedness among the remaining
samples in the subset. A graph was generated for 12 popular strains (Table 2.3) to show
how the r-mean value change within a strain when outliers were removed.
Results
The microsatellite analyses show genetic inconsistencies in Cannabis strains
acquired from different facilities. While popular strains were widely available, some
strains were found only at two dispensaries (Table 2.2). Since the aim of the research was
not to identify specific locations where strain inconsistencies were found, dispensaries are
coded to protect the identity of businesses.
There was no evidence of linkage-disequilibrium when all samples were treated
as a single population. All loci deviate significantly from HWE, and all but one locus was
monomorphic in at least two strains. All but one locus had excess homozygosity and
therefore possibly null alleles. Given the inbred nature and extensive hybridization of
Cannabis, deviations from neutral expectations are not surprising, and the lack of
linkage-disequilibrium indicates that the markers are spanning multiple regions of the
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genome. The number of alleles ranged from 5-10 across the ten loci (Table 2.4). There
was no evidence of null alleles due to scoring errors.
STRUCTURE HARVESTER calculated high support (∆K=146.56) for two
genetic groups, K=2 (Figure 2.1). STRUCTURE assignment is shown in Figure 1 with
the strains ordered by the purported proportions of Sativa phenotype (Wikileaf 2018).

Figure 1.

Figure STRUCTURE
2.1. STRUCTURE
HARVESTER.
Graph K=2
indicating
K=2
is highly support
HARVESTER
graph indicating
is highly
supported
(∆K=146.56)
as the number
of genetic
groups
for this
data.data.
(∆K=146.56)
as the number
of genetic
groups
for this
A clear genetic distinction between Sativa and Indica types would assign 100% Sativa
strains (“Durban Poison”) to one genotype and assign 100% Indica strains (“Purple
Kush”) to the other genotype (Table 2.3, Figure 2.2, and 2.3). Division into two genetic
groups does not support the commonly described Sativa and Indica phenotypes. “Durban
Poison” and “Purple Kush” follow what we would expect if there was support for the
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Sativa/Indica division. Seven of nine “Durban Poison” (100% Sativa) samples had 96%
assignment to genotype 1, and three of four “Purple Kush” (100% Indica) had 89%
assignment to genotype 2 (Figure 2.2, 2.3). However, samples of “Hawaiian” (90%
Sativa) and “Grape Ape” (100% Indica) do not show consistent patterns of predominant
assignment to genotype 1 or 2. Interestingly, two predominantly Sativa strains “Durban
Poison” (100% Sativa) and “Sour Diesel” (90% Sativa) have 86% and 14% average
assignment to genotype 1, respectively. Hybrid strains such as “Blue Dream” and “Tahoe
OG” (50% Sativa) should result in some proportion of shared ancestry, with assignment
to both genotype 1 and 2. Eight of nine samples of “Blue Dream” show > 80%
assignment to genotype 1, and three of four samples of “Tahoe OG” show < 7%
assignment to genotype 1.

44

Figure 2.1. STRUCTURE graphs for 122 individuals. Bar plot graphs generated from STRUCTURE analysis for 122 individuals from 30
strains dividing genotypes into two genetic groups, K=2. Samples were arranged by purported proportions from 100% Sativa to 100%
Indica and then alphabetically within each strain by city. Each strain includes reported proportion of Sativa in parentheses and each sample
includes the coded location and city from where it was acquired. Each bar indicates proportion of assignment to genotype 1 (blue) and
genotype 2 (yellow).
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Figure 2.2. Bar plot graphs generated from STRUCTURE analysis for individuals from twelve popular strains (Table 2.3),
dividing genotypes into two genetic groups, K=2. Each sample includes the coded location and city from where it was acquired. Each
bar indicates proportion of assignment to genotype 1 (blue) and genotype 2 (yellow).
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A Principal Coordinate Analyses (PCoA) was conducted using GENALEX
(Figure 2.3). Principal Coordinate Analyses (PCoA) is organized by color from 100%
Sativa types (red), through all levels of Hybrid types (green 50:50), to 100% Indica types
(purple; Figure 2.3). Strain types with the same reported proportions are the same color
but have different symbols. The PCoA of all strains represents 14.90% of the variation in
the data on coordinate axis 1, 9.56% on axis 2, and 7.07% on axis 3 (not shown).
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Figure 2.3. Principal Coordinates Analysis (PCoA) generated in GENALEX using Nei’s genetic distance matrix. Samples are a color-coded continuum by
proportion of Sativa (Table 2.2) with the strain name given for each sample: Sativa type (red: 100% Sativa proportion, Hybrid type (dark green: 50% Sativa
proportion), and Indica type (purple: 0% Sativa proportion). Different symbols are used to indicate different strains within reported phenotype. Coordinate axis 1
explains 14.29% of the variation, coordinate axis 2 explains 9.56% of the variation, and Coordinate axis 3 (not shown) explains 7.07%.
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Lynch & Ritland (Lynch and Ritland 1999) pairwise genetic relatedness (r)
between all 122 samples was calculated in GENALEX. The resulting 7381 pairwise rvalues were converted to a heat map using purple to indicate the lowest pairwise
relatedness value (-1.09) and green to indicate the highest pairwise relatedness value
(1.00; Figure 2.4).
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Figure 2.4. A genetic heat map chart of Lynch & Ritland pairwise genetic relatedness (r) values for 122 samples. Purple
indicates no genetic relatedness (minimum value -1.09) and green indicates a high degree of relatedness (maximum value 1.0). Sample
strain names and location of origin are indicated along the top and down the left side of the chart. Pairwise genetic relatedness (r)
values are given in each cell and cell color reflects the degree to which two individuals are related.
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Figure 3. 2.5. Heat maps of six prominent strains (A-F) using Lynch & Ritland (Lynch
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indicative of clones or seeds from the same mother (Green 2005; SeedFinder 2018). First
order relatives (full siblings or mother-daughter) share 50% genetic identity (r-value =
0.50), second order relatives (half siblings or cousins) share 25% genetic identity (r-value
= 0.25), and unrelated individuals are expected to have an r-value of 0.00 or lower.
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Negative values arise when individuals are less related than expected under normal
panmictic conditions (Moura et al. 2013; Norman et al. 2017).
Individual pairwise r-values were averaged within strains to calculate the overall
r-mean as a measure of genetic similarity within strains which ranged from -0.22
(“Tangerine”) to 0.68 (“Island Sweet Skunk”) (Table 6). Standard deviations ranged from
0.04 (“Jack Herer”) to 0.51 (“Bruce Banner”). The strains with higher standard deviation
values indicate a wide range of genetic relatedness within a strain, while low values
indicate that samples within a strain share similar levels of genetic relatedness. In order to
determine how outliers impact the overall relatedness in a strain, the farthest outlier
(lowest pairwise r-mean value) was removed and the overall r-means and SD values
within strains were recalculated (Table 2.5).
In all strains, the overall r-means increased when outliers were removed. In
strains with more than three samples, a second outlier was removed, and the overall rmeans and SD values were recalculated. Overall r-means were used to determine degree
of relatedness as clonal (or from stable seed; overall r-means > 0.9), first or higher order
relatives (overall r-means 0.46 – 0.89), second order relatives (overall r-means 0.26 0.45), low levels of relatedness (overall r-means 0.00 - 0.25), and not related (overall rmeans <0.00). Overall r-means are displayed for all 30 strains (Table 2.5), and
graphically for 12 popular strains (Figure 2.6).
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Table 2.5. Lynch & Ritland (Lynch and Ritland 1999) pairwise relatedness
comparisons of overall r-means (Mean) and standard deviations (SD) for samples
of 30 strains. Including r-mean and SD after the first and second (where possible)
outliers were removed. Outliers were samples with the lowest r-mean.
#
Samples

Mean ± SD

Mean ± SD
(Outlier 1 removed)

Mean ± SD
(Outlier 2 removed)

Durban Poison*

9

0.31 ± 0.4

0.43 ± 0.37

0.58 ± 0.30

Hawaiian

2

-0.115

-

-

Sour Diesel*

7

0.44 ± 0.29

0.57 ± 0.22

0.60 ± 0.18

Trainwreck

2

-0.001

-

-

Island Sweet Skunk

3

0.68

1

-

AK-47

Strain

3

0.16

0.45

-



Golden Goat*

7

0.25 ± 0.32

0.31 ± 0.36

0.46 ± 0.36



Green Crack
Bruce Banner*

3

0.38

0.88

-

6

0.30 ± 0.51

0.51 ± 0.5

0.9 ± 0.05

Flo*

4

0.29 ± 0.38

0.55 ± 0.39

-

Jillybean

3

-0.033

0.039

-

Pineapple Express*

5

0.02 ± 0.16

0.04 ± 0.17

0.13 ± 0.19

Purple Haze

3

0.041

0.26

-

Tangerine

2

-0.22

-

-

3

0.1

0.13

-

OG Kush*

4

0.13 ± 0.19

0.25 ± 0.22

-

Blue Dream*
Tahoe OG

9

0.50 ± 0.39

0.63 ± 0.34

0.76 ± 0.24

4

0.21

0.406

0.539

Chemdawg*

7

0.42 ± 0.31

0.51 ± 0.31

0.64 ± 0.28

Headband

2

0.107

-

-

Banana Kush*

4

0.13 ± 0.20

0.24 ± 0.13

-

8

0.08 ± 0.27

0.13 ± 0.30

0.22 ± 0.32

2

0.62

-

-

Larry OG

3

0.32

0.67

-

G-13

3

0.29

0.562

-

2

0.1

-

-

4

0.25

0.25

0.43

Pre98-Bubba Kush

2

-0.02

-

-

Grape Ape

2

-0.05

-

-

0.16 ± 0.22

-

Jack Herer


Girl Scout Cookies*
Jack Flash

Lemon Diesel
Hash Plant







4
0.03 ± 0.21
Purple Kush*
* Twelve popular strains

Clone only strains (SeedFinder 2018)
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Figure 2.6. Iterative removal of pairwise genetic relatedness (r) outliers from Table
2.5. This graph indicates the mean pairwise genetic relatedness (r) initially (light purple),
and after the removal of one (medium purple) or two (dark purple) outlying samples in 12
popular strains.

Initial overall r-means indicate only three strains are first or higher order relatives (Table
2.5). Removing first or second outliers, depending on sample size, revealed that the
remaining samples for an additional ten strains are first or higher order relatives (0.46 –
1.00), three strains are second order relatives (r-means 0.26 - 0.45), ten strains show low
levels of relatedness (r-means 0.00 - 0.25; Table 2.5), and five strains are not related (rmeans <0.00). The impact of outliers can be clearly seen in the heat map for “Durban
Poison” which shows the relatedness for 36 comparisons (Figure 2.5A), six of which are
nearly identical (r-value 0.90 - 1.0), while 13 are not related (r-value <0.00). However,
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removal of two outliers, Denver 1 and Garden City 2, reduces the number of comparisons
ranked as not related from 13 to zero.
Discussion
Cannabis is becoming an ever-increasing topic of discussion, so it is important
that scientists and the public can discuss Cannabis in a similar manner. Currently, not
only are Sativa and Indica types disputed (Clarke and Merlin 2013, 2015, 2016; De
Meijer and Keizer 1996; Emboden 1974; Hillig 2005; McPartland 2017; Piomelli and
Russo 2016; Russo 2007; Small 2015a), but experts also are at odds about nomenclature
for Cannabis (Clarke and Merlin 2013, 2015, 2016; De Meijer and Keizer 1996;
Emboden 1974; Hillig 2005; McPartland 2017; Piomelli and Russo 2016; Russo 2007;
Small 2015a). We postulated that genetic profiles from samples with the same strain
identifying name should have identical, or at least, highly similar genotypes no matter the
source of origin. The multiple genetic analyses used here address paramount questions
for the medical Cannabis community and bring empirical evidence to support claims that
inconsistent products are being distributed. An important element for this study is that
samples were acquired from multiple locations to maximize the potential for variation
among samples. Maintenance of the genetic integrity through genotyping is possible only
following evaluation of genetic consistency and continuing to overlook this aspect will
promote genetic variability and phenotypic variation within Cannabis. Addressing strain
variability at the molecular level is of the utmost importance while the industry is still
relatively new.
Genetic analyses have consistently found genetic distinction between hemp and
marijuana, but no clear distinction has been shown between the common description of
Sativa and Indica types (De Meijer and Keizer 1996; Dufresnes et al. 2017; Lynch et al.
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2016; Sawler et al. 2015; Soler et al. 2017). We found high support for two genetic
groups in the data (Figure 2.1) but no discernable distinction or pattern between the
described Sativa and Indica strains. The color-coding of strains in the PCoA for all 122
samples allows for visualization of clustering among similar phenotypes by color: Sativa
(red/orange), Indica (blue/purple) and Hybrid (green) type strains (Figure 2.4). If genetic
differentiation of the commonly perceived Sativa and Indica types previously existed, it
is no longer detectable in the neutral genetic markers used here. Extensive hybridization
and selection have presumably created a homogenizing effect and erased evidence of
potentially divergent historical genotypes.
Wikileaf maintains that the proportions of Sativa and Indica reported for strains
are largely based on genetics and lineage (Nelson 2016), although online databases do not
give scientific evidence for their categorization other than parentage information from
breeders and expert opinions. This has seemingly become convoluted over time (Clarke
and Merlin 2013; Russo 2007; Small 2015b; Small 2016). Our results show that
commonly reported levels of Sativa, Indica and Hybrid type strains are often not reflected
in the average genotype. For example, two described Sativa type strains “Durban Poison”
and “Sour Diesel”, have contradicting genetic assignments (Figure 2.1, 2.2 & Table 2.1).
This analysis indicates strains with similar reported proportions of Sativa or Indica may
have differing genetic assignments. Further illustrating this point is that “Bruce Banner”,
“Flo”, “Jillybean”, “Pineapple Express”, “Purple Haze”, and “Tangerine” are all reported
to be 60/40 Hybrid type strains, but they clearly have differing levels of admixture both
within and among these reportedly similar strains (Figure 2.1, Table 2.1). From these
results, we can conclude that reported ratios or differences between Sativa and Indica
phenotypes are not discernable using these genetic markers. Given the lack of genetic

56
distinction between Indica and Sativa types, it is not surprising that reported ancestry
proportions are also not supported.
To accurately address reported variation within strains, samples were purchased
from various locations, as a customer, with no information of strains other than publicly
available online information. Evidence for genetic inconsistencies is apparent within
many strains and supported by multiple genetic analyses. Soler et al. (Soler et al. 2017)
found genetic variability among seeds from the same strain supplied from a single source,
indicating genotypes within strains are variable. When examining the STRUCTURE
genotype assignments, it is clear that many strains contained one or more divergent
samples with a difference of > 0.10 genotype assignment (e.g. “Durban Poison” – Denver
1; Figure 2.1, 2.2, 2.5A). Of the 30 strains examined, only four strains had consistent
STRUCTURE genotype assignment and admixture among all samples. The number of
strains with consistent STRUCTURE assignments increased to 11 and 15 when one or
two samples were ignored, respectively. These results indicate that half of the included
strains showed relatively stable genetic identity among most samples. Six strains had
only two samples, both of which were different (e.g., “Trainwreck” and “Headband”).
The remaining nine strains in the analysis had more than one divergent sample (e.g.,
“Sour Diesel”) or had no consistent genetic pattern among the samples within the strain
(e.g., “Girl Scout Cookies”; Table 2.5, Figure 2.2, 2.2, 2.5B). It is noteworthy that many
of the strains used here fell into a range of genetic relatedness indicative of first order
siblings (see Lynch & Ritland analysis) when samples with high genetic divergence were
removed from the data set (Table 2.5; Figure 2.6). Eight of the 30 strains examined are
identified as clone only (Table 2.3). All eight of the strains described as clone only show
differentiation of at least one sample within the strain (Figure 2.1). For example, one
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sample of “Blue Dream” is clearly differentiated from the remaining eight, and “Girl
Scout Cookies” has little genetic cohesiveness among the eight samples (Figure 2.1, 2.2).
Other genetic studies have similarly found genetic inconsistencies across samples within
the same strain (Lynch et al. 2016; Sawler et al. 2015; Soler et al. 2017). These results
lend support to the idea that unstable genetic lines are being used to produce seed.
A pairwise genetic heat map based on Lynch & Ritland (Lynch and Ritland 1999)
pairwise genetic relatedness (r-values) was generated to visualize genetic relatedness
throughout the data set (Figure 2.3). Values of 1.00 (or close to) are assumed to be clones
or plants from self-fertilized seed. Six examples of within-strain pairwise comparison
heat maps were examined to illustrate common patterns (Figure 2.4). The heat map
shows that many strains contain samples that are first order relatives or higher (r-value >
0.49). For example, “Sour Diesel” (Figure 2.4) has 12 comparisons of first order or
above, and six have low/no relationship. There are also values that could be indicative of
clones or plants from a stable seed source such as “Blue Dream” (Figure 2.2, 2.5F),
which has 10 nearly identical comparisons (r-value 0.90-1.00), and no comparisons in
“Blue Dream” have negative values. While “Blue Dream” has an initial overall r-mean
indicating first order relatedness within the samples (Table 2.5, Figure 2.5F), it still
contains more variation than would be expected from a clone only strain (SeedFinder
2018). Other clone-only strains (SeedFinder 2018) e.g., “Girl Scout Cookies” (Table 2.2,
Figure 2.5B) and “Golden Goat” (Table 3, Figure 6D), have a high degree of genetic
variation resulting in low overall relatedness values. Outliers were calculated and
removed iteratively to demonstrate how they affected the overall r- mean within the 12
popular strains (Table 2.2, Figure 2.6). In all cases, removing outliers increased the mean
r-value, as illustrated by “Bruce Banner”, which increased substantially, from 0.3 to 0.9
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when samples with two outlying genotypes were removed. There are unexpected areas in
the entire data set heat map that indicate high degrees of relatedness between different
strains (Figure 2.4). For example, comparisons between “Golden Goat” and “Island
Sweet Skunk” (overall r- mean 0.37) are higher than within samples of “Sour Diesel”.
Interestingly, “Golden Goat” is reported to be a hybrid descendant of “Island Sweet
Skunk” (Leafly 2018b; NCSM 2018; PotGuide.com 2018; Seedfinder 2018; Wikileaf
2018) which could explain the high genetic relatedness between these strains. However,
most of the between strain overall r- mean are negative (e.g., “Golden Goat” to “Durban
Poison” -0.03 and “Chemdawg” to “Durban Poison” -0.22; Figure 2.5), indicative of
limited recent genetic relationship.
While collecting samples from various dispensaries, it was noted that strains of
“Chemdawg” had various different spellings of the strain name, as well as numbers
and/or letters attached to the name. Without knowledge of the history of “Chemdawg”,
the assumption was that these were local variations. These were acquired to include in the
study to determine if and how these variants were related. Upon investigation of possible
origins of “Chemdawg”, an interesting history was uncovered, especially in light of the
results. Legend has it that someone named “Chemdog” (a person) grew the variations
(“Chem Dog”, “Chem Dog D”, “Chem Dog 4”) from seeds he found in a single bag of
Cannabis purchased at a Grateful Dead concert (Danko 2016). However, sampling
suggests dispensaries use variations of the name, and more often the “Chemdawg” form
of the name is used, albeit incorrectly (Danko 2016). The STRUCTURE analysis
indicates only one “Chemdawg” individual has > 0.10 genetic divergence compared to
the other six samples (Figure 2.1, 2.5C). Five of seven “Chemdawg” samples cluster in
the PCoA (Figure 4), and six of seven “Chemdawg” samples are first order relatives (r-
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value >0.50; Table 2.2, Figure 2.5C). The history of “Chem Dog” is currently
unverifiable, but the analysis supports that these variations could be from seeds of the
same plant. This illustrates how Cannabis strains may have come to market in a nontraditional manner. Genetic analyses can add scientific support to the stories behind
vintage strains and possibly help clarify the history of specific strains.
Genetic inconsistencies may come from both suppliers and growers of Cannabis
clones and stable seed, because currently they can only assume the strains they possess
are true to name. There is a chain of events from seed to sale that relies heavily on the
supplier, grower, and dispensary to provide the correct product, but there is currently no
reliable way to verify Cannabis strains. The possibility exists for errors in plant labeling,
misplacement, misspelling (e.g., “Chem Dog” vs. “Chemdawg”), and/or relabeling along
the entire chain of production. Although the expectation is that plants are labeled
carefully and not re-labeled with a more desirable name for a quick sale, these misgivings
must be considered. Identification by genetic markers has largely eliminated these types
of mistakes in other widely cultivated crops such as grapes, olives and apples. Modern
genetic applications can accurately identify varieties and can clarify ambiguity in closely
related and hybrid species (Costantini et al. 2005; Guilford et al. 1997; Hokanson et al.
1998; Sarri et al. 2006; United States Department of Agriculture 2014).
Matching genotypes within the same strains were expected, but highly similar
genotypes between samples of different strains could be the result of mislabeling or
misidentification, especially when acquired from the same source. The pairwise genetic
relatedness r-values were examined for incidence of possible mislabeling or re-labeling.
There were instances in which different strains had r-values = 1.0 (Figure 2.4, 2.5),
indicating clonal genetic relationships. Two samples with matching genotypes were
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obtained from the same location (“Larry OG” and “Tahoe OG” from San Luis Obispo 3,
Figure 2.1). This could be evidence for mislabeling or misidentification because these
two samples have similar names. It is unlikely that these samples from reportedly
different strains have identical genotypes, and more likely that these samples were
mislabeled at some point. Misspelling may also be a source of error, especially when
facilities are handwriting labels. An example of possible misspelling may have occurred
in the sample labeled “Chemdog 1” from Garden City 1. “Chemdawg 1”, a described
strain, could have easily been misspelled, but it is unclear whether this instance is
evidence for mislabeling or renaming a local variant. Inadvertent mistakes may carry
through to scientific investigation where strains are spelled or labeled incorrectly. For
example, Vergara et al. (Vergara et al. 2016) reports genome assemblies for “Chemdog”
and “Chemdog 91” as they are reported in GenBank (GCA_001509995.1), but neither of
these labels are recognized strain names. “Chemdawg” and “Chemdawg 91” are
recognized strains (Leafly 2018b; NCSM 2018; PotGuide.com 2018; Seedfinder 2018;
Wikileaf 2018; Marijuana strains database 2019), but according to the original source, the
strain name “Chemdawg” is incorrect, and it should be “Chem Dog” (Danko 2016), but
the name has clearly evolved among growers since it emerged in 1991 (Danko 2016).
Another example that may lead to confusion is how information is reported in public
databases. For example, data are available for the reported monoisolate of “Pineapple
Banana Bubba Kush” in GenBank (SAMN06546749), and while “Pineapple Kush”,
“Banana Kush” and “Bubba Kush” are known strains (Leafly 2018b; NCSM 2018;
PotGuide.com 2018; Seedfinder 2018; Wikileaf 2018; Marijuana strains database 2019),
the only record we found of “Pineapple Banana Bubba Kush” is in GenBank. This study
has highlighted several possible sources of error and how genotyping can serve to
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uncover sources of variation. Although this study was unable to confirm sources of error,
it is important that producers, growers and consumers are aware that there are errors and
they should be documented and corrected whenever possible.
Conclusions
Over the last decade, the legal status of Cannabis has shifted and is now legal for
medical and some recreational adult use, in the majority of the United States as well as
several other countries that have legalized or decriminalized Cannabis. The recent legal
changes have led to an unprecedented increase in the number of strains available to
consumers. There are currently no baseline genotypes for any strains, but steps should be
taken to ensure products marketed as a particular strain are genetically congruent.
Although the sampling in this study was not exhaustive, the results are clear: strain
inconsistency is evident and is not limited to a single source, but rather exists among
dispensaries across cities in multiple states. Various suggestions for naming the genetic
variants do not seem to align with the current widespread definitions of Sativa, Indica,
Hybrid, and Hemp (Clarke and Merlin 2013; Hillig 2005). As our Cannabis knowledge
base grows, so does the communication gap between scientific researchers and the public.
Currently, there is no way for Cannabis suppliers, growers or consumers to definitively
verify strains. Exclusion from USDA protections due to the Federal status of Cannabis as
a Schedule I drug has created avenues for error and inconsistencies. Presumably, the
genetic inconsistencies will often manifest as differences in overall effects (Minkin
2014). Differences in characteristics within a named strain may be surprising for a
recreational user, but differences may be more serious for a medical patient who relies on
a particular strain for alleviation of specific symptoms.
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This study shows that in neutral genetic markers, there is no consistent genetic
differentiation between the widely held perceptions of Sativa and Indica Cannabis types.
Moreover, the genetic analyses do not support the reported proportions of Sativa and
Indica within each strain, which is expected given the lack of genetic distinction between
Sativa and Indica. Instances were found where samples within strains are not genetically
similar, which is unexpected given the manner in which Cannabis plants are propagated.
Although it is impossible to determine the source of these inconsistencies as they can
arise at multiple points throughout the chain of events from seed to sale, we theorize
misidentification, mislabeling, misplacement, misspelling, and/or relabeling are all
possible. Especially where names are similar, there is the possibility for mislabeling, as
was shown here. In many cases genetic inconsistencies within strains were limited to one
or two samples. We feel that there is a reasonable amount of genetic similarity within
many strains, but currently there is no way to verify the “true” genotype of any strain.
Although the sampling here includes merely a fragment of the available Cannabis strains,
our results give scientific merit to previously anecdotal claims that strains can be
unpredictable.
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Abstract
Public comfort with Cannabis (marijuana and hemp) has recently increased,
resulting in revisions of previously strict Cannabis regulations to now allow for hemp
cultivation, medical use, and in some states, recreational consumption. There is a growing
interest in the potential medical benefits of the various chemical constituents produced by
the Cannabis plant. Currently, the University of Mississippi, funded through the National
Institutes of Health/National Institute on Drug Abuse (NIH/NIDA), is the sole Drug
Enforcement Agency (DEA) licensed facility to cultivate Cannabis for research purposes.
Hence, most federally funded research where participants consume Cannabis for
medicinal purposes relies on NIDA supplied product. Previous research found that
cannabinoid levels in research grade marijuana supplied by NIDA did not align with
commercially available Cannabis from Colorado, Washington and California. Given
NIDA chemotypes were found to misaligned with commercial Cannabis, we sought to
investigate where NIDA’s research grade marijuana falls on the genetic spectrum of
Cannabis groups. NIDA research grade marijuana was found to genetically group with
Hemp samples along with a small subset of commercial drug-type Cannabis. A majority
of commercially available drug-type Cannabis was genetically very distinct from NIDA
samples. These results suggested that subjects consuming NIDA research grade
marijuana may have different effects than average consumers
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Introduction
Humans have a long history with Cannabis sativa (marijuana and hemp), with
evidence of cultivation dating back as far as 10,000 years ago (Abel 2013). The World
Health Organization proclaims Cannabis as the most widely cultivated, trafficked and
abused illicit drug, and reports over half of worldwide drug seizures are of Cannabis
(World Health Organization 2018). Phytochemicals of interest in Cannabis are primarily
Δ9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), both of which
require a decarboxylation conversion to the biologically active forms, THC and CBD,
respectively. The United States is currently experiencing drastic changes in patterns of
Cannabis use associated with widespread relaxation of laws that previously limited both
medical and recreational marijuana consumption (Cousijn et al. 2018) and hemp
cultivation. This has led to a need for extensive research into the basic biology and
taxonomy of Cannabis sativa (Clarke and Merlin 2013; Hillig 2005; Lynch et al. 2016;
Small 2017; Vergara et al. 2016), and the possible benefits and threats from Cannabis
consumption (Baron 2018; Cousijn et al. 2018).
Although Cannabis sativa is the only described species in the genus Cannabis
(Cannabaceae), there are several commonly described subcategories of Cannabis that are
widely recognized. There are two primary Cannabis usage groups, which are well
supported by genetic analyses (Dufresnes et al. 2017; Lynch et al. 2016; Sawler et al.
2015; Soler et al. 2017): hemp is defined by a lack of THC (< 0.3% THC in the U.S.),
and marijuana or drug-types have moderate to high THC concentrations (> 0.3% THC in
the U.S.). Hemp-type Cannabis tends to have higher concentrations of CBD than drugtypes (de Meijer et al. 1992). Drug-type Cannabis usually contains > 12% THC and
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averages ~ 10-23% THC in commercially available dispensaries (Jikomes and Zoorob
2018; Potter et al. 2008; Vergara et al. 2017). Within the two major usage groups,
Cannabis can be further divided into varietals, which are referred to as strains. The drugtype strains are commonly categorized further: Sativa strains reportedly have uplifting
and more psychedelic effects, Indica strains reportedly have more relaxing and sedative
effects, and Hybrid strains, which result from breeding Sativa and Indica strains, have a
spectrum of intermediate effects. There is extensive debate among experts surrounding
the appropriate taxonomic treatment of Cannabis groups, which is confounded by
colloquial usage of these terms versus what researchers suggest is more appropriate
nomenclature (Clarke and Merlin 2013, 2015; Emboden 1977, 1981; McPartland 2017;
McPartland and Guy 2017; Small 2015b; Small 2016; Small et al. 1976). Commercially
available drug-type strains for medical or recreational consumption are labeled with a
strain name, as well as the levels of THC and often CBD as a percent of the dry weight.
Genetic analyses have not shown clear and consistent differentiation among the three
commonly described drug-type strains (Lynch et al. 2016; Sawler et al. 2015), but both
the recreational and medical Cannabis communities maintain there are distinct
differences in effects between Sativa and Indica strains (Smith 2012; Leaf Science 2016;
Leafly 2018b).
Although Cannabis has been federally controlled since 1937 (1937), many states
now allow regulated medical (33 states and the District of Columbia) and recreational use
(10 states and the District of Columbia) (ProCon 2018b). There were > 3.5 million
registered medical marijuana patients reported as of May 2018 (ProCon 2018a).
However, the United States Drug Enforcement Agency (DEA) lists Cannabis sativa as a
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Schedule 1 Substance (United States Congress 1970), and as such, research on all aspects
of this plant has been limited. U.S. Surgeon General Jerome Adams recently expressed
concern that the current scheduling in the most restrictive category is inhibiting research
on Cannabis as a potentially therapeutic plant (Jaeger 2018). A Schedule 1 substance is
described as a drug with no accepted medical use and a high potential for abuse (United
States Congress 1970). The University of Mississippi, funded through the National
Institutes of Health/National Institute on Drug Abuse (NIH/NIDA), currently holds the
single license issued by the DEA for the cultivation of Cannabis for research purposes
(National Institute on Drug Abuse 2018). As such, NIDA serves as the sole legal provider
of Cannabis for federally funded medical research in the United States. Bulk research
grade marijuana supplied by NIDA is characterized by the level of THC and CBD. They
offer Cannabis for research with four levels of THC: low (< 1%), medium (1-5 %), high
(5-10 %) and very high (>10%), with the additional option of four levels of CBD: low (<
1%), medium (1-5%), high (5-10%) and very high (> 10%).
The National Institute on Drug Abuse funds a wide range of research on drugtype Cannabis, including long and short-term effects on behavior, pain, mental illness,
brain development, use and abuse, and impacts of policy changes related to marijuana
(National Institute of Health and National Institute on Drug Abuse 2018a; National
Institute of Health and National Institute on Drug Abuse 2018b). Additionally, the NIH
provides support for researching cannabinoids as separate constituents. Funding for CBD
related research is reported as $36M (2015 - 2017) and projected to be $36M for 2018 2019 (National Institute of Health and National Institute on Drug Abuse 2018b), while
cannabinoid related research is reported as $366M from 2015 - 2017 and projected to be
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$292M for 2018 - 2019 (National Institute of Health and National Institute on Drug
Abuse 2018a).
Recent research has documented that NIDA provided Cannabis has distinctly
different cannabinoid profiles than commercially available Cannabis (Vergara et al.
2017). Specifically, Vergara et al. (2017) found that NIDA samples contained only 27%
of the amount of THC and 48% of CBD levels of commercially available Cannabis. The
substantial chemical differences between NIDA and commercially available Cannabis
raises significant questions about whether research conducted with federal Cannabis is
indicative of the experience consumers are having.
Medical research on Cannabis primarily focuses on THC and CBD (Baron 2018;
Borgelt et al. 2013; Citti et al. 2018; Cousijn et al. 2018; Maa and Figi 2014; Minkin
2014; National Institute of Health and National Institute on Drug Abuse 2018a, 2018b),
but there are hundreds of other chemical constituents in Cannabis (ElSohly 2007),
including cannabinoids and terpenes, which have largely been ignored (Baron 2018).
There is evidence to suggest that chemical constituents in various combinations and
abundances work in concert in various ways to create the suite of physiological effects
reported (Baron 2018). The chemical makeup of each variant of Cannabis is influenced
by the genetic makeup as well as environmental conditions. Given that previous research
has determined the cannabinoid levels of research grade marijuana from NIDA is
significantly different from commercially available Cannabis (Vergara et al. 2017),
genetic investigations are warranted to determine if NIDA Cannabis is genetical distinct
from other sources.
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In the current study we investigated the genetic relationship of NIDA provided
Cannabis to commercially available drug-type strains, as well as feral and cultivated
hemp. Ten variable nuclear microsatellite regions were used to examine genetic
differentiation among our samples. Sampling included NIDA (High THC and High
THC/CBD), high THC drug-type, low THC/high CBD drug-type, wild growing hemp
(presumed escapees from cultivation), and commercial hemp. This study aimed to
investigate where research grade marijuana supplied by NIDA falls on the genetic
spectrum of Cannabis groups.
Methods
Sampling
A total of 49 Cannabis samples were used in this research (Table 7), including:
wild hemp (5), cultivated hemp (4), NIDA strains (2), high CBD drug-type strains (3),
and drug-types strains (35). Drug-type strains were further subdivided into three
commonly used categories: Sativa (11), Hybrid (14), and Indica (10) based on
information available online (Leafly 2018b; Wikileaf 2018). The drug-type strains were
randomly chosen from a much larger pool of samples. Duplicate accessions within strains
were not included.
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Table 3.1. Sampling Information. Sample names, ID code, accession number/ strain name, and the suppliers name and location
Name
Wild Hemp 1
Wild Hemp 2
Wild Hemp 3
Wild Hemp 4
Wild Hemp 5
Wild Hemp 6
Wild Hemp 7
Wild Hemp 8
Wild Hemp 9
NIDA THC
NIDA THC/CBD
Otto (High CBD)
Juanita La Lagrimosa
Fuck Cancer
Durban Poison
El Dorado
Hawaiian
Sour Diesel
Island Sweet Skunk
Agent Orange
Cinderella 99
AK-47
Gorilla Glue #4
Golden Goat
Green Crack
Bruce Banner
Flo

ID Code
1019
24845
25572
22831M
28381M
UnkM
Cara#2_4
Carm
CoGo
NIDA_THC
NIDA_THC-CBD
Otto1
JLL_2
FuCa
DuPo_19
ElDo_1
Hawa_9
SoDi_2a
ISS_1
AgOr_1
Cin99_1
AK47_21
GoGl#4_20
GoGo_19
GrCr_2b
BrBa_19
Flo_9

Accession/ Strain Name
Hemp 1019
Hemp 24845 Male
Hemp 25572 Male
Hemp 22831 Male
Hemp 28381 Male
Hemp Unknown Male
Hemp Cara#2
Hemp Carmagnola
Hemp Colorado Gold
NIDA High THC
NIDA THC/CBD
Otto (High CBD)
Juanita La Lagrimosa (High CBD)
Fuck Cancer
Durban Poison
El Dorado
Hawaiian
Sour Diesel
Island Sweet Skunk
Agent Orange
Cinderella 99
AK-47
Gorilla Glue #4
Golden Goat
Green Crack
Bruce Banner
Flo

Supplier Origin
DBG Herbarium
DBG Herbarium
DBG Herbarium
UNC Herbarium
DBG Herbarium
Cannabis Genomic Research Initiative
Cannabis Genomic Research Initiative
Colorado Seed, Caren Kershner
Colorado Seed, Caren Kershner
Univ. of Mississippi
Univ. of Mississippi
Centennial Seeds
Nature's Herbs and Wellness
Matt Kahl
The Kind Room
Smokey's 420
Best Colorado Meds
Nature's Herbs and Wellness
Smokey's 420
Nature's Herbs and Wellness
Smokey's 420
Herbal Alternative
Colorado Wellness
The Kind Room
Nature's Herbs and Wellness
The Kind Room
Best Colorado Meds

City

State

Denver
Denver
Denver
Greeley
Denver
Boulder
Boulder
Co. Springs
Co. Springs
Mississippi
Mississippi
Co. Springs
Garden City
Co. Springs
Denver
Garden City
Fort Collins
Garden City
Garden City
Garden City
Garden City
Denver
Denver
Denver
Garden City
Denver
Fort Collins

Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
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Table 3.1. continued
Name

ID Code

Accession/ Strain Name

Supplier Origin

City

State

Pineapple Express
Purple Haze
White Widow
Jack Herer
OG Kush
Blue Dream
Tahoe OG
Chem Dawg
Banana Kush
Chem Dawg D
Girl Scout Cookie
G13
Lemon Diesel
Hash Plant
Australian Hash Plant
Bubba Kush 98
Mother of Berries
Northern Lights
Grape Ape
Purple Kush

PiEx_2
PuHa_22
WhWi_1
JaHe_12
OGKu_21
BlDr_19
TaOG_11
ChDa_8
BaKu_2
ChDaD_19
GSC_14
G13_10
LeDi_2
HaPl_1
HaPlAu_1
Bub98_19
MoBe_2
NoLi_15
GrAp_16
PuKu_19

Pineapple Express
Purple Haze
White Widow
Jack Herer
OG Kush
Blue Dream
Tahoe OG
Chem Dawg
Banana Kush
Chem Dawg D
Girl Scout Cookie
G13
Lemon Diesel
Hash Plant
Australian Hash Plant
Bubba Kush
Mother of Berries
Northern Lights
Grape Ape
Purple Kush

Nature's Herbs and Wellness
Lucy Sky
Smokey's 420
The Milkman
Herbal Alternative
The Kind Room
KindCare
The Station
Nature's Herbs and Wellness
The Kind Room
Day & Night
Infinite Wellness
Nature's Herbs and Wellness
Smokey's 420
Smokey's 420
The Kind Room
Nature's Herbs and Wellness
CannaExpress
Slow Burn
The Kind Room

Garden City
Denver
Garden City
SLO
Denver
Denver
Fort Collins
Boulder
Garden City
Denver
SLO
Fort Collins
Garden City
Garden City
Garden City
Denver
Garden City
SLO
Union Gap
Denver

Colorado
Colorado
Colorado
California
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
California
Colorado
Colorado
Colorado
Colorado
Colorado
Colorado
California
Washington
Colorado

Toro Bora

ToBo_4

Toro Bora

Cannabis Genomic Research Initiative

Boulder

Colorado
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Deoxyribonucleic Acid Extraction
Deoxyribonucleic acid was extracted using a modified CTAB extraction protocol
(Doyle 1987) with 0.035- 0.100 grams of dried flower tissue per extraction. The
Cannabis draft genome from ‘Purple Kush’ (GenBank accession AGQN00000000.1) was
scanned for microsatellite repeat regions using MSATCOMMANDER-1.0.8-beta
(Faircloth 2008). Primers were developed de-novo flanking thirty microsatellites with 3-6
nucleotide repeat units and optimized for temperature and magnesium concentration. One
primer in each pair was tagged with a 5’ universal sequence (M13, CAGT or T7) so that a
matching sequence with a fluorochrome tag could be incorporated via PCR following the
protocol of Schwabe et al. (2013). Microsatellite primers were optimized (Table 2.4)
(Schwabe and McGlaughlin 2018), and ten loci were amplified and analyzed using the
Microsatellite Analysis External Plugin ver. 1.4.5 (Biomatters Ltd.) in GENEIOUS ver.
8.1.8 (Biomatters Ltd.).
Statistical Analyses
GENALEX ver. 6.4.1 (Peakall and Smouse 2006; Peakall and Smouse 2012) was
used to calculate pairwise genetic differentiation (FST) and Nei’s genetic distance (D)
between each of the six groups. PCoA eigenvalues calculated in GENALEX were used to
plot the PCoA in RStudio with the ggplot package (R Studio Team 2015) with 95%
confidence intervals ellipses. GENALEX was also used to generate a pairwise genetic
distance square matrix which was then used to generate a hierarchical cluster analysis
dendrogram with Ward’s method and Euclidean Genetic distance parameters in PC-ORD
(McCune and Mefford 1999).
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Genotypes were analyzed using the Bayesian cluster analysis program
STRUCTURE ver. 2.4.2 (Pritchard et al. 2000). Burn-in and run-lengths of 50,000
generations were used with ten independent replicates for each STRUCTURE analysis.
The number of genetic groups for the data set was determined by STRUCTURE
HARVESTER (Earl and vonHoldt 2012), which implements the Evanno et al. method
(Evanno et al. 2005).
Maverick v1.0.5 (Verity and Nichols 2016) was used as an additional verification
of Bayesian clustering analysis using thermodynamic integration to determine the
appropriate number of genetic groups. The following parameters were used: admixture
parameter (alpha) of 0.03 with a standard deviation (alphaPropSD) of 0.008, 10 replicates
(mainRepeats), 1,000 Burn-in iterations (mainBurnin), 5,000 sample iterations
(mainRepeats), 100 TI rungs (thermodynamicRungs), 500 TI Burn-in iterations
(thermodynamicBurnin), and 1,000 TI iterations (thermodynamicSamples).
EDENetworks ver. 2.18 (Kivela et al. 2015) was used to construct a web of
genetic relationships using the Linear Manhattan distance measure. Auxiliary data were
imported to maintain the spatial coordinates and to color individuals by group
assignment. The automatic percolation threshold was first derived, and threshold was set
to 8.1. Networks were generated for subsequent iterative threshold intervals of 0.5.
Increasing the threshold lowers the stringency for genetic relationships, and as the
threshold increases, more relationships are formed in the network. EDENetworks
diagrams were constructed for the percolation threshold of 8.1, 8.5, 13.7 and 16.9. These
are the values that connect: NIDA samples to each other, but not to any other samples in
the data set (8.5), connect a single NIDA sample to the larger network (13.7), and finally
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connect all samples in the network (16.9). The size of each node is proportionate to the
number of relationship connections to other members in the network. The line color and
width indicated the strength of the relationship between two individuals- lighter thicker
lines indicate stronger genetic relationships, while the darker thinner lines indicate
weaker genetic relationships.
Results
Our analyses examined the genetic differentiation and structure of samples from
six groups: 1) NIDA – research grade marijuana samples obtained from NIDA classified
as High THC or High THC/CBD; 2) Hemp – Cannabis obtained from hemp cultivators
and feral collected hemp; 3) High CBD – drug-type Cannabis with relatively high levels
of CBD and low levels of THC; and commercially available drug-type Cannabis
described as 4) Sativa, 5) Hybrid, or 6) Indica strains. Analyses were also performed on
samples at the individual level to control for biases that might arise due to the potential
artificial nature of named groups and varying group sample sizes.
Genetic Differentiation
Pairwise genetic differentiation (Fst and Nei’s D) calculated in GENALEX ver.
6.4.1 (Peakall & Smouse 2006, Peakall & Smouse 2012) found the highest level of
divergence between hemp and high CBD drug-type strains (Fst = 0.215) and between
hemp and Sativa drug-type strains (Nei’s D = 0.614) (Table 8). The least divergence was
observed among the drug-type strains (Fst = 0.023-0.04; Nei’s D = 0.66-0.109) (Table
3.2).
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Table 3.2. Genetic Differentiation. Pairwise Fst values (below the diagonal) and
Nei’s D (above the diagonal) for major Cannabis groups.
NIDA
NIDA
Hemp
High CBD
Sativa
Hybrid
Indica

0.120
0.166
0.114
0.117
0.078

Hemp
0.519
0.215
0.160
0.149
0.124

High CBD
0.527
0.489
0.137
0.135
0.121

Sativa
0.553
0.614
0.329
0.04
0.035

Hybrid
0.48
0.585
0.310
0.098

Indica
0.441
0.459
0.281
0.109
0.066

0.023

Clustering Analysis
Principal Coordinate Analysis (PCoA) was conducted in GENALEX and plotted
in R Studio with the ggplot package (R Studio Team 2015) with 95% confidence interval
ellipses around the major groups (Figure 8). No confidence intervals were drawn for
NIDA (n = 2) or High CBD (n = 3) due to small sample size. Coordinate 1 explains
13.26% of the genetic variation and an additional 11.39% of the genetic variation is
explained by coordinate 2. The drug-type strains (Indica, Sativa, Hybrid, and High CBD)
all occupy the same character space. There is clear separation of hemp samples from the
drug-types, with NIDA samples clustering within the hemp confidence interval.
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Figure 3.1. Principal Coordinates Analysis. 95% confidence intervals are around the
major groups (hemp = yellow, NIDA = blue, High CBD = orange, Sativa = red, Hybrid =
green, Indica = purple). Approximately 25% of the genetic variation in these groups is
shown (coordinate 1= 13.26% and coordinate 2 = 11.39%). No confidence intervals were
drawn for NIDA or High CBD samples due to the small sample size (n = 2 and n = 3,
respectively).

PC-Ord version 6 (McCune and Mefford 1999) was used to generate a
dendrogram with Ward’s method and Euclidean Genetic distance parameters based on
pairwise genetic distance values generated in GENALEX (Figure 3.2). The initial
branching split the samples into two clusters, A and B. Cluster A contains all but one
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hemp sample (88%), as well as the NIDA samples (100%) and two drug-type samples
(5%). Cluster B contains the remaining drug-type samples (95%) and one hemp sample
(12%). Cluster B further branches into three clusters (C, D, and E), where Sativa, Hybrid
and Indica drug type strains are dispersed throughout.
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Wild Hemp 1
NIDA THC
NIDA THC/CBD
Colorado Gold
Wild Hemp 5

A

Durban Poison
Hash Plant
Wild Hemp 2
Wild Hemp 3
Wild Hemp 4
Unknown Male Hemp
Carmagnola
C. ruderalis
Juanita La Lagrimosa
Fuck Cancer
Bruce Banner
OG Kush
Grape Ape

C

Hawaiian
Otto
Jack Herer
Pineapple Express
Mother of Berries
Purple Haze
Australian Hash Plant
Cinderella 99
Green Crack
Golden Goat
Island Sweet Skunk
Blue Dream
Jilly Bean
Flo
G13

D

Agent Orange

B

Lemon Diesel
Northern Lights
AK-47
White Widow
Sour Diesel
Chem Dawg D
Gorilla Glue #4
Eldorado
Girl Scout Cookies

E

Banana Kush
Tahoe OG
Bubba Kush 98
Chem Dawg
Purple Kush
Tora Bora

Figure 3.2. PC-Ord group linkage dendrogram. Samples are color-coded (Hemp =
yellow, NIDA = blue, High CBD = orange, Sativa = red, Hybrid = green, Indica =
purple).
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STRUCTURE ver. 2.4.2 (Pritchard et al. 2000) was used to examine sample
assignment to genetic groups while allowing admixture. The appropriate number of
STRUCTURE groups was validated using STRUCTURE HARVESTER (Earl and
vonHoldt 2012), which had high support two genetic groups (K = 2, ∆K = 67.68) and
weak support for three genetic groups (K = 2, ∆K = 4.48) (Figure 3.3).

Figure 3.3. STRUCTURE HARVESTER graph showing high support for two
genetic groups (K = 2, ∆K = 67.68). There is weak support for three genetic groups (K =
2, ∆K = 4.48).

Additionally, MavericK 1.0.5 (Verity and Nichols 2016) was used to independently test
group assignments, which also had strong support for two genetic groups (K = 2,
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probability 0.901) and weaker support for three genetic groups (K = 3, probability 0.097)

0.6
0.4
0.0

0.2

posterior probability

0.8

1.0

(Figure 3.4), with the sample assignments matching STRUCTURE.
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2
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6

7

8

9

10

K

Figure 3.4. MavericK 1.0.5 thermodynamic integration evidence estimates
normalized to a sum of 1.0.

The two genetic group STRUCTURE analyses (Figure 3.5) show consistent
differentiation between hemp and drug-type strains. All hemp samples were assigned to
genetic group 1 (yellow) with a proportion of inferred ancestry (Q) greater than 0.82
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(hemp mean group 1, Q = 0.94). Drug-type samples showed some admixture with the
majority of the genetic signal of 31 samples (82%) being assigned to genetic group 2
(drug-type mean group 2, Q = 0.72). NIDA samples were assigned to genetic group 1
(NIDA mean group 1, Q = 0.97), demonstrating a strong association with hemp.
Although not strongly supported, the three genetic group analysis shows some additional
genetic structure among drug-type strains.

K=2

K=3

Figure 3.5. Bayesian clustering analysis from STRUCTURE. The proportion of
inferred ancestry for two genetic groups (K = 2, top), and for three genetic groups (K = 3,
bottom).
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Genetic Relatedness Network
EDENetwork ver. 2.18 (Kivela et al. 2015) was used to generate a web of genetic
relationship based on pairwise linkages (Figure 3.6). The automatically selected
percolation threshold was 8.1 (Figure 3.6A), although not all individuals were connected
at this level. The threshold was raised iteratively to connect more divergent samples and
explore larger patterns of genetic relationships. The two NIDA samples were united at a
threshold of 8.5 (Figure 3.6B). When the threshold was raised to 13.7 (Figure 13C) the
NIDA samples become connected to the network via the drug-type sample Eldorado. At a
threshold level of 16.9 (Figure 3.6D) all samples in the data set are included in the
relationship network.
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Figure 3.6. EDENetworks genetic relationship network with incrementally decreasing stringency of required genetic relatedness among samples in the
data set. (A) Threshold 8.1: the percolation threshold determined by the analysis. (B) Threshold 8.5: the threshold required to connect NIDA samples to each
other, but not to any other samples in the data set. (C) Threshold 13.7: the threshold necessary to connect the NIDA sample to the larger network with the
connection via the drug-type strain Eldorado. (D) Threshold 16.9: the required threshold to connect all samples in the network. Nodes are colored to indicate
group designation (Hemp = yellow, NIDA = blue, High CBD = orange, Sativa = red, Hybrid = green, Indica = purple). Node size is proportionate to the number
of connections to that individual within the network. Lines thinner and lighter in color indicate weak genetic relationships, while thicker darker lines indicate
stronger relationships.
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Discussion
The purpose of this study was to examine the genetic relationship of Cannabis
samples from the National Institute on Drug Abuse (NIDA) to hemp and drug-type
samples. Our results clearly demonstrate that NIDA Cannabis samples are substantially
different from most commercially available drug-type strains, sharing a genetic affinity
with hemp samples in most analyses. Previous research has found that medical and
recreational Cannabis from California, Colorado and Washington, differs significantly in
cannabinoid levels from the research grade marijuana supplied by NIDA (Vergara et al.
2017). Our genetic investigation adds to this previous research, indicating that the genetic
makeup of NIDA Cannabis is also distinctive from commercially available medical and
recreational Cannabis.
The genetic data collected in this study indicates that two major genetic groups
exist within Cannabis sativa. The first group contained a majority of hemp (88 - 100%,
depending on analysis) and both NIDA samples (100%), while the second group
contained a majority of drug-type samples (82 - 95%). These results contribute to the
growing consensus that hemp and drug-type Cannabis can be consistently differentiated
(Datwyler and Weiblen 2006; Dufresnes et al. 2017; Forapani et al. 2001; Hakki et al.
2007; Lynch et al. 2016; McPartland 2006; Sawler et al. 2015; Soler et al. 2017). This is
the first genetic study to include research grade marijuana from NIDA, and its placement
with hemp samples was unexpected. However, it is important to note that some drug-type
samples (e.g. Durban Poison, Figure 3.2, 3.4) are also placed in the hemp group.
Although the sample size of NIDA samples could impact their placement in group-based
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analyses such as genetic distances (Table 3.2), all other analyses were carried out at an
individual level (Figure 3.1, 3.2, 3.4, 3.5) to avoid this issue.
According to the University of Mississippi National Center for Natural Products
Research (NCNPR), which produces research grade marijuana for NIDA, the first
experimental plots of Cannabis were planted in 1968 with seeds from “Mexico, Panama,
Southeast Asia, Korea, India, Afghanistan, Iran, Pakistan, and Lebanon” (Khan 2018;
University of Mississippi 2017). Over the next decade, cultivation techniques were
standardized, with over 100 varieties planted in 1976 (University of Mississippi 2017).
Between the late 1970’s and today, the University of Mississippi has continued to be the
sole producer of research grade marijuana for NIDA, and it has refined cultivation
techniques and extraction procedures, particularly for THC and CBD (Mississippi 2017).
The program does not provide variety or strain information when filling Cannabis orders,
so it is unclear what is currently grown by NCNPR for federally funded marijuana
research. The NCNPR director recently stated that “The marijuana project currently
stocks 27 plant varieties with different cannabinoid profiles, various CBG potencies, and
a wide range of THC levels” (Khan 2018). However, the NCNPR website states that only
three Cannabis varieties were grown in 2014 (University of Mississippi 2017). Our data
suggest that the NIDA Cannabis analyzed in this study was sourced from a single strain
or two very closely related strains within the NCNPR stock. Without additional
information about NCNPR Cannabis production, it is difficult to know how many strains
are being used in research
This study indicates the need for additional research and refinement of our
understanding of Cannabis genetic structure and how those difference might impact
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Cannabis consumers. Although medicinal research on Cannabis has predominantly
focused on THC and CBD (Baron 2018; Borgelt et al. 2013; Citti et al. 2018; Cousijn et
al. 2018; Maa and Figi 2014; Minkin 2014; National Institute of Health and National
Institute on Drug Abuse 2018a, 2018b), it is becoming apparent that other chemical
constituents in various combinations and abundances likely have important effects (Baron
2018). If researchers are solely interested in the effects of THC and CBD at know
concentrations, then NIDA Cannabis could serve as a representative source, although in
these cases, isolates of these molecules may be more appropriate. However, given the
genetic distinction between NIDA and commercially available Cannabis, patients in
federally funded Cannabis research are likely experiencing effects that are specific to the
plant material provided by NIDA. As the interest for medical Cannabis increases, it is
important that research examining the threats and benefits of Cannabis use accurately
reflect the experiences of the general public.
Given the rapidly changing landscape of Cannabis regulations and consumption
(ProCon 2018b), it is not surprising that commercially available Cannabis contains a
diversity of genetic types. Commercially available Cannabis has come to market through
non-traditional means leading to many inconsistencies. We have previously documented
(Schwabe and McGlaughlin 2018) that there is substantial genetic divergence among
samples within named strains, which only exacerbates questions about the impacts of
Cannabis consumption. This calls to increase regulation and consistency within the
Cannabis marketplace, and the need for research grade Cannabis to accurately represent
what consumers have access to.
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Conclusion
In conclusion, this study highlights the genetic difference between research grade
marijuana provided by NIDA and commercial Cannabis available to medical and
recreational users. This finding highlights that research conducted with NIDA Cannabis
may not be indicative of the effects that consumers are experiencing. Additionally,
research has found that Cannabis distributed by NIDA has lower levels of the principal
medicinal cannabinoids (THC and CBD) and higher levels of degradation byproducts of
cannabinoids (cannabinol, CBN) (Vergara et al. 2017). Taken together, these results
demonstrate the need for there to be greater diversity of Cannabis available for medical
research and that the genetic provenance of those samples to be established to fully
understand the implications of results.
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Abstract
There are thousands of Cannabis varietals (strains) which are generally described
based on psychotropic effects and phytochemical profile. Recent research has found that
aroma profiles are distinctive among strains, but also that multiple accessions of the same
strain from different sources show genetic inconsistencies. Genetic variation may lead to
differences in consumer-relevant phenotypic traits such as terpene content, and therefore
differences in aroma. By combining molecular genotyping and olfactory phenotyping
techniques, we sought to determine whether genetically inconsistent samples within a
commercial strain display inconsistent aroma profiles. We genotyped 42 samples from
five strains to determine the consensus genotype as well as genetic outliers (if any) based
on 10 variable microsatellite regions. Results were used to select four strains (15
samples) for olfactory testing: “Blue Dream” (5), “OG Kush” (4), “Mob Boss” (3), and
“Durban Poison” (3). A genetic outlier sample was included for each strain except
“Durban Poison”, which served as a control where all samples had an identical genetic
profile. Aroma profiles were produced by 55 untrained sniff panelists (33 men, 22
women) using check-all-that-apply ballots with 40 previously validated odor descriptors.
The sensory aroma profile for the “Mob Boss” genetic outlier was at odds with the
consensus samples as well as the strain’s previously observed aroma profile. All “OG
Kush” samples displayed the strain-typical aroma profile previously described, but the
genetic outlier expressed a high-scoring yet atypical “cheese” note. The pungent,
chemical, and skunk descriptors were reported far more often in the “Blue Dream”
genetic outlier than the for the consensus samples. Although all three samples of “Durban
Poison” were genetically identical, the scent profiles do not seem to follow a particular
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pattern, which could be due to different growing, curing, storing or age differences
among dispensaries. It appears that within-strain differences identified by microsatellite
genotyping are associated with differences in aroma profile.
Introduction
Cannabis has been domesticated and cultivated for millennia for fiber, seed and
the psychotropic qualities of Δ9-tetrahydrocannabinol (THC) from the female flower
(Clarke and Merlin 2015; Small 2015a; Small 2016, 2017). Recent legalization in many
states (National Conference of State Legislatures 2018) and a handful of countries
worldwide has created a flourishing retail industry. Marijuana Business Daily estimates
retail Cannabis sales in the U.S. may reach as high as $7.3 billion in 2019 (Marijuana
Business Daily 2017). Currently, there are thousands of described strains (Leafly 2018b;
NCSM 2018; PotGuide.com 2018; Wikileaf 2018) sold as dried flower “buds” that vary
in levels of psychotropic cannabinoids and also emit characteristic aromas. The aroma of
Cannabis is striking and quite unique, and, while some find the odor quite overwhelming
and noxious, many people enjoy the aroma and appreciate the subtle nuances among
strains. The subtleties underlying the characteristic earthy skunky odor of Cannabis often
contribute to the multitude of creative strain names. “Sour Diesel” as one can imagine is
pungent and possesses a characteristic diesel aroma. Strains with names such as “Cherry
Pie”, “Lemon Haze”, “Lavender” and “Banana Kush” lend a suggestion as to their scent.
Aromatic terpene molecules in various combinations and abundances are
responsible for creating unique odors associated with Cannabis. The terpene profile of
each plant is the result of genotype and environmental conditions (Elzinga et al. 2015), is
variable over time as the plant matures (Aizpurua-Olaizola et al. 2016) and is also
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presumably impacted by differences in curing (drying) techniques, and time in storage.
Chemical profile, including terpene profile, has been suggested as a possible mechanism
of identification for Cannabis cultivars (Casano et al. 2011). Presumably, like other
plants such as grapes (de Boubee et al. 2000; Jackson and Lombard 1993) and hops
(Patzak et al. 2010; Pavlovic et al. 2012; Sharp et al. 2014), phytochemical production in
Cannabis is influenced by soil, nutrients, temperature, carbon dioxide, and light, among
other environmental factors (Figueiredo et al. 2008). Since chemical profiles change over
time, and there are no standard growing conditions yet defined for the Cannabis industry,
it is unclear if differences in aromatic profiles are due to changes in terpenes over time
and/or differences in growing conditions, or perhaps a reflection of genetic variation, or a
combination of variables. Steep Hill (Steep Hill Analytics and Research, Berkeley CA)
has produced “strain fingerprints” for multiple strains, which are chemical profiles that
reportedly characterize ranges of cannabinoids and terpenes specific to strains. The strain
fingerprints were initially published on the online strain database Leafly providing details
about the levels of seven cannabinoids (THC,CBD, CBN, CBG, THCV, CBC, and CBL)
and five terpenes (linalool, -myrcene, a-pinene, D-limonene, and -caryophyllene), but
they have since been replaced with a set of three icons that describe the dominant flavors
of the strain (Leafly 2018b). For example, “Green Crack” flavors are described as earthy,
citrus and sweet (Leafly 2018b).
With the legalization of marijuana in many jurisdictions, expert cultivators and
connoisseurs are emerging. Cultivators are crossing strains and creating a wide diversity
of new strains with an array of aromas and taste profiles. Competitions, such as the
Cannabis Cup, allow cultivators to present and connoisseurs to judge aromas, effects, and
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quality of novel strains. Retail experts, such as behind-the-counter personnel referred to
as “budtenders”, ideally have knowledge about strains and their unique characteristics,
especially those in high demand. Scent profiles within a strain should be highly similar,
as they are labeled as the same product, presumably with similar genotypes. Several
recent genetic studies (Lynch et al. 2016; Sawler et al. 2015; Schwabe and McGlaughlin
2018; Soler et al. 2017) have found genetic differences among samples within Cannabis
strains, which is interesting as Cannabis strains are often produced through cloning
methods. Cloning propagation in the legal Cannabis industry is often preferred over seed
germination for several reasons, arguably the most important being the ability to produce
consistent products for consumers. Although genetic variation can result in phenotypic
variation, the extent to which genetics might play a role in Cannabis strain aroma was
previously unknown. Similarities in phenotype, including scent profile, may be a factor
leading to misidentification and could be one reason why variation in genetic profiles has
been found within strains.
Previous work has identified two dominant aroma groups among a small number
of retail strains (Gilbert and DiVerdi 2018). These two groups were described as Cluster
A with earthy, woody and herbal aromas, and Cluster B with citrus, lemon, sweet and
pungent aromas (Gilbert and DiVerdi 2018). This study included duplicate samples of
two strains, “Durban Poison” and “G13”, and both accessions of “G13” fell within
Cluster A, while both accessions of “Durban Poison” fell in Cluster B. The “Durban
Poison” samples were purchased from different dispensaries and were separated from one
another in the cluster. The two “G13” samples were purchased from the same dispensary
and had the same harvest date. These samples grouped together as having highly similar
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profiles in Cluster A. The researchers were investigating olfactory lexicons to
characterize Cannabis strains available in the recreational market, but the results raised
some interesting questions in light of recent genetic research.
We wondered if genetically anomalous samples labeled as the same strain would
have different detectable odors from those that were genetically cohesive. We
purposefully identified genetic outliers in a set of otherwise genetically cohesive samples
obtained from multiple sources to determine if genetic anomalies are detected through
validated sensory methods. In order to assess if genetic anomalies within a strain have
different aromas, molecular genotyping and olfactory phenotyping techniques were
combined in a two-part study. Based on previous research (Schwabe and McGlaughlin
2018), we determined that in order to maximize our chances of capturing both a
consensus and outlying genetic profile, 6-10 samples needed to be collected from
different retail facilities. Five strains were chosen based on reported availability at
dispensaries and aromatic profile clusters previously described by Gilbert and DiVerdi
(2018). Forty-two samples from five strains were genotyped using ten previously
published variable short repeating regions of DNA (microsatellites) (Schwabe and
McGlaughlin 2018) to determine the consensus genotype and find genetic outliers (if
any). For the sensory portion, we predetermined that 15 samples were needed in order to
obtain reliable results and not present too many samples in a single setting. These two
combined studies aim to demonstrate whether or not genetic anomalies within strains
have different odors from samples with a highly similar genotype.
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Methods
Genetic Methods
Strain selection. Recreational dispensary strain information was researched
online (Weedmaps 2018) to determine which strains were most likely to be available
from multiple sources. Online scent profiles (Leafly 2018b) were examined to select a
subset of strains with reportedly unique scent profiles in order to minimize aromatic
similarity of the strains to include in the olfactory analysis. Fifteen strains were crossreferenced with the results from Gilbert and DiVerdi (2018), and five strains were chosen
based on reported availability at dispensaries and aromatic profile (Table 4.1). “Durban
Poison” was selected as having an aromatic profile representative of the citrus, lemon,
sweet, pungent group (Cluster B) (Gilbert and DiVerdi 2018). “OG Kush” is reportedly
unique in both genetic and aromatic profiles (Elzinga et al. 2015; Gilbert and DiVerdi
2018; Leafly 2018b) and was selected as having an aromatic profile representative of the
earthy, woody, herbal group (Cluster A) (Gilbert and DiVerdi 2018). “Sour Diesel” was
chosen as it was previously observed to have aromatic properties of both groups (Clusters
A and B) (Gilbert and DiVerdi 2018) and is described online as earthy, pungent, and
diesel (Leafly 2018b). “Blue Dream” had not previously been analyzed for aromatic
profile. However, because the online odor descriptors of berry, blueberry, and sweet
(Leafly 2018b) indicated this strain might be unique compared to the others, it was
chosen for inclusion in the olfactory perception analysis. During sample acquisition,
“Mob Boss” was available at many locations, so it was collected in addition to the
previously chosen strains. Gilbert and DiVerdi (2018) placed “Mob Boss” in the earthy,
woody, herbal group (Cluster A) (Gilbert and DiVerdi 2018). Both “Mob Boss” and “OG
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Kush” have the same earthy, pine, and woody descriptors described online (Leafly
2018b).
Table 4.1. The number of samples of five selected Cannabis strains. The
Scent Cluster assignment (Gilbert & DiVerdi 2018), and the Leafly database
scent profile (Leafly 2018b).
Strain
Sample number Scent Cluster
Leafly
Durban Poison

8

B

earthy, pine, sweet

OG Kush

8

A

earthy, woody, pine

Sour Diesel

10

A/B

diesel, pungent, earthy

Blue Dream

10

unknown

sweet, berry, blueberry

Mob Boss

6

A

pine, pungent, sweet

(A) earthy, woody, herbal (B) citrus, lemon, sweet, pungent

Genetic material. A total of 42 retail Cannabis samples were purchased from 25
recreational Cannabis dispensaries in six Colorado cities (Table 4.2). The names for each
dispensary have been withheld to protect the identity of businesses where genotypes may
deviate from the norm. The locations of the dispensaries in this experiment were chosen
based solely on the availability of strains. A minimum of six samples of each strain were
collected. All samples were purchased legally over-the-counter. The dispensary weighed
2 grams of each sample, and these samples are labeled as ‘SN’, indicating eligibility for
the scent analysis in the olfactory portion of this study. Additional samples were added to
the genetic study, labeled as ‘GN’, in order to capture the variation contained in a strain,
without the intention of using them in the olfactory portion of this study. Purchase
receipts and original packaging labels were retained for reference.
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Table 4.2. Information for all samples included in the genetic portion of this
study.
Strain
Durban Poison

Location

Date Acquired

Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Fort Collins
Aug 6 2018
Garden City
Aug 7 2018
Breckenridge
May 9 2018
Garden City
April 28 2018
OG Kush
Denver
Aug 7 2018
Denver
Aug 7 2018
Fort Collins
Aug 6 2018
Denver
Aug 7 2018
Denver
Aug 9 2018
Denver
Aug 9 2018
Denver
Aug 9 2018
Denver
Aug 7 2018
Sour Diesel
Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Fort Collins
Aug 6 2018
Garden City
Aug 6 2018
Garden City
Aug 7 2018
Denver
Aug 7 2018
Frisco
May 9 2018
Breckenridge
May 9 2018
Frisco
May 9 2018
Blue Dream
Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Fort Collins
Aug 6 2018
Garden City
Aug 6 2018
Denver
Aug 9 2018
Breckenridge
May 9 2018
Frisco
May 9 2018
Breckenridge
May 9 2018
Mob Boss
Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Denver
Aug 7 2018
Fort Collins
Aug 7 2018
Boulder
Aug 8 2018
*Labeled with the same grower and same lot number

Sample ID
DuPo_1SN
DuPo_2SN
DuPo_3SN
DuPo_4SN
DuPo_5SN
DuPo_6SN
DuPo_7GN
DuPo_8GN
OGKu_1SN*
OGKu_2SN
OGKu_3SN
OGKu_4SN*
OGKu_5SN*
OGKu_6SN
OGKu_7SN
OGKu_8GN
SoDi_1SN
SoDi_2SN
SoDi_3SN
SoDi_4SN
SoDi_5SN
SoDi_6SN
SoDi_7SN
SoDi_8GN
SoDi_9GN
SoDi_10SN
BlDr_1SN
BlDr_2SN
BlDr_3SN
BlDr_4SN
BlDr_5SN
BlDr_6SN
BlDr_7SN
BlDr_8GN
BlDr_9GN
BlDr_10GN
MoBo_1SN
MoBo_2SN
MoBo_3SN
MoBo_4SN
MoBo_5SN
MoBo_6SN
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Deoxyribonucleic acid extraction, Polymerase Chain Reaction and fragment
analysis. Deoxyribonucleic acid was extracted using a modified CTAB extraction
protocol (Doyle 1999) with 0.035-0.100 g of dried flower tissue per extraction. Ten
primers developed de-novo from the ‘Purple Kush’ genome were used to amplify DNA
fragments containing variable microsatellite regions as described in Chapter II (Schwabe
and McGlaughlin 2018).
Genetic statistical analysis. GENALEX ver. 6.4.1 (Peakall and Smouse 2006;
Peakall and Smouse 2012) was used to calculate Lynch & Ritland (Lynch and Ritland
1999) mean pairwise genetic relatedness (r) within each strain. A genetic pairwise
relatedness heat map for each strain was generated in Microsoft EXCEL. Samples with
identical genotypes share 100% genetic identity (r-value = 1.00), first order relatives (full
siblings or mother-daughter) share 50% genetic identity (r-value = 0.50), second order
relatives (half siblings or cousins) share 25% genetic identity (r-value = 0.25), and
unrelated individuals are expected to have an r-value of 0.00 or lower. PCoA
eigenvalues were calculated in GENALEX and plotted in RStudio (R Studio Team 2015)
with the ggplot package (Wickham 2016) with 95% confidence interval ellipses.
GENALEX was also used to generate a pairwise genetic distance square matrix to
generate a hierarchical cluster analysis dendrogram with Ward’s method and Euclidean
Genetic distance parameters in PC-ORD (McCune and Mefford 1999). Genotypes were
analyzed using the Bayesian cluster analysis program STRUCTURE ver. 2.4.2 (Pritchard
et al. 2000). Burn-in and run-lengths of 100,000 generations were used with ten
independent replicates for each STRUCTURE analysis. STRUCTURE HARVESTER
(Earl and vonHoldt 2012), which implements the Evanno et al. (2005) method, was used
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to determine the K value that best describes the number of genetic groups for the data set.
Missing data for seven of ten “Blue Dream” samples at one locus did not change the
results when removed, therefore all analyses in GENALEX and STRUCTURE were
conducted using ten loci.
Sample selection. The samples included in the sensory portion of this study were
chosen based on the results of the genetic analysis (see Genetic Results section). The
“Sour Diesel” samples obtained for this study did not have enough genetic variation in
any of the samples to be considered for the sensory portion. The selected samples were
assigned a random identification number for the double-blind olfactory study (Table 4.3).
Neither the study conductor nor the participant was provided information to disclose the
name of the strain.
Table 4.3. Samples used in the olfactory study. The Sample ID is included with
genetic outliers identified with and asterisk and the random Sample Code.
Strain

Sample ID

Sample Code

Durban Poison

DuPo_1SN
DuPo_4SN
DuPo_5SN
OGKu_1SN*
OGKu_2SN
OGKu_3SN
OGKu_4SN
BlDr_1SN
BlDr_3SN*
BlDr_4SN
BlDr_5SN
BlDr_6SN
MoBo_1SN
MoBo_3SN
MoBo_5SN*

245
351
403
584
752
781
437
925
116
700
307
312
187
482
659

OG Kush

Blue Dream

Mob Boss

99
Sensory Methods
Odor Stimuli
Odor stimuli consisted of 15 cannabis samples drawn from four strains: “Durban
Poison” (3), “OG Kush” (4), “Blue Dream” (5), “Mob Boss” (3). Each stimulus (1 g of
dried cannabis flower) was presented in a wide mouth 118 mL (4 oz) amber glass bottle
labeled with a three-digit code (Figure 4.1). Samples were kept in a freezer at -2° C and
thawed at room temperature for two hours before testing. The stimuli were exchanged for
fresh samples midway through the study. Our use of strain designations provided by the
retail dispensaries was a matter of convenience; it does not imply a position regarding the
taxonomic validity or botanical derivation of these strains. Our goal was to characterize
olfactory variation in commercially available offerings.

Figure 4.1. Samples (1 gram) of dried Cannabis flower. Samples were presented to
participants in wide mouth 118 mL (4 oz) amber glass bottles labeled with a three-digit
code.
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Odor Descriptors
Forty odor descriptors were chosen from online sources that describe
characteristic scents for strains (Gilbert and DiVerdi 2018; Leafly 2018b) (Table 4.4).
Due to the wide variety of strains and descriptive scent characters, the selection aimed to
include the majority of previously detected odors in a variety of Cannabis strains (Gilbert
and DiVerdi 2018).

Table 4.4. The 40 odor descriptors used to characterize the samples in this study in
alphabetical order.
Ammonia
Apricot
Berry
Blue cheese
Butter
Cheese
Chemical
Chestnut
Citrus
Coffee

Diesel
Earthy
Flowery
Grape
Grapefruit
Herbal
Honey
Lavender
Lemon
Lime

Mango
Menthol
Mint
Nutty
Orange
Peach
Pepper
Pine
Pineapple
Pungent

Rose
Sage
Skunk
Spicy
Sweet
Tea
Tobacco
Tropical fruit
Violet
Woody

Rating Scales and Presentation
Participants rated each sample using a Check All That Apply (CATA) ballot with
40 descriptors, presented in alphabetical order on a single screen of a touch-screen device
(Apple iPad 2). Data were automatically entered into a spreadsheet; scale presentation
and data collection were designed using free online services (Google Forms and Google
Sheets).
Ethics Statement
This study protocol was approved by the Western Institutional Review Board
(Puyallup, Washington) (WIRB Protocol #20170080). All participants provided informed
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written consent using a form approved by WIRB. At no time did participants come into
direct contact with the Cannabis samples. Retail sale of marijuana for recreational use to
adults 21 years of age and older has been legal in the state of Colorado since January 1,
2014.
Participants
Test participants were recruited from Fort Collins and vicinity. Participants from a
previous study (Gilbert and DiVerdi 2018) who indicated a willingness to participate in
further research were re-contacted. A notice (text approved by WIRB) was posted to an
online bulletin board for the local community. Printed text emphasized “current, former,
and non-users all welcome” and that only sniffing was required (“no touching, no
smoking, no eating”). All participants were at least 21 years of age, residents of
Colorado, and had a self-reported normal sense of smell. Exclusion criteria included selfreported pregnancy, active nasal allergy, and current head cold. Subjects were paid
$20.00 for their participation.
Sensory Statistical Analyses
A Friedman’s nonparametric repeated-measures ANOVA was performed on the
summed frequencies for each odor descriptor across all samples within a given strain
using SPSS Statistics v. 24 (IBM Corp. 2016). A Wilcoxon signed-rank test on all
pairwise combinations of samples within each strain (analogous to post-hoc t-tests in
ANOVA) was conducted using SPSS Statistics v. 24 (IBM Corp. 2016). Calculations for
histograms and tables were conducted using Microsoft Excel.
Within strain scent profiling was analyzed using two measures: Perceived Shared
Character Category and Cannabis Lexicon Category. For the Perceived Shared Character
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Category analyses aroma descriptors were assigned to one of five categories by A.
Schwabe. The five Perceived Shared Character Categories were: “Earthy” which
included soil, buttery, nutty or roasted aromas, “Spicy” which included spices and dried
leafy scents, “Sweet” which included scents associated with fruits, “Floral” scents as
fresh plants/flowers, and “Pungent” which included sharp and/or unpleasant aromas
(Table 4.5).
Table 4.5. Perceived Shared Character categories. Each of the 40 odor descriptors
assigned to one of five categories. The total number of descriptors is in parentheses.
Earthy (7)
Spicy (6)
Sweet (14)
Floral (6) Pungent (7)
Earthy
Herbal
Apricot
Flowery
Ammonia
Butter
Sage
Berry
Lavender
Skunk
Coffee
Pepper
Citrus
Rose
Cheese
Pine
Spicy
Grape
Violet
Chemical
Woody
Tea
Grapefruit
Mint
Blue cheese
Nutty
Tobacco
Lemon
Menthol
Pungent
Chestnut
Lime
Diesel
Mango
Orange
Peach
Pineapple
Citrus
Sweet
Tropical fruit
Honey

For the Cannabis Lexicon Category analyses, aroma descriptors were assigned to four
categories by combining characters of two Cannabis lexicons, the Terpene Flavor Wheel
©

(The Holden Company and Western Cultured 2016) and The Flavor Wheel TM (Green

House Seed Company 2018). The wheels are similar, but a combination of the two was
used to capture all 40 scent descriptors used in this study. The four categories in
Cannabis Lexicon Categories were “Sweet”, “Sour”, “Spicy” and “Bitter” (Table 4.6).
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Table 4.6. Cannabis Lexicon Categories. Each of the 40 odor descriptors
assigned to one of four categories. The total number of descriptors is in
parentheses.
Sweet (12)
Sour (8)
Spicy (9)
Bitter (11)
Apricot
Berry
Flowery
Grape
Honey
Mango
Peach
Pineapple
Rose
Sweet
Tropical fruit
Violet

Blue cheese
Butter
Cheese
Citrus
Grapefruit
Lemon
Lime
Orange

Herbal
Lavender
Menthol
Mint
Pepper
Pine
Sage
Spicy
Woody

Ammonia
Chemical
Chestnut
Coffee
Diesel
Earthy
Nutty
Pungent
Skunk
Tea
Tobacco

The Perceived Shared Character Category and Cannabis Lexicon Category data
were analyzed separately for the genetically cohesive samples and for the genetic outlier
sample. A frequency of detection scale was calculated for each sample by dividing the
total number of positive detections by the number of descriptors in the category
multiplied by the number of samples in the strain group, multiplied by 55 (the number of
possible positive detections) (Equation 1).
∑positive detections
55 (n descriptor x n strain samples)

Equation 1.

The frequency of detection metric normalizes the data and allows for comparisons across
categories with different numbers of scents, as well as across strain groups with different
numbers of samples. The range of the frequency of detection scale is 0.00-1.00, where
zero means no participants detected any scents in that category, and 1.00 means every
participant detected every scent in the category. Given the subjective and personal nature
of olfactory ratings, we would not expect to see a value of 1.00. Histograms for the
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frequencies were generated in Excel to compare differences in the mean frequencies of
the genetic consensus sequences compared and the genetic outlier. As these are
frequencies of detection, the data were normalized to demonstrate the scent profile of
consensus versus outlier samples in each strain.
Genetic Results
Genetic Relatedness
Lynch & Ritland (Lynch and Ritland 1999) pairwise genetic relatedness within
each strain was calculated in GENELEX (Figure 4.2). Values of r = 1.00 are indicative of
identical individuals as observed in clones. Values of r < 0 between two individuals
indicate the individuals have a very low level of relatedness. Samples 1SN, 4SN and 5SN
in “Durban Poison” were identical (r = 1.00) and 8GN was a genetic anomaly compared
to the other samples (r = -0.18; Figure 4.2C). Samples 2SN and 3SN, and 6SN and 8GN
in “OG Kush” had a high level of genetic relatedness (r = 1.00 and r = 0.91,
respectively), and other pairwise relatedness between samples were low to moderate (r
=0.06 – 0.75; Figure 4.2D). Samples 1SN, 4SN, 7SN and 10GN in “Sour Diesel” had a
high level of genetic relatedness (r =0.91 - 1.00), and the remaining samples had
moderate to low genetic relatedness (r =-0.19 - 0.72; Figure 4.2B). Samples 1SN, 2SN,
4SN, 5SN, 6SN, and 8GN in “Blue Dream” were genetically identical (r = 1.00), and
3SN had a very low level of relatedness to all identical samples in the set (r = - 0.21;
Figure 4.2A). Samples 1SN and 3SN in “Mob Boss” were identical (r = 1.00) and 5SN
had a very low level of relatedness to all identical samples in the set (r = -0.29 – 0.05;
Figure 4.2E).
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A

Blue Dream
1SN

2SN

3SN

4SN

5SN

6SN

1.00
1.00
1.00
0.58

-0.21
-0.21
-0.21
-0.10

1.00
1.00
0.58

1.00
0.58

0.58

1.00
1.00

1.00
1.00

-0.21
-0.17

1.00
1.00

1.00
1.00

0.40

0.40

-0.07

0.40

0.40

2SN
3SN

1.00
-0.21 -0.21

4SN
5SN
6SN
7SN

1.00
1.00
1.00
0.58

8GN
9GN
10GN

B

7SN

8GN

1.00
1.00

0.58
0.58

1.00

0.40

0.15

0.40

9GN

2SN

2SN
3SN
4SN

0.49
0.16
0.95

0.00
0.35

0.23

5SN

0.52

0.18

-0.08

0.53

6SN
7SN

0.39
0.91

0.11
0.55

-0.02
0.01

0.37
0.72

0.13
0.44

0.33

8GN

0.15

0.21

-0.08

0.08

0.40

0.01

9GN

-0.19 -0.07 -0.07 -0.17 -0.13 -0.06 -0.13 -0.05

10GN 0.91

0.55

3SN

0.01

4SN

0.72

5SN

0.44

6SN

7SN

8GN

2SN
3SN
4SN
5SN
6SN
7SN
8GN

D
0.55

Sour Diesel
1SN

C

9GN

2SN

3SN

*4SN *5SN

6SN

7SN

2SN 0.12
3SN 0.12
*4SN 0.15
*5SN 0.12
6SN 0.06
7SN 0.43
8GN -0.28

1.00
0.44
0.71
0.40
0.75
0.39

0.44
0.71
0.40
0.75
0.39

0.29
0.28
0.44
0.17

0.40
0.91

0.14

0.21
1.00

0.21

OG Kush
*1SN

E

0.33

Durban Poison
1SN 2SN 3SN 4SN 5SN 6SN 7SN
-0.03
0.17 0.17
1.00 -0.03 0.17
1.00 -0.03 0.17 1.00
0.19 0.51 0.15 0.19 0.19
0.00 -0.14 -0.02 0.00 0.00 0.01
-0.18 0.08 -0.02 -0.18 -0.18 -0.03 -0.09

-0.13

2SN
3SN
4SN
5SN
6SN

0.29
0.51
0.30

Mob Boss
1SN

2SN

4SN

5SN

0.79
1.00 0.79
0.84 0.51 0.77
-0.22 -0.29 -0.17 -0.17
0.38 0.56 0.83 0.36

3SN

0.05

Figure 4.2. Lynch & Ritland pairwise genetic relatedness within each strain. Values
of r = 0.50 are indicative identical as observed in clones, r < 0 indicates a low level of
genetic relatedness. “OG Kush” samples 1SN, 4SN and 5SN (asterisk) were labeled with
the same Retail Marijuana Cultivation Facility and the same lot number even though they
were purchased from different dispensaries.

Clustering Analyses
Principal Coordinates Analysis (Figure 4.3) was conducted in GENALEX and
plotted using the ggplot package in R Studio with 95% confidence interval ellipses
around the major groups (Figure 4.3) (R Studio Team 2015). The samples that fell
outside the confidence intervals, “OG Kush” 1 SN, “Blue Dream” 3SN, and “Mob Boss”
5SN were considered genetic outliers (Figure 4.3).
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Figure 4.3. Principal Coordinate Analysis generated using ggplot in R Studio (R
Studio Team 2015). The samples are colored by strain name, and 95% confidence
interval ellipses are drawn around each cluster.

STRUCTURE ver. 2.4.2 (Pritchard et al. 2000) was used to examine individual
assignment to genetic groups. STRUCTURE HARVESTER (Earl and vonHoldt 2012)
calculated the appropriate number of STRUCTURE groups using the Evanno method
(Evanno et al. 2005). This data set had extremely high support for three genetic groups
(K = 3, ∆K = 216.07) and weak support for two or six genetic groups (Figure 4.4).
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Figure 4.4. STRUCTURE HARVESTER output as calculated using the Evanno
method, showing robust support for three genetic groups (K = 3) in this data set ( K =
216.07).
The three groups represented in STRUCTURE are color coded as blue (group 1),
green (group 2) and yellow (group 3) (Figure 4.5). All but one sample of “OG Kush” was
comprised largely of group 1 genetic assignment (blue, 87.1- 98.9 %); sample 1SN had
only 20.5 % group 1 genetic assignment and 78.1 % assignment to group 3 (yellow). All
but one sample of “Blue Dream” was largely assigned to group 2 (green, 91.2 - 98.6 %);
sample 3SN had a 98 % assignment to group 3 (yellow). The remaining samples from
“Durban Poison”, “Mob Boss”, and “Sour Diesel” were assigned to group 3 (66.8 – 98.8
%). “Durban Poison” 8GN was assigned to group 2 (green, 74.8 %), but there was not
enough sample for the sensory study. However, “Durban Poison” 2SN and “Mob Boss”
5SN had relatively low assignment to group 3 (66.8 % and 69.5 % respectively) and were
considered in this analysis to be comparative outliers. All samples of “Sour Diesel” were
assigned to group 3 (yellow, > 95%).
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Figure 4.5. STRUCTURE graph with the proportion of genetic assignment to each
of the three genetic groups as indicated by the proportion of each color in each bar
representing an individual. “OG Kush” samples 1SN, 4SN and 5SN (asterisk) were
labeled with the same Retail Marijuana Cultivation Facility and the same lot number even
though they were purchased from different dispensaries.

Two dendrograms were created based on pairwise genetic distance values labeled
with the sample names and color coded by strain (Figures 4.6, 4.7). The analysis of all 42
samples (Figure 4.6) showed an initial split of “OG Kush” from the remaining samples.
Within the remaining strains there was clear groups consisting of seven “Blue Dream”,
four “Mob Boss”, three “Durban Poison”, and six “Sour Diesel” samples.
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Blue Dream (BlDr)
Mob Boss (MoBo)
Sour Diesel (SoDi)
OG Kush (OGKu)
Durban Poison (DuPo)

Figure 4.6. PC-Ord hierarchical genetic cluster analysis based on genetic distance
color coded by strain. Clear genetic outliers assigned to a conflicting cluster are
indicated by the arrows. “Durban Poison” and “Sour Diesel” samples span several
clusters therefore no clear genetic outlier is indicated. “Blue Dream” (BlDr) samples are
blue, “Mob Boss” (MoBo) samples are green, “Sour Diesel” (SoDi) are red, “OG Kush”
(OGKu) samples are purple, and “Durban Poison” (DuPo) samples are yellow.
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Sample Selection for the
Sensory Study
Genetic relatedness, PCoA clustering, genetic structure, and hierarchical
clustering based on genetic distance clearly identified genetic outliers and consensus
samples within strains, with the exception of “Sour Diesel” which was omitted from the
sensory study. The genetic outliers “Durban Poison” 8GN, “OG Kush” 1SN, “Blue
Dream” 3SN, and “Mob Boss” 5SN consistently showed differentiation from the other
samples in the strain, but there was insufficient sample of “Durban Poison” 8GN to be
included in the study. Three identical “Durban Poison” samples were included to
examine scent variation among samples with identical genotypes. The remaining 12
samples selected for the sensory study had either identical or an extremely high degree of
genetic similarity (Table 4.2). Samples from the sensory selection were included in a
second dendrogram to confirm clustering and genetic outliers (Figure 4.7).

Blue Dream (BlDr)
Mob Boss (MoBo)
OG Kush (OGKu)
Durban Poison (DuPo)

*
*
*

Figure 4.7. Hierarchical genetic cluster analysis of the cannabis samples. Arrows
indicates genetic outliers. “Blue Dream” (BlDr) samples are red, “Mob Boss” (MoBo)
samples are green, “OG Kush” (OGKu) samples are purple, and “Durban Poison” (DuPo)
samples are yellow.
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Sensory Results
Subject Demographics
Fifty-five people (33 men, 22 women; mean age 29.5 ± 7.8 years) were tested. Of
these, all but eight had purchased Cannabis since January 1, 2014, and all but five
subjects had smoked it. The high rates of purchase (85.5%) and use (90.9%) among study
participants occurred despite efforts to recruit former and non-users as well. Seven
subjects (12.7%) had taken part in previous cannabis sniff studies (Gilbert & DiVerdi
2018; Gilbert & DiVerdi, submitted).
Hierarchical Cluster Analysis
Hierarchical cluster analysis (HCA) yielded a configuration consisting of two
large clusters, designated as Cluster A’ and Cluster B’ (Figure 21). Previous sensory
research examining scent profiles in Cannabis found two clusters and designated them as
Cluster A and Cluster B (Gilbert and DiVerdi 2018). To avoid confusion between the
previous work and the present study, we designated the two main clusters from this work
as Cluster A’ and Cluster B’ (Figure 4.8). We feel that Gilbert and DiVerdi’s (2018)
Cluster A and Cluster B largely correspond to the current Cluster A’ and Cluster B’, but
there are some minor discrepancies. Cluster A’ contains “OG Kush”, as it was previously
assigned to Cluster A and described as citrus, lemon, sweet and pungent (Gilbert and
DiVerdi 2018). Cluster A’ contained all four samples of “OG Kush”, which scored high
on earthy, woody, and herbal descriptors, which is consistent with previous aromatic
profiling and descriptions online (Gilbert and DiVerdi 2018; Leafly 2018b). Cluster B’
contains “Durban Poison”, as it was previously assigned to Cluster B, and described as
citrus, lemon, sweet, pungent (Gilbert and DiVerdi 2018). However, in this analysis two
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samples of “Durban Poison” were described as sweet, citrus, flowery, lemon, and the
third was described as herbal, woody, flowery, and earthy, differing from Gilbert and
DiVerdi (2018). This is the first study to provide olfactory analysis of the “Blue Dream”
strain, and the results are ambiguous; three samples were assigned to Cluster B’, while
two samples, including the genetic outlier, were assigned to Cluster A’. “Mob Boss” was
previously grouped with strains in Cluster A (earthy, woody, herbal) (Gilbert and
DiVerdi 2018). In this study, only one sample of “Mob Boss” was characterized this way
(MoBo_3SN), with the other two samples, including the genetic outlier, assigned to
Cluster B’.

B’

A’

Figure 4.8. Hierarchical cluster analysis (HCA) for 15 samples included in the sensory study
containing two large clusters, Cluster B’ and Cluster A’. Strains are color coded and arrows
indicate the genetic outlier for each if the strains. All “Durban Poison” samples were genetically
identical. “Blue Dream” (BlDr) samples are blue, “Mob Boss” (MoBo) samples are green, “OG
Kush” (OGKu) samples are purple, and “Durban Poison” (DuPo) samples are yellow.
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Within Strain Descriptor Profiles
The aim of this study was to assess if the aroma profile of an anomalous genetic
sample differed from those of the consensus samples. As a first effort, a Friedman’s
nonparametric repeated-measures ANOVA was performed on the summed frequencies
for each odor descriptor across all samples within a given strain. All four strains returned
significant chi-square values (Table 4.7). Thus, for example, aroma profiles of the five
samples of “Blue Dream” differ significantly.
Table 4.7. Results of Friedman’s test on the summed frequencies for each odor
descriptor across all samples within a given strain for each Cannabis strain. The
number of samples (N) in each strain, along with the Chi-square value, degrees of
freedom (df) and asymptotic significance (Asymp. Sig).
Blue Dream
Mob Boss
OG Kush
Durban Poison
N
5
3
4
3
Chi-Square
117.668
69.398
107.223
91.776
df
39
39
39
39
Asymp. Sig.
0.000
0.002
0.000
0.000
This analysis, however, does not address differences between specific samples
within a strain, and in particular, if an anomalous sample differed from consensus
samples. A Wilcoxon signed-rank test on all pairwise combinations of samples within
each strain (analogous to post-hoc t-tests in ANOVA) was conducted. None of these
pairwise comparisons yielded a statistically significant difference. We are not the first to
note that this is a paradoxical result, given the significant results of the overall Friedman
tests (Zimmerman and Zumbo 1993).
In order to assess the question of within strain aromatic differences with special
interest to the genetic outlier, characterization of within-strain aroma differences was
analyzed using the number of times particular odor descriptors were reported among the
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participants. The five most frequently endorsed odor descriptors for each sample were
identified and pooled within each strain. This resulted in 12 pooled descriptors for both
“Blue Dream” and “Durban Poison”, nine for “Mob Boss”, and eight for “OG Kush”.
Frequency counts for each descriptor were averaged across a strain’s consensus samples
and compared to the counts for the genetic outlier sample (Figures 4.8 – 4.11).
The results for “Durban Poison” were interesting and somewhat unexpected.
Although three samples were genetically identical, all three differed across the 12 pooled
descriptors (Figure 4.9, Table 4.8). However, when examining the pooled five most
frequently endorsed odor descriptors of the consensus samples of “Blue Dream”, “Mob
Boss” and “OG Kush” (Figure 4.10, Table 4.8) there is also evidence of inconsistency in
the aromas of the genetically cohesive samples of all strains. In order to examine the
aroma consistency of “Durban Poison” we calculated the mean, standard deviation, and
average standard deviation of the top descriptors for the consensus samples for each
strain (Table 4.7). Since the strains have different aromas, we focused on the range of
standard deviations and the average standard deviation: “Durban Poison” standard
deviation range = 2.08-7.64, average standard deviation = 4.29; “OG Kush” standard
deviation range = 1-7.57, average standard deviation = 4.37; “Blue Dream” standard
deviation range = 2-7.18, average standard deviation = 5.12; and “Mob Boss” standard
deviation range = 0.71-8.49, average standard deviation = 3.22.
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Figure 4.9. Detection frequency of top-rated odor descriptors for “Durban Poison”.
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Figure 4.10. Detection frequency of top-rated descriptors for consensus samples of
“Blue Dream”, “Mob Boss” and “OG Kush” and the mean for each descriptor.
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Table 4.8. Frequencies plus mean and standard deviation of the top five pooled odor descriptors for the genetic consensus samples of
"Durban Poison", "OG Kush", "Blue Dream" and "Mob Boss".
Flowery Herbal
Citrus
Sweet
Earthy
Woody
Lemon Lavender Pungent
Sage
Tea
Pine
DuPo_1SN
DuPo_4SN
DuPo_5SN
Mean
SD

OGKu_2SN
OGKu_3SN
OGKu_4SN
Mean
SD

BlDr_1SN
BlDr_4SN
BlDr_5SN
BlDr_6SN
Mean
SD

MoBo_1SN
MoBo_3SN
Mean
SD

15
23
19
19.00
4.00

15
19
21
18.33
3.06

19
22
12
17.67
5.13

20
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15
17.00
2.65

19
11
17
15.67
4.16

13
6
21
13.33
7.51

11
21
6
12.67
7.64
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The results for “OG Kush” (Figure 4.11) show that the genetic outlier sample was
far more cheesy and less pungent and tea-like, than the mean of the consensus samples.
“OG Kush” was characterized by Gilbert and DiVerdi (Gilbert and DiVerdi 2018) as
having the earthy/woody/herbal aroma profile characteristic of Cluster A. All the “OG
Kush” samples in the present study, including the genetic outlier, were rated highly on
these three descriptors, confirming the earlier results. The fact that cheese was a
relatively frequently endorsed descriptor for the anomalous genetic sample is noteworthy:
cheese was not a highly ranked descriptor for any of the 11 strains tested previously
(Gilbert and DiVerdi 2018). The blue cheese descriptor was also reported more than
twice the frequency for the outlier than the consensus samples. Although blue cheese was
not in the five most frequently endorsed odor descriptors, it lends more evidence for the
unusual scent profile of the genetic outlier in the set. Thus, the “OG Kush” genetic outlier
was distinctive from both the strain-typical profile, as well as the consensus samples.
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Figure 4.11. Detection frequency of top-rated odor descriptors for “OG Kush”
samples; error bars indicate standard deviation from the mean of the consensus samples.
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The results for “Blue Dream” (Figure 4.12) show that the genetic outlier was far
more pungent, chemical, and skunk-like than the mean of the four consensus samples.
HCA configuration (above) indicates that two “Blue Dream” samples align with Cluster
A’, and three with Cluster B’. Despite this anomalous result, within-strain comparison
shows the genetic outlier sample to have unique and marked differences from the other
samples.

Figure 4.12. Detection frequency of top-rated odor descriptors for “Blue Dream”
samples; error bars indicate standard deviation from the mean of the consensus samples.

The results for “Mob Boss” (Figure 4.13) show that the genetic outlier was
strikingly more flowery, sweet, and berry-like, and less woody and chemical than the
consensus samples. Gilbert & DiVerdi (Gilbert and DiVerdi 2018) found that “Mob
Boss” has an earthy/woody/herbal aroma profile typical of Cluster A strains. The
consensus genetic samples of “Mob Boss” tested here fit the Cluster A profile: they were
described as earthy/woody/herbal/chemical and woody/earthy/citrus/chemical,
respectively. In contrast, the description of the genetic outlier sample (MoBo_5SN) as
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flowery/sweet/herbal/berry was at odds with both the consensus samples and the
previously established Cluster A profile.
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Figure 4.13. Detection frequency of top-rated odor descriptors for “Mob Boss”
samples; error bars indicate standard deviation from the mean of the consensus samples.
Additional Within-Strain
Scent Profiling Analyses
In order to lend a more holistic analysis of the aroma profiles, the 40 odor
descriptors (Table 4.4) were broken down into smaller subsets which included categories
of scents based on broad characters common to the scents included in each category.
These categories were then used to determine if there were differences in overall
characteristic aromas between the samples within strains that were identified as
genetically cohesive and the sample identified as the genetic outlier (Table 4.3).
Within Strain Scent Profiling:
Perceived Shared Character
Categories
The Perceived Shared Character Category analyses was used to determine if
genetics consensus and outlier samples differ when organized by categories including all
scents. The “OG Kush” outlier was identified as pungent and earthy, but less sweet than
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the consensus samples (Figure 4.14C). The genetic outlier of Blue Dream” was far more
pungent than the consensus samples (Figure 4.14A). The genetic outlier of “Mob Boss”
has unique and marked differences from the other samples in that it was identified as
floral and sweet, and less pungent (Figure 4.14B). “Durban Poison” was not included in
this analysis as all the samples were genetically identical.

Table 4.9. Shared Character Category Frequency of Detection. Scores for each
scent category (Pungent, Sweet, Floral, Earthy, Spicy) for the genetic consensus
samples and the genetic outlier.
Pungent Sweet
Floral
Earthy Spicy
Blue Dream
Mob Boss
OG Kush

Consensus Mean
Outlier
Consensus Mean
Outlier
Consensus Mean
Outlier

A

0.074
0.239
0.117
0.068
0.087
0.133

0.084
0.074
0.070
0.157
0.123
0.058

0.081
0.085
0.068
0.194
0.049
0.091

0.139
0.135
0.111
0.099
0.149
0.210

0.141
0.142
0.099
0.124
0.152
0.148

B

Consensus Mean

Consensus Mean

C

Consensus Mean

Figure 4.14. Shared Character Category Histograms. Frequency of Detection Scores
of Pungent, Sweet, Floral, Earthy, Spicy detected among the samples by the 55
participants for “Blue Dream” (A), “Mob Boss” (B) and “OG Kush” (C).
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Within Strain Scent Profiling:
Cannabis Lexicon Categories
A second analysis looking at the impact of grouping scents used Cannabis
Lexicon Categories. With these groupings, the “OG Kush” outlier identified far more
similarly to the consensus samples but was less bitter (Figure 4.15C). The genetic outlier
of Blue Dream” was far more bitter than the consensus samples (Figure 4.15A). The
genetic outlier of “Mob Boss” was identified as sweet, with less spicy and bitter notes
(Figure 4.15B). “Durban Poison” was not included in this analysis as all the samples were
genetically identical.
Table 4.10. The Frequency of Detection Scores. Scores for each Cannabis Lexicon
Category for the genetic consensus samples and the genetic outlier.
Sweet
Sour
Spicy
Bitter
Consensus Mean
0.105
0.158
0.158
0.130
Blue Dream
Outlier
0.063
0.139
0.139
0.195
Consensus
Mean
0.079
0.155
0.155
0.170
Mob Boss
Outlier
0.202
0.129
0.129
0.074
Consensus Mean
0.068
0.162
0.162
0.170
OG Kush
Outlier
0.068
0.162
0.162
0.132
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Figure 4.15. Histograms for Frequency of Detection Scores of each Cannabis
Lexicon category (Sweet, Sour, Spicy and Bitter). Frequency of categorical scents
detected among the samples by the 55 participants for “Blue Dream” (A), “Mob Boss”
(B) and “OG Kush” (C).
Discussion
In the present study we purposefully targeted Cannabis strains with different
scent profiles and sought to evaluate if genetic variation manifests as discrepant aromatic
characterization. Using the combination of previously published genotyping methods and
olfactory phenotyping techniques, a two-part study was designed to uncover the
relationship between genotype and phenotype in Cannabis. First, samples were collected
and genotyped to identify cohesive samples and genetic outliers in five strains. Then, a
sensory study was conducted using non-expert participants to determine if participant
descriptors aligned with the genetic results.
Genetic analyses were conducted on multiple samples of targeted strains to
identify genetically cohesive and outlier samples. Previous research (Schwabe and
McGlaughlin 2018) (Chapter II) found genetic variability in “Durban Poison”, “OG
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Kush”, “Sour Diesel” and “Blue Dream”, and although “Mob Boss” had not been
genotyped, all strains analyzed showed variation. The genetic results were clear and
robust with support for three genetic groups (Figures 4.4 and 4.5). Relatedness statistics
and clustering analyses revealed four of five strains had a cohesive genetic signal in the
majority of the samples, and one clear genetic outlier. The requirement for samples
selection for the sensory portion were that the genetically cohesive and outlying samples
were supported in each of the analyses conducted. Two strains, “OG Kush” and “Blue
Dream”, had consistent consensus genotypes with a clear outlier, fitting the requirements
for inclusion in the sensory study. The outlier for “Mob Boss” was not as divergent but
fulfilled the requirements for sensory inclusion. “Sour Diesel” had no consistent genetic
outlier, and therefore was not included in the sensory study, even though this strain
reportedly has a unique aromatic profile (Gilbert and DiVerdi 2018; Leafly 2018b).
“Durban Poison” had a clear outlier, but there was not enough sample tissue to be
included in the sensory portion. However, three identical “Durban Poison” samples were
chosen to serve as a control to examine scent variation among samples with identical
genotypes.
Fifteen samples from four strains were selected for inclusion in the sensory study:
“Durban Poison” (3), “OG Kush” (4), “Blue Dream” (5), and “Mob Boss” (3) (Table
4.3). Clustering analysis of the sensory data was at odds with the clustering analysis of
the genetic data (Figure 4.7 and 4.8). Three “Durban Poison” were assigned to Cluster A’
indicating a degree of aroma similarity. Four “OG Kush” samples were assigned to
Cluster B’. Genetic consensus samples of “Blue Dream” were assigned to both Cluster A’
(1) and Cluster B’ (3), indicating some dissimilarity between those genetic consensus
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samples. One genetic consensus sample of “Mob Boss” was assigned each to Cluster A’
and B’, indicating some dissimilarity between those genetic consensus samples. The
genetic outliers for “OG Kush”, “Blue Dream”, and “Mob Boss” clustered with at least
one genetic consensus sample.
Analysis of variance (ANOVA) revealed samples within strains differed
significantly from one another (Table 4.7). This is evident in “Durban Poison” where
frequently endorsed odor descriptors show a high degree of variation, even though the
genotypes are identical (Figure 4.9). “Blue Dream” and “Mob Boss” with identical
genotypes, and “OG Kush” (4SN) with difference at one locus, all had a high degree of
variation in the frequently endorsed odor descriptors (Figure 4.10). Due to this variation,
a method to uncover within strain aromatic differences with special interest to the genetic
outlier was needed. As this type of study combining genetic and sensory data had not
previously been published, a novel approach was required. The first approach was to pool
the five most frequently reported strain descriptors for the genetic consensus samples for
each strain. The mean frequency for each descriptor for the genetic consensus samples
was compared to the number of reports for the descriptor for the genetic outlier. This
analysis revealed substantial differences in the aromatic profiles of the outliers in each
strain (Figures 4.10 - 4.12). The second approach used categories of scents to calculate
frequencies of detection in each category to compare aroma profiles of the genetic
consensus samples to the genetic outlier. Two different scent category profiles were
created, one from perceived shared characters (Shared Characteristics Category) and one
from Cannabis flavor lexicons (Cannabis Lexicon Category). Both the profiles returned
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at least one category in which the genetic outlier was considerably different than those of
the genetic consensus samples (Figures 4.14 and 4.15).
“OG Kush” is reportedly a clone only strain (Chapter II) described online as
woody, pine and earthy (Leafly 2018b) and is assigned to Gilbert and DiVerdi’s (2018)
earthy, woody and herbal Cluster A. Hierarchical Cluster Analysis of the scent data
grouped all “OG Kush” samples, including the genetic outlier, in Cluster A’ with the
genetic outlier nested with consensus samples (Figure 4.8). Analyses using frequently
endorsed odor descriptors (Figure 4.11) indicate the “OG Kush” outlier had less of a tea
scent and a distinctive cheese aroma when compared to the consensus samples. The
standard deviation from the mean of the consensus samples of the 11 pooled descriptors
ranged from 1.0 (woody) to 7.57 (pungent) (Figure 4.10, Table 4.8). Analysis of
frequencies in scent categories show the genetic outlier in “OG Kush” is less sweet and
more earthy according to Shared Character Category (Figure 4.14C) and more bitter
according to Cannabis Lexicon Category (Figure 4.15C) relative to consensus samples.
The odor descriptors reported for all “OG Kush” samples align with consumer
expectations as earthy, woody and herbal (Figure 4.11), however the outlier has some
unique aromatic qualities that separate it from the consensus samples (Figure 4.11, 4.14C
and 4.15C) indicating the genetic outlier could be identified using sensory perception
methods.
“Blue Dream” is reportedly a clone-only strain (Chapter II) described as having
blueberry, berry and sweet flavors (Leafly 2018b) but has not been previously described
using validated sensory methods (Gilbert and DiVerdi 2018). Hierarchical Cluster
Analysis of the scent data split the “Blue Dream” samples over the two major scent
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clusters with two samples, including the genetic outlier, in a cluster A’, and the remaining
three samples in Cluster B’ (Figure 4.8). HCA was unable to differentiate the “Blue
Dream” outlier. Further analyses using frequently endorsed odor descriptors (Figure 4.12)
indicate the “Blue Dream” outlier was less herbal and tea, but far more pungent, chemical
and skunk aromas were detected compared to the consensus samples. The standard
deviation from the mean of the consensus samples of the 10 pooled descriptors ranged
from 2.0 (herbal) to 7.18 (tea) (Figure 4.10, Table 4.8). Analysis of frequencies in scent
categories show that the genetic outlier in “Blue Dream” is overwhelmingly more
pungent according to Shared Character Category (Figure 4.14A) and bitter according to
Cannabis Lexicon Category (Figure 4.15A) than consensus samples. The odor
descriptors reported for the outlier do not align with consumer expectations as a
blueberry, berry and sweet strain, indicating the genetic outlier could be identified using
sensory perception methods.
“Mob Boss” is described online as woody, pine and earthy (Leafly 2018b) and is
assigned to Gilbert and DiVerdi’s (2018) earthy, woody and herbal Cluster A.
Hierarchical Cluster Analysis of the scent data split the “Mob Boss” samples over the two
major scent clusters with two samples, including the genetic outlier, in Cluster B’ and one
consensus sample in Cluster A’ (Figure 4.8). Analyses using frequently endorsed odor
descriptors (Figure 4.13) indicate the “Mob Boss” outlier was less earthy, woody and
chemical, but extensive flowery, sweet, and berry aromas were detected compared to the
consensus samples. The standard deviation from the mean of the consensus samples of
the 10 pooled descriptors ranged from 0.71 (pungent) to 8.49 (earthy) (Figure 4.10, Table
4.8). Analysis of frequencies in scent categories show the genetic outlier in “Mob Boss”
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overwhelmingly more floral (Figure 4.14B) and sweet (Figure 4.14B and 4.15B)
according to Shared Character Category, and less pungent (Figure 4.14B) and bitter
(Figure 4.15B) according to Cannabis Lexicon Category than the consensus samples. The
odor descriptors reported for the outlier do not align with consumer expectations as a
woody, pine and earthy strain. Floral, sweet, and berry (Figures 4.9, 4.14B, and 4.15B),
and are uncharacteristic of aromas associated with “Mob Boss”, indicating the genetic
outlier was identified using sensory perception methods.
“Durban Poison” is described online as earthy, pine and sweet (Leafly 2018b)
which is quite different from Gilbert and DiVerdi’s (2018) assignment to the citrus,
lemon, sweet, and pungent Cluster B. Three genetically identical “Durban Poison”
samples were selected for the sensory study (Table 4.3, Figures 4.2, 4.3, 4.5 - 4.7) to
determine variation in the scent profile of samples from different origins with no genetic
variation. The HCA assigned the three samples in to the Cluster B’ (Figure 4.8)
indicating a similar major aromatic profile among the three. The frequency of detection
for 12 descriptors (Figure 4.13) indicated there was variation in scent detection by the
participants. As these three samples were genetically identical, it would stand to reason
that they should have similar aroma profiles. This expectation was not met in “Durban
Poison” as all samples deviated from one another across the most frequently reported
odor descriptors. Moreover, there was not a single sample that consistently deviated from
the others. There was variation in scent detection by the participants in the genetic
consensus samples in all four strains. (Figure 4.13 and 4.14; Table 4.8). Additionally,
“Durban Poison” and “Blue Dream” had higher average standard deviations (4.37 and
5.12 respectively) than “Durban Poison” and “Mob Boss” (4.29 and 3.22 respectively).
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From this analysis it is clear that genetic identity alone does not control aroma profiles
and that differences were observed among consensus samples for all strains.
The utility of combining genetic and sensory methods to determine if genetic
anomalies are detectable through sensory perception was confirmed for the samples used
here. However, several challenges and limitations need to be addressed. It is unclear from
the results of this study how much variation in aromatic profiles is standard within
strains, as all the consensus sequences have scent profile variation (Figure 4.9, 4.10;
Table 4.8). Participants for sensory studies such as this are limited by sensory overload to
a maximum of 15 samples per sitting, resulting in a forced small samples size, but the
number of participants in the study give strong support for the results herein. We are
aware that sensory perception is personal and subjective, but the aim of the study was not
to identify samples, but rather to determine if genetic outliers have a different aroma
profile from genetically cohesive samples, which was achieved in the three strains with
an outlier. We are also aware that an untrained consumer panel such as that used here
tends to show greater variation in descriptor use than a highly trained expert panel. Thus,
some participants may be very lax in reporting the odors they detect, while others may be
more conservative, and of course there is everything in between. However, we feel that
the number of participants in this study well represent consumer perceptions. The data
were difficult to analyze because each 55 participants have the option to detect 40 aromas
in 15 samples, and both presence and absence of scents are considered character states.
Standard statistical analyses methods detected differences among all samples, and within
strains, but given the variation seen among genetically cohesive samples of the same
strain, standard statistical analyses were not appropriate. For this reason, the data analysis
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required a novel approach. Grouping scents into categories is novel, and not necessarily a
validated method for analyzing sensory data such as these, but this approach did reveal
differences between genetically anomalous samples and those with cohesive genotypes.
Terpenes are aromatic phytochemicals produced in many plants that contribute to
the multitude of aromas associated with leaves, flowers, and fruits, including those of
Cannabis. Previous research has found terpenes vary in concentration over time
(Aizpurua-Olaizola et al. 2016). As there are no standard growing conditions or harvest
protocols in place for the Cannabis industry, scent variation in genetically identical
samples could be due to differences in growing conditions (nutrients, light, etc.), harvest
time and/or post-harvest flower processing (Cervantes 2006) among different grow
facilities. In drug-type Cannabis strains, terpenes in flowers increase in concentration
from day 122 until about day 165 of the growth cycle when levels began to decrease
(Aizpurua-Olaizola et al. 2016). However, there is no standard time to harvest Cannabis
flowers. Maturity varies among plants, and different strains reportedly mature at different
times, ranging from 3-6 months (Leafly 2018b). Growers harvest flowers by examining
the color of the stamens and the cloudiness of the trichomes under a magnifying glass.
Growers aim to harvest at the height of THC production, which is when the stamens have
dried and turned amber and trichomes have developed a spherical head and have clear or
a creamy appearance (Figure 4.16) (Cervantes 2006). Although there have been studies
analyzing cannabinoid and terpene production over time in plants grown under
standardized conditions (Aizpurua-Olaizola et al. 2014), harvesting and processing
information are not provided to consumers, and may well be beyond what consumers are
willing to take into account when purchasing Cannabis. Our results suggest there can be
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significant variation in terpenes, as seen through aroma descriptors, even when samples
are genetically identical (Table 4.8), which could be surprising for those expecting certain
characteristics in a strain. Although this study included a relatively small sampling of
Cannabis strains, it demonstrates genetic variation is reflected in aromatic profile
differences. However, in order to determine what is a reasonable amount of variation in
scent profiles of Cannabis, more in-depth studies examining other factors known to
influence terpene production are needed.

Figure 4.16. The glandular trichomes of the female flower of Cannabis sativa at 40X
magnification.
Conclusion
The purpose of this study was to investigate if genetic inconsistencies are
reflected in aroma profiles. Strains were selected based on availability, previous
genotyping (Schwabe and McGlaughlin 2018) (Chapter II), and sensory research (Gilbert
and DiVerdi 2018). We found that the tested strains provided additional evidence that
samples of the same strain from different origins can have unexpected genetic and aroma
variation, but consensus samples seem to align with previous sensory analysis profiles
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(clusters A and B; Gilbert and DiVerdi 2018), as well as online descriptions (Gilbert and
DiVerdi 2018; Leafly 2018b). Comparison of top-rated odor descriptors revealed that,
compared to consensus samples, genetic outliers have distinctive aroma profiles. Broader
scent categories, Shared Character Category and Cannabis Lexicon Category revealed
genetic variants have different scent profiles than those of the consensus samples. In
samples with identical genotypes there were notable differences in reported aroma
descriptors, which could be attributed to differences in growing and curing processes
among different grow facilities. We believe genetic variation in the samples included
here were adequately reflected in differences in aromas, but aroma variation in samples
with highly similar genotypes is substantial, which could be the result of different
cultivation practices among different Cannabis grow facilities. These results show not
only that genetic imposters within a strain can be detected and result in aromatic
differences, but also that there is considerable variation in aromas among samples with
identical genetic identity.
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Abstract
This research investigates how genetic variation in neutral genetic markers is
related to variation in cannabinoid and terpene content of Cannabis. The expanding
Cannabis industry needs to provide consistent products to the ever-increasing customer
base in both the recreational and medical marketplaces. Sources of variation are
numerous and genetic variation has been found where there should be little to none,
especially when striving for consistency. Moreover, there are currently no widely
practiced standard growing or harvesting protocols to minimize variation among growing
facilities. Variation in growing conditions, harvest time, curing and storage conditions
can affect Cannabis chemotypes, but to what extent is largely a mystery. We conducted a
small investigation with 15 samples from four strains. Using 10 microsatellite markers,
we identified genetically cohesive samples of “Durban Poison” (n=3), “Blue Dream”
(n=4), “Mob Boss” (n=2), and “OG Kush” (n=3). We also identified one genetic outlier
for “Blue Dream”, “Mob Boss”, and “OG Kush”. We compared the chemotypes of the
genetic outliers to the genetic consensus samples to investigate whether genotypic
differences are reflected as chemotypic differences. A panel of nine cannabinoids and 21
terpenes were analyzed using HPLC-DAD and GC-MS, respectively. An additional three
strains were added to the terpene analysis to examine terpene variation among strains.
The results from this study show that cannabinoids and terpenes are highly variable
among samples independent of their genetic similarity, as well as among strains. The
relationship between genetic assignment and cannabinoid profile is less pronounced than
the terpene profile, where genetic outliers differed substantially from the consensus
samples in > 50% of the 21 terpenes analyzed. Although the sampling in this study was
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not extensive and include a relatively small number of cannabinoids and terpenes, the
results clearly demonstrate both are quantitatively and qualitatively inconsistent among
samples, and, therefore, using chemotype to identify Cannabis strains is not
recommended.
Introduction
Overview

Human driven dispersal across the globe along with cultivation for thousands of
years have resulted in many different varieties of Cannabis, which have been selected for
a multitude of desirable characters, the most notorious of which are the
phytocannabinoids. Although research on the chemical constituent differences among
Cannabis strains is abundant (e.g., Pacifico et al. 2006), there are few studies examining
the genetic contribution to chemotypic variation within strains (de Meijer and Hammond
2005; Lynch et al. 2016; Sawler et al. 2015).
Cannabis varietals are preferably propagated through cloning techniques to
ensure minimal phenotypic variation among plants within strains. For some strains, stable
seeds are available, but there is a lack of information for many of these seeds, and it is not
clear how much variation there is within seed lots from many sources. Recent research
has shown substantial genetic variation within strains from different sources (Schwabe
and McGlaughlin 2018) as well as within seeds of the same varietal (Soler et al. 2017).
Medical and recreational drug type Cannabis breeders aim to produce a consistent
product and maximize yield by using all female clones from a single mother plant. Given
that desirable Cannabis strains are grown from clones or from a single parent seed,
strains should be similar regardless of where the product was purchased. An organism’s
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physical appearance (phenotype) is a product of both environmental factors and genetic
makeup (genotype). Likewise, the chemical profile (chemotype) of Cannabis is
determined by a combination of both genotype and environmental factors. While the
chemical profile is inherited from the parents, the expression levels of the various
chemicals within each plant can vary under different growing conditions (Cervantes
2006; Fischedick et. al 2010; Elzinga 2015; Jikomes and Zoorob 2018). To what extent
the environment contributes to variation in the chemotype of Cannabis strains is largely
unknown. Even when grown in controlled conditions, small but significant variation in
mean THC/CBD ratios have previously been found among offspring of the same inbred
line (de Meijer et al. 2002; de Meijer and Hammond 2005). As more people look to
Cannabis for medical and recreational purposes, it is important to determine if there are
inconsistencies observed in the chemotype within Cannabis strains.
Chemical Constituents of Cannabis
The number of isolated chemical constituents from Cannabis has increased from
423 in 1980 (Turner et al. 1980) to 490 in 2005 (ElSohly and Slade 2005), and there are
currently more than 560 described chemical constituents (ElSohly et al. 2017). Chemical
constituents found in Cannabis include approximately 120 phytocannabinoids,
approximately 140 terpenes and an additional approximately 305 non-cannabinoids
which include fatty acids, amino acids, carbohydrates and other chemical constituents
(ElSohly et al. 2017). While terpenes are abundant in the plant kingdom,
phytocannabinoids are rarely found outside the Cannabaceae, and are largely unique to
Cannabis sativa (Small 2015b). Phytocannabinoids are a unique set of chemicals, which
mimic compounds in the endocannabinoid system of many animals, excluding insects
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(McPartland et al. 2001; Small 2015a). Glandular trichomes on the flowers of female
plants are the main production site of phytocannabinoids and terpenes (Figure 5.1).

Figure 5.1. The glandular trichomes of the female flower of Cannabis sativa
magnified 4X.
Cannabinoids. Anandamide (N-arachidonylethanolamine) is a neurotransmitter
of the endocannabinoid system in humans. Anandamide binds to neuromodulatory CB1
receptors in the central nervous system and the immunomodulatory CB2 receptors in the
peripheral nervous system (Small 2015a). The cannabinoids THC (Δ9tetrahydrocannabinol) and CBD (cannabidiol) mimic anandamide and 2arachidonoylglycerol by binding to the CB1 and CB2 receptors (Mechoulam et al. 1995;
Pertwee 2008). THC functions as an agonist by binding to and activating the receptor,
while CBD is an agonist that binds to but does not activate the receptor. However, THC
and CBD are not naturally produced in the Cannabis plant. Rather, Cannabis produces

137
THCA (Δ9-tetrahydrocannabinolic acid) and CBDA (cannabidiolic acid), which are nonbioactive precursors to THC and CBD. Both THCA and CBDA can be converted to the
bioactive forms through decarboxylation methods, which is often achieved through
heating the flower material. Consumers are generally most interested in the effects of the
active cannabinoid forms, and therefore Cannabis products that are not prepared for
smoking or vaporizing have been processed prior to sale. Smoking and vaporizing are
accomplished by applying a flame or heat to the Cannabis product and inhaling the
smoke or vapors. Cannabinoids are fat soluble and infusing fat or oil allows the
compounds to be more biologically available and absorbed more readily. ‘Edibles’ can be
prepared using butter, oils, or sprays that have been infused with THC and/or CBD by
heating flower material in oil or butter slowly over time. The four most widely
recognized cannabinoids (THCA, CBDA, THC and CBD) are often reported separately
or as a total calculated amount (see Methods Cannabinoids) on the labels of retail
products as a percent of dry weight. Other cannabinoids and compounds, however, are
produced in varying levels in Cannabis, and are only sometimes included on retail labels.
Medical and retail marijuana laws in Colorado as of January 2018 are mandated
by the Colorado Department of Revenue Marijuana Enforcement Division. Testing
protocols are published in the Colorado Department of Public Health and Environment’s
reference library. Retail Marijuana Cultivation Licensees are required to test two harvest
batches for microbial contaminants every 30 days and potency once per quarter
(Colorado Department of Revenue 2017). Cannabinoids are required to be listed as a
percentage which represents an average of the results from all batch test samples
(Colorado Department of Revenue 2017). Colorado requires analysis of five compounds
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(THC, THCA, CBD, CBDA and cannabinol (CBN)) (Colorado Department of Revenue
2017).
Chemical analysis in Cannabis is generally conducted using gas chromatography
(GC), high performance liquid chromatography (HPLC), mass spectroscopy (MS), or
some variation of these assays such as HPLC- Diode Array Detector (HPLC-DAD) or
High-Speed Liquid Chromatography (HSLC) (DeBacker et al. 2009, Hazecamp &
Fischedick 2012, de Cássia Mariotti et al. 2015, Aizpurua-Olaizola et al. 2014, Chan
2014, Elzinga et al. 2015, Gul et al. 2015). Cannabinoids commonly analyzed include
THCA, THC, CBDA, CBD, CBN, cannabigerolic acid (CBGA), cannabigerol (CBG),
tetrahydrocannabivarin (THCV), and Δ9-trans- cannabichromene (CBC), (Gul et al.
2015). Gas chromatography is less expensive than HPLC, but GC uses high temperatures
and therefore is not an accurate way to measure levels of THCA and CBDA since those
compounds are converted to THC and CBD when heated. Chemical analysis for
commercial Cannabis in Colorado can be conducted by any licensed testing facility that
adheres to state-mandated protocols, but variation in sample storage, testing equipment,
and technicians may introduce variation.
Terpenes. Terpenes are a large group of chemicals that contribute to
characteristics found in many herbal plants and essential oils. Terpenes are also partially
responsible for some of the pharmacological properties of Cannabis. The terms terpene
and terpenoid are often used interchangeably, although terpenes are basic hydrocarbons,
while terpenoids contain additional functional groups. There are more than 120 identified
terpenes found in Cannabis that are categorized as primary or secondary terpenes based
on abundance. It is thought that terpenes work in concert with cannabinoids, and the
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various levels and combinations of each in different varieties are responsible for the suite
of pharmacological benefits reported for medicinal marijuana. This synergistic
mechanism of action has been termed “the entourage effect” (Ben-Shabat et al. 1998).
Terpenes are classified according to the number of repeating units of 5-carbon building
blocks (isoprene units). The molecular structure of monoterpenes has 10 carbons,
sesquiterpenes have 15 carbons, and triterpenes have 30 carbons. Yield and distribution
of phytochemicals are the result of genetics, environmental conditions, and plant maturity
(Meier and Mediavilla 1998). Monoterpenes dominate the volatile terpene profile of
Cannabis, but there are a few common, sesquiterpenes. Research on Cannabis
phytochemicals has traditionally focused on terpene and cannabinoid levels, because it is
these phytochemicals that give the psychoactive effects, therapeutic benefits, and unique
aromas associated with Cannabis.
Monoterpenes. Monoterpenes are the most common terpenes found in Cannabis
(ElSohly 2007). -Pinene (Figure 5.2A) is the most abundant terpene in the plant
kingdom and is found in conifers, pines, sage, parsley, dill and basil (PCRlabs 2019). The
therapeutics of -pinene are anti-inflammatory, anti-osteoarthritic, and anti-nociception
properties (PCRlabs 2019). -Myrcene (Figure 5.2B) is found in lemongrass, basil, bay
leaves, thyme, parsley, hops and tropical fruits (PCRlabs 2019). The therapeutics of myrcene are anti-inflammatory, analgesic, muscle relaxation, and sedative/hypnotic
properties (PCRlabs 2019). D-limonene (limonene) (Figure 5.2C) is the second most
abundant terpene and is found in the rinds of citrus fruits (PCRlabs 2019). The
therapeutics of limonene are anti-inflammatory, analgesic, anti-depressant, muscle
relaxation and sedative properties (PCRlabs 2019). Linalool (Figure 5.2D) is found in
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flowers and spices such as lavender, rosewood, birch, and coriander (PCRlabs 2019). The
therapeutics of linalool are anti-inflammatory, anesthetic, analgesic, anti-convulsant, antianxiety, and sedative properties (PCRlabs 2019).

A

B

C

D

Figure 5.2. The chemical structures of four monoterpenes. (A) -pinene), (B) myrcene, (C) D-limonene, and (D) linalool.

Sesquiterpenes. Sesquiterpenes are also found in Cannabis but are less prevalent
(ElSohly 2007). -Caryophyllene (Figure 5.3A) is found in many spices and plants such
as clove, cinnamon, black pepper, hops, oregano and basil (PCRlabs 2019). Therapeutics
of -caryophyllene are anti-inflammatory and analgesic effects. -Caryophyllene
(humulene) (Figure 5.3B) is found in spices and herbs such as clove, basil, hops, sage,
spearmint, ginseng, as well as some fruits and vegetables (PCRlabs 2019). Therapeutics
of -caryophyllene are anti-inflammatory and analgesic effects (PCRlabs 2019).
A

B

Figure 5.3. The chemical structures of two sesquiterpenes. (A) -caryophyllene, and
(B) -caryophyllene.
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Summary
This study aimed to investigate if genetic variation in neutral genetic markers is
paralleled with variation in nine cannabinoids and 21 terpenes. The genotypes from four
strains totaling 15 samples were previously assessed for genetic variation (Chapter IV).
Samples from an additional three strains were added to the terpene analysis to examine
terpene variation among strains. Cannabinoid profiles were analyzed using HPLC-DAD,
and terpenes were analyzed using GC. To determine phytochemical variation in retail
Cannabis strains, this study examined variation (1) among samples that are genetically
identical (2) within strains, and (3) among different strains. Variation within strains was
compared to genetic variation to assess whether genetic variation is associated with
cannabinoid and terpene variation.
Methods
The genetic assessment (see Chapter IV) generated a set of 15 Cannabis samples
selected from four strains: “Blue Dream” (5), “OG Kush” (4), “Mob Boss” (3), and
“Durban Poison” (3). All three “Durban Poison” samples had identical genotypes, while
one sample each of “Blue Dream” (3SN), “OG Kush” (1SN), and “Mob Boss” (5SN) was
identified as having a unique genotype from the others, which were genetically cohesive
within the strain. Samples were purchased from 11 dispensaries licensed by the state of
Colorado for retail recreational sales located in Denver, Fort Collins, and Garden City.
The coded, dried cannabis flower samples (1 g) from the sensory study (Table 11;
Chapter IV) were sent to Mile High Labs (Loveland, Colorado) for blind analysis.
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Cannabinoids
Potency and related cannabinoid analysis of raw material were reported for nine
cannabinoids (THC, THCA, CBD, CBDA, CBG, CBGA, THCV, CBN, and CBC). Mile
High Labs analyzed the samples following standard protocols with a gradient HPLC
system using a reverse-phase column and guard column with a C18 stationary phase. A
1260 Infinity II HPLC with DAD detection at 240 nm, (bandwidth 4 nm) and reference
360 nm (bandwidth 100 nm) was used per Colorado state compliance requirements
(Table 5.1 - 5.3).
Table 5.1. HPLC Method Parameters
HPLC Information
Column Type:
Restek Raptor ARC-18, 2.7 mm, 150 x 4.6 mm, PN 9314A65
Guard Cartridge: Restek Raptor ARC-18, 2.7 mm, 5 x 4.6 mm, PN 9314A0250
Column Temperature: 35 °C
Sample Tray
Temperature: Ambient
Flow Rate: 1.5 mL/min
Stop Time: 12 min
Post Time: 3 min
Method Type: Gradient
MP A: 0.015% formic acid in water
MP B: 0.010% formic acid in acetonitrile
Gradient
DAD Detector Settings
Time
0:00
2:00
8:00
12:00

Injection Volume
Needle Wash

MP
MP A B
(%) (%)

30
30
5
5

Detection:
70
Detection BW:
70
Reference:
95
Reference BW:
95
Collect UV Spectra:
Peakwidth:
Slit Width:
Injector Settings

10 μL
Methanol

240m nm
4 nm
360 nm
100 nm
190 -400 nm
> 0.05 min (2.5 Hz)
4 nm
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Table 5.2. Injection Sequence
# of
Description
Injections
Reagent Blank
NLT 1
Reagent Blank
1
RL Standard
1
Resolution Standard
1
Standard A
6

Standard B
Samples
Standard A*

1
1
1

Parameter
System equilibration
Contamination check and non-interference
Reporting Limit Recovery
Resolution

CBD / ISTD peak area ratio

Mean CBD USP Tailing Factor

Mean CBD USP Theoretical Plates
CBD Percent Recovery
Sample analysis
Check Standard Recovery

*Inject standard A as a drift check at least every six samples and at the end of each sequence

Table 5.3. Peak Relative Retention Time (RRT) and Relative Response Factor
(RRF) Values
Approx. retention
Approx.
Cannabinoids
time
RRT
RRF
tetrahydrocannabinolic acid (THCA)
7.28
1.69
0.66
tetrahydrocannabinol (Δ9-THC)
6.38
1.48
0.89
cannabidiolic acid (CBDA)
3.67
0.85
0.71
cannabidiol (CBD)
4.3
1
1
cannabigerolic acid (CBGA)
3.96
0.92
1
cannabigerol (CBG)
4.15
0.97
1.02
tetrahydrocannabivarin (THCV)
4.46
1.04
1
cannabinol (CBN)
5.64
1.31
0.33
Δ9-trans- cannabichromene (CBC)
7.07
1.64
0.32
The analytical column used was a Restek Raptor ARC-18, 2.7 m, 150 x 4.6 mm,
PN 9314A65. The guard column was a Restek Raptor ARC-18, 2.7 m, 5 x 4.6 mm, PN
9314A0250 and Restek EXP Direct Connect Holder PN 25808. HPLC-grade acetonitrile
(CAS# 75-050-8), methanol (CAS# 76-56-1) and water (CAS# 7732-18-5) were used, as
well as GC grade di-n-octyl phthalate (CAS# 117-84-0), reagent grade formic acid
(CAS# 64-18-6), Cerilliant 1 mg/mL Cannabigerol Ampoule PN C-141 (dissolved in
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methanol), Cerilliant 1 mg/mL Cannabidiol Ampoule PN C-045 (dissolved in methanol),
and Cerilliant © Certified Cannabinoid Standards for ID (Redrock, Texas): C-045, C046, C-144, T-005, C-140, C-141, T-093, C-143, C154, C171, C-150, C-152, T-032, C153, T-094, and C-142. A 10ul aliquot of composite cannabinoid sample was injected
using Acq. Method TM-001 – 1260.amx and Processing method *TM-002UV.pmx with
no manual modification (Figure 5.4, Table 5.4)

Figure 5.4. Composite HPLC-DAD chromatogram.
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Table 5.4. Retention Times, Peak Height, Peak Area and Response Factor for the
composite HPLC-DAD Analysis.
Signal: DAD1A,Sig=240,4 Ref=360,100
Name

Tailing

CBDV

CBDA
CBGA
CBG
CBD
THCV

CBN

THC
CBC
THCA

0.90
1.00
1.00
1.40
1.00
0.80
1.20
1.00
1.10
1.40
1.10
1.00
1.10
1.00
1.00
1.00
2.00
1.10
1.10
1.10
0.80
1.80
1.00
1.00
1.20
1.50
1.30
1.50
0.90

Plates
18093.00
15160.00
10827.00
4192.00
14444.00
11883.00
17393.00
16971.00
21209.00
17392.00
23925.00
34299.00
29880.00
30199.00
33788.00
39558.00
63140.00
68243.00
74373.00
90899.00
92846.00
38836.00
121577.00
136042.00
122548.00
142309.00
114404.00
27536.00
149960.00

RT
(Min)

Peak
Height
(mAU)

Area
(mAU*sec)

Res
(USP)

1.56
1.62
1.73
1.96
2.08
2.29
2.42
2.68
3.10
3.27
3.58
3.76
3.88
4.04
4.18
4.34
5.00
5.32
5.51
6.04
6.25
6.32
6.80
6.94
7.18
7.56
7.67
7.95
8.39

0.68
1.03
0.80
1.24
1.69
4.34
105.22
74.34
0.68
1.00
79.60
1.74
86.21
64.32
62.61
79.61
0.38
0.55
242.42
0.39
95.07
155.45
125.48
245.48
87.26
292.93
73.85
1.14
0.31

1.17
2.00
2.24
5.21
4.34
14.73
293.92
230.00
2.20
4.13
278.90
5.17
291.14
224.49
212.93
260.05
1.42
1.67
737.08
1.13
264.29
749.53
367.14
701.31
273.92
902.20
255.63
10.58
1.33

1.10
1.90
2.40
1.20
2.80
1.60
3.40
5.00
1.80
3.20
2.10
1.40
1.80
1.60
1.70
8.00
4.00
2.30
6.60
2.60
0.60
4.70
1.90
3.00
4.70
1.40
1.90
3.20

Mobile phase A (0.015% formic acid in water) was prepared by combining 150
L of formic acid with 1 L of water. Mobile phase B (0.010% formic acid in acetonitrile)
was prepared by mixing 100 L of formic acid with 1 L of acetonitrile. Stock Standard
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solutions were stored at -80C for < 88 days, and the Internal Standard (ISTD), A/B
Standard solutions and RL solutions were stored at -80 C for < 7 days. The Sample
ISTD was prepared by diluting 200.00  20 mg di-n-octyl phthalate in methanol to a total
volume of 100.0-mL. The Standard ISTD was prepared by adding methanol to 5.0 mL of
the Sample ISTD to a final volume of 20 mL. Standard A was prepared with 100.00  10
mg of Cannabidiol Isolate Standard to a sufficient volume of methanol in a 100-mL
volumetric flask to just below the QS line and sonicated for 2 minutes. The solution was
then allowed to equilibrate to room temperature and diluted to volume with methanol. In
order to create the Standard A Preparation with a nominal concentration of 50 g/mL
cannabidiol, 5.0 mL of the sonicated Cannabidiol Isolate Standard in methanol was
diluted with 5.0 mL and brought to a final volume of 100.0 mL with methanol. Standard
B was prepared with 100.00  10 mg of Cannabidiol Isolate Standard to a sufficient
volume of methanol in a 100-mL volumetric flask to just below the QS line and sonicated
for 2 minutes. The solution was then allowed to equilibrate to room temperature and
diluted to volume with methanol. In order to create the Standard B Preparation with a
nominal concentration of 50 g/mL cannabidiol, 5.0 mL of the sonicated Cannabidiol
Isolate Standard in methanol was diluted with 5.0 mL and brought to a final volume of
100.0 mL with methanol. Standard A/B are prepared to ensure standards were made
correctly. If Standard B recovery fell within a 4% range of Standard A then all
quantitation was determined to be accurate using Standard A during sample processing.
5.0 mL of Stock Standard A was diluted to a volume of 100.0 mL with methanol to
prepare the RL Stock Standard I Preparation with a nominal concentration of 50 g/mL
cannabidiol. A 5.0 mL aliquot of Stock RL Standard was diluted to a volume of 100.0
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mL with methanol to prepare the RL Stock Standard II Preparation with a nominal
concentration of 2.5 g/mL cannabidiol. A 10.0 mL aliquot of RL Stock Standard II and
5.0 mL of the Standard ISTD was diluted to a volume of 100.0 mL with methanol to
prepare the RL Standard Preparation with a nominal concentration of 0.25 g/mL
cannabidiol. The Resolution and RC Identification Standard was prepared by adding ~1.0
mL of each Cerilliant © Certified Cannabinoid Standards (Redrock, Texas) to a 20.0 mL
volumetric flask and diluted to volume with methanol. A 10 uL aliquot of RL standard
was injected and Acq. Method TM-001 – 1260.amx and Processing method *TM002UV.pmx were used with no manual modification (Figure 5.5, Table 5.5).

Figure 5.5. RL standard HPLC-DAD chromatogram.
Table 5.5. Retention Times, Peak Height, Peak Area and Response Factor for the
RL standard HPLC-DAD analysis.
Signal: DAD1A,Sig=240,4 Ref=360,100

Name

Tailing

Plates

RT
(Min)

Peak Height
(mAU)

Area
(mAU*sec)

Res
(USP)

Blank
CBD
ISTD

1.10
1.20
0.90

18713.00
34891.00
271187.00

2.45
4.19
10.48

0.87
0.30
33.46

2.47
1.02
101.04

21.60
74.00
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Cannabis samples were prepared by weighing 200.00  10 mg of dried flower
material and transferred to a 100 mL volumetric flask, and 5.0 mL of the Sample ISTD
was added. To prepare a Potency and Related Cannabinoid Stock Sample Preparation
with a nominal concentration of 2000 g/mL, a sufficient amount of methanol was added
to bring the volume to just below the QS line and the solution was sonicated at 40 C for
10 minutes. The solution was mixed thoroughly then brought to room temperature. The
Stock Sample Solution was then filtered into a scintillation vial using a Pall Acrodisc
CR13 0.2-m PTFE syringe filter. The first ~1 mL of filtrate was discarded followed by
collection of > 5.5 mL of filtrate. The final Potency and Related Cannabinoid Sample
Preparation with a nominal concentration of 500 g/mL was prepared by dilution 5.0 mL
of Stock Sample Solution to 20.0 mL with methanol. A 10 uL aliquot of sample
extraction (For example 752, OG Kush 2 Figure 5.6, Table 5.6) was injected using Acq.
Method TM-001 – 1260.amx, Processing method *TM-002UV.pmx with no manual
modification.

Figure 5.6. Sample HPLC-DAD chromatogram for sample 752 (OG Kush 2).
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Table 5.6. Retention Times, Peak Height, Peak Area and Response Factor for the
sample 752 (OG Kush 2) HPLC-DAD analysis.
Signal: DAD1A,Sig=240,4 Ref=360,100
Name

Blank
CBDA
CBGA
CBG

CBN
THC

CBC
THCA

ISTD

Tailing

Plates

RT
(Min)

1.10
1.60
1.50
0.80
1.00
0.80
1.50
1.00
1.10
1.80
1.40
0.60
1.20
1.30
1.30
1.10
1.30
1.10
1.10
0.90
0.80

5418.00
17959.00
27959.00
28583.00
28834.00
45876.00
51644.00
57983.00
99474.00
77805.00
98167.00
103677.00
132966.00
124679.00
131948.00
200307.00
225435.00
245819.00
223202.00
271602.00
127297.00

2.29
2.44
3.59
3.89
4.04
4.67
5.32
5.51
6.25
6.37
6.62
6.87
6.94
7.16
7.60
8.25
8.35
8.77
9.03
10.47
11.81

Peak
Height
(mAU)
0.88
1.04
0.50
4.61
1.35
1.30
1.48
0.48
31.11
2.52
0.50
0.58
1.39
227.63
8.00
0.54
1.13
0.73
1.36
30.46
0.54

Area
(mAU*sec)

Res
(USP)

4.32
3.81
1.71
20.09
5.02
5.05
5.25
1.70
93.18
9.92
1.62
2.26
3.99
713.80
26.04
1.46
2.93
1.90
3.93
91.75
3.12

1.60
14.50
3.30
1.60
6.90
7.20
2.10
8.70
1.40
2.80
2.90
0.80
2.90
5.30
8.20
1.40
5.90
3.60
18.30
12.60

The Reagent Blank Solution was prepared by following the steps for sample preparation
but excluding the addition of the dried flower material (Figure 5.7, Table 5.7). Each
sample was extracted in triplicate to ensure consistency and ensure quantitation was
accurate.
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Figure 5.7. HPLC-DAD chromatogram for the blank.
Table 5.7. Retention Times, Peak Height, Peak Area and Response Factor for the
blank HPLC-DAD analysis.
Signal :DAD1A,Sig=240,4 Ref=360,100
RT
Name Tailing
Plates
(Min)
Blank
ISTD

1.00
1.00
1.00

19083.00
154781.00
270998.00

2.44
9.40
10.49

Peak Height
(mAU)

Area
(mAU*sec)

Res
(USP)

0.63
9.66
24.36

1.67
34.88
73.85

83.60
12.40

Many of the major cannabinoids (THC, CBD, CBG, CBC, but not CBN) have the
molecular formula C21H30O2. However, the acidic forms (THCA, CBDA, CBGA and
CBCA) are the naturally occurring form manufactured by the trichomes in the flowers.
The acidic forms have an additional CO2 and chemical formula C22H30O4. In order to
calculate the THCTOTAL, a conversion factor must be used to account for the CO2 molecule
removed during decarboxylation. The molecular weight of the acidic cannabinoids is
358.48 and the neutral cannabinoids is 314.47, therefore 12.28% THCA is lost in the
form of CO2(g) during the decarboxylation process. The conversion factor to account for
this loss is 0.877 (314.47/358.48). This formula can be applied to calculate THCTOTAL,
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CBDTOTAL, CBGTOTAL and CBCTOTAL. The conversion factor can be used to calculate the
conversion of acidic cannabinoid forms when they lose a CO2 molecule
(decarboxylation) and are converted to the neutral bioactive form (Equation 5.2 & 5.3).

THCTOTAL (%) = % THC + (% THCA x 0.877)

Equation 5.1.

CBDTOTAL (%) = % CBD + (% CBDA x 0.877)

Equation 5.2.

Total Cannabinoids (%) =  individual related cannabinoids  0.05%

Equation 5.3.

Dispensaries may report %THC and %THCA as separate values or %THCTOTAL. The
sample packaging used in this study did not disclose analysis methods; although we
assume if %THC and %THCA were reported, HPLC-DAD analysis was conducted.
Since both HPLC-DAD and GC are acceptable analyses to use to determine potency in
retail cannabis, the %THCTOTAL can be calculated from HPLC-DAD analysis.
The percent dry weight of nine cannabinoids in the fifteen samples were compiled
into a table using Microsoft Excel and bar plots for the cannabinoid profiles were graphed
in Excel. For each sample, bar plots were generated for (1) the percent dry weight for the
full cannabinoid panel, (2) the proportions of cannabinoids within the total cannabinoid
fraction, (3) the percent dry weight for THCA and THC, and (4) the percent dry weight
for CBDA, CBG, CBGA, THCV, CBN, and CBC. None of the samples possessed
measurable amounts of CBD; therefore CBD was not included in any of the subsequent
analyses. Histograms of percentages by dry weight of the average level of THCA in the
consensus sequences and the genetic outlier were generated in Microsoft Excel.
Histograms of average level of the remaining cannabinoids in the consensus sequences
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were graphed with standard deviation error bars against the cannabinoid levels of the
genetic outlier. Microsoft Excel was also used to generate a scatter plot to determine the
relationship between the two cannabinoids (THCA and CBDA) representing the majority
of the variation in the data.
A hierarchical cluster analysis dendrogram for eight cannabinoids (CBDA, CBG,
CBGA, CBC, CBN, THCV, THC, THCA) in 15 samples using Ward’s method and
Euclidean distance parameters was conducted in PC-ORD (McCune and Mefford 1999).
However, because the investigation was examining variation within strains, cannabinoid
dendrograms for each strain were also generated to assess the relationship between the
genetic outlier and the consensus samples. Since THCA had overwhelmingly higher
levels than the other cannabinoids, a second clustering analysis was conducted with
THCA and THC removed from the data set. Dendrograms were generated for the full
samples set and for each strain. PC-ORD was also used to generate a Principal
Components Analysis (PCA) for eight cannabinoids (CBDA, CBG, CBGA, CBC, CBN,
THCV, THC, THCA) using Ward’s method and Euclidean distance parameters. Since
THCA had overwhelmingly higher levels than the other cannabinoids, a second PCA was
conducted with THCA and THC removed from the data set.
Terpenes
The terpene profiles for 21 Cannabis samples from seven strains were determined
using a GC-MS. Mile High Labs analyzed the samples following standard protocols with
reference standards to calibrate the GC-MS system. Samples were prepared by weight in
ACS-grade methanol. Preparation concentrations were from approximately 10-15% by
weight. All weights were obtained to within 0.1 mg. Dry sample material was crushed to
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a fine solid, suitable for weighing and transfer. Tare weights were obtained for the crimpsealed vials, and then the sample was added and weighed followed by addition of
methanol with subsequent weighing. Samples were then placed into a 50-55C sonicating
bath for 15 minutes followed by vortexing while still warm and allowed to settle at room
temperature. Once cooled, the liquid was decanted via pipette and syringe filtered
through a 0.45 m filter into GC vials for analysis. An Agilent 6890 GC with a 5973 inert
MS detector in EI mode was used for analysis. The calibration curves for components
were created using the 21-component terpene standard from RESTEK (data not
provided). A five- point calibration was used for standards. The column used was a
RESTEK Rxi-624 and helium was used as the carrier gas. A computing integrator
recorded the chromatograph and mass spectrometer analysis, and relative retention times
of terpene peaks from the reference standards were used to identify and determine
presence and average abundance of terpenes in samples of seven strains. Two replicates
for each sample were analyzed. The peaks were then calculated as normalized area
percentages of each of the terpenes present in the samples. Terpene distribution and
relative proportions for 21 terpenes was assessed. The terpene levels were used to assess
the relationship between genetic consensus samples and a genetic outlier within a strain,
as well as terpene variation among different strains.
PCA eigenvalues generated in PC-ORD for 21 terpenes using Ward’s method and
Euclidean distance parameters were used to plot the PCA in RStudio with the ggplot
package (R Studio Team 2015). Histograms of peak area percentages of each terpene
present in the strain samples were generated in Microsoft Excel. The average terpene
levels of the genetic consensus samples were graphed with standard deviation error bars
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against the terpene levels of the genetic outlier. The five highest terpene of the genetic
consensus samples were pooled for “Blue Dream” (12), “Mob Boss” (12), and “OG
Kush” (10), and compared to terpene levels of the genetic outlier. Twenty-one terpenes
levels for seven strains and the average level each terpene was reported when multiple
samples were included. Finally, the terpenes with the highest average standard deviation
were graphed for the seven strains in order to assess terpene variation among strains.
Results
Cannabinoids
All the samples used in this investigation had high THC concentrations (7.97 –
22.70 % dry weight) (Table 5.8). Five samples had a detectable level of CBDA (0.04294
– 0.06520 % dry weight), while CBD was not detected in any sample and was not
included in the results (Table 5.8).
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Table 5.8. Percentages of eight cannabinoid levels in four strains by HPLC-DAD as percent dry weight for eight cannabinoids, and calculated
THCTOTAL (Equation 5.1). Identification abbreviations are listed for each sample and the genetic outliers are indicated with an asterisk and highlighted in
gray.
Strain

Identification

THCA

THC

CBDA

CBGA

CBG

THCV

CBN

CBC

Durban Poison

1SN

12.73

0.42

0.00

0.32

0.00

0.00

0.04

0.09

4SN

12.28

0.04

0.00

0.76

0.09

0.00

0.00

0.02

5SN

17.52

0.27

0.05

0.79

0.07

0.05

0.00

0.00

Consensus
1SN

14.17 ± 2.90
14.48

0.24 ± 0.19
0.10

0.02 ± 0.03
0.00

0.62 ± 0.26
0.12

0.05 ± 0.05
0.00

0.02 ± 0.03
0.00

0.01 ± 0.02
0.00

0.04 ± 0.05
0.00

4SN

8.85

0.21

0.00

0.14

0.00

0.00

0.00

0.00

5SN

12.72

0.20

0.00

0.11

0.00

0.00

0.00

0.00

6SN

17.11

0.25

0.04

0.13

0.00

0.00

0.00

0.00

Consensus

13.29 ± 3.47

0.19 ± 0.06

0.01 ± 0.02

0.12 ± 0.01

0.00

0.00

0.00

0.00

3SN*

15.07

0.15

0.00

0.11

0.00

0.00

0.00

0.02

1SN

11.88

0.24

0.00

0.96

0.16

0.05

0.04

0.04

3SN

15.05

0.27

0.00

1.41

0.08

0.00

0.00

0.00

Consensus

13.47 ± 2.25

0.26 ± 0.02

0.00

1.19 ± 0.32

0.12 ± 0.05

0.03 ± 0.04

0.02 ± 0.03

0.02 ± 0.03

5SN*

11.54

0.31

0.00

0.21

0.12

0.00

0.05

0.04

2SN

25.34

0.47

0.07

1.08

0.28

0.00

0.03

0.07

3SN

20.52

0.07

0.04

0.74

0.11

0.00

0.00

0.00

4SN

15.24

0.23

0.05

0.21

0.08

0.00

0.04

0.02

Consensus

20.37 ± 5.05

0.26 ± 0.20

0.05 ± 0.01

0.68 ± 0.44

0.15 ± 0.11

0.00

0.02 ± 0.02

0.03 ± 0.04

1SN*

12.59

0.18

0.00

0.39

0.07

0.00

0.02

0.00

mean ± SD
Blue Dream

mean ± SD
Mob Boss
mean ± SD
OG Kush

mean ± SD
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To compare cannabinoid composition and quantity among samples within strains,
histograms of eight cannabinoids were generated to show variation (Figure 5.8). The
“Durban Poison” samples were genetically identical, and yet the cannabinoid levels
varied among all samples. When the total cannabinoid fraction (% by dry weight) with
relative abundance of the chemotype by proportion was graphed, THCA levels appear to
be similar, but levels of THC, CBGA and CBC seem to be the highest contributors to the
variation (Figure 5.9). Samples 1SN and 4SN had similar levels of THC (Table 5.6,
Figure 5.10A) and 5SN had higher THC. Examination of the other cannabinoids showed
1SN and 4SN differ substantially in both composition and relative levels of CBGA, CBG,
CBC, and CBN, while 4SN and 5SN had similar levels of CBGA and CBG but differed
in CBC, CBDA and THCV (Figure 5.11A). PCA clustering analysis using data from
eight cannabinoids produced two large clusters, with assignment of 1SN and 4SN to one
cluster and 5SN to the other (Figure 5.14), indicating 5SN is more distinct in
cannabinoids than1SN and 4SN are from each other. This is supported in the clustering
analysis containing only “Durban Poison” samples where 1SN and 4SN clustered
together (Figure 5.15A). There is a possibility that the less prevalent minor cannabinoids
(CBDA, CBG, CBGA, CBC, CBN, THCV) may be a better reflection of the genetic
relationships among the samples in drug-type strains. Therefore, additional PCAs of the
minor cannabinoids were generated (Figure 5.13 and 5.17A). Although the “Durban
Poison” samples were still assigned to different clusters (Figure 5.16), and “Durban
Poison” 4SN and 5SN clustered together while 1SN was the chemical deviant (Figures
5.16 and 5.17A).
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Figure 5.8. Percent dry weight (mg) of eight cannabinoids measured by HPLC-DAD in 15 samples of four commercially
available strains. Arrows and asterisks indicate the genetic outlier.
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Figure 5.9. Chemotype by proportions of detected cannabinoids within the total cannabinoid fraction (% by dry weight)
measured by HPLC-DAD in 15 samples of four commercially available strains. Asterisks indicate genetic outlier.
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A

B

C

D

Figure 5.10. Percent dry weight (mg) of THC and THCA (six cannabinoids
excluded). Arrows and asterisks indicate the genetic outlier.
A

B

C

D

Figure 5.11. Percent dry weight (mg) of six minor cannabinoids (THC and THCA
excluded). Arrows and asterisks indicate the genetic outlier. Predominant minor
cannabinoids are CBGA and CBG.
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B

C

Figure 5.12. Average levels of THCA (total % dry weight) in the genetic consensus
samples compared to the genetic outlier. Error bars represent the standard deviation.
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Blue Dream

A
0.3

% Dry Weight

0.3
0.2
0.2
0.1
0.1
0.0
-0.1

THC

CBDA

CBGA

CBG

Outlier

B

THCV

CBN

CBC

CBN

CBC

CBN

CBC

Consensus mean

Mob Boss
2.0

% Dry Weight

1.5
1.0
0.5
0.0
-0.5

THC

CBDA

CBGA

CBG

Outlier

THCV

Consensus mean

OG Kush

C
1.2
% Dry Weight

1.0
0.8
0.6
0.4
0.2
0.0
-0.2

THC

CBDA

CBGA

Outlier

CBG

THCV

Consensus mean

Figure 5.13. Average levels of the minor cannabinoids (total % dry weight) in the
genetic consensus samples compared to the levels of the genetic outlier. Error bars
represent the standard deviation.
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Figure 5.14. Hierarchical clustering dendrogram for 15 samples of four strains based on levels of eight cannabinoids (CBDA,
CBG, CBGA, CBC, CBN, THCV, THC, and THCA). The genetic outliers are indicated with arrows.
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Figure 5.15. Hierarchical clustering dendrogram for 15 samples within (A) “Durban Poison”, (B) “Blue Dream”, (C) “Mob
Boss”, and (D) “OG Kush” based on levels of eight cannabinoids (CBDA, CBG, CBGA, CBC, CBN, THCV, THC, and
THCA).
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Figure 5.16. Hierarchical clustering dendrogram for 15 samples of four strains based on levels of six minor cannabinoids
(CBDA, CBG, CBGA, CBC, CBN, THCV).
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B

C

D

Figure 5.17. Hierarchical clustering dendrogram for 15 samples of (A) “Durban Poison”, (B) “Blue Dream”, (C) “Mob Boss”,
and (D) “OG Kush” based on levels of six minor cannabinoids (CBDA, CBG, CBGA, CBC, CBN, THCV).
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The genetic consensus “Blue Dream” samples varied from one another, and the
genetic outlier did not appear to be anomalous compared to the consensus samples. When
the total cannabinoid fraction (% by dry weight) with relative abundance of the
chemotype by proportion was graphed, levels of THCA, THC and CBGA seem to be the
highest contributors to the variation, although the levels of each are within 3% of the
relative abundance of THCA, 4SN seems to be the most different (Figure 5.9). Among
“Blue Dream”, most samples are similar in THCA (Table 5.4) although 4SN is noticeably
lower (Figure 5.10B). Examination of the minor cannabinoids in “Blue Dream” are low,
but have comparable levels of CBGA, and differing in only CBC and CBDA in 3SN and
6SN, respectively (Figure 5.11B). No other cannabinoids were detected in the “Blue
Dream” samples. Hierarchical clustering analysis using data from eight cannabinoids
produced two large clusters, with assignment of 1SN, 3SN* and 6SN to one cluster,
while 4SN and 5SN were assigned to the other (Figure 5.14). Clustering analysis
containing only “Blue Dream” samples clustered 1SN and 3SN together, while 4SN, 5SN
and 6SN are assigned to the other cluster (Figure 5.15B). Hierarchical clustering analysis
of the minor cannabinoids assigned all five “Blue Dream” samples to one cluster
indicating none of the samples substantially differed in the less prominent cannabinoids
(Figure 5.16). However, when “Blue Dream” samples were examined together, 1SN and
3SN* formed a cluster, while the remaining samples were assigned to a second cluster
(Figure 5.17B).
The genetic consensus “Mob Boss” samples varied from one another, although
the genetic outlier did not appear to be anomalous compared to the consensus samples
and had a similar level of THCA to 1SN (Figure 5.8). When the total cannabinoid

167
fraction (% by dry weight) with relative abundance of the chemotype by proportion was
graphed, levels of THCA and CBGA seem to be the highest contributors to the variation,
although levels of THCA, THC and CBGA in the genetic outlier is markedly different
(Figure 5.9). Among “Mob Boss”, the outlier shares a similar THC profile with 1SN
(Figure 5.10C). Examination of the minor cannabinoids reveals the “Mob Boss” samples
are vastly different in CBGA content, and differ in CBN, CBC and THCV (Figure
5.11C). Only CBG and CBGA were detected in 3SN, while CBN and CBC were detected
in 5SN* and 1SN, and THCV in 1SN. Hierarchical clustering analysis using data from
eight cannabinoids produced two large clusters, with assignment of the genetic outlier
and one consensus sample to one cluster, while the other consensus sample was assigned
to the other cluster (Figure 5.14). Clustering analysis containing only “Mob Boss”
samples clustered 1SN and 3SN together, while the outlier was assigned to the other
cluster (Figure 5.15C). Hierarchical clustering analysis of the minor cannabinoids
assigned all genetic consensus “Mob Boss” samples to one cluster and the genetic outlier
to the other, indicating the genetic outlier differed in the less prominent cannabinoids
(Figure 5.16). Clustering analysis of “Mob Boss” samples supported the difference in less
prominent cannabinoids in the genetic outlier (Figure 5.17C).
The genetic consensus “OG Kush” samples varied, and the genetic outlier
appeared to be most similar to 4SN in cannabinoid levels (Figure 5.8). When the total
cannabinoid fraction (% by dry weight) with relative abundance of the chemotype by
proportion was graphed, levels of THCA, THC and CBGA seem to be the highest
contributors to the variation, although levels of THCA are similar in 1SN*, 3SN and 4SN
(Figure 5.9). THC in 3SN differs from the other samples, and 1SN* is the only sample
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with no CBDA detected. All samples contained CBG and CBGA, although 4SN
contained far less CBGA. CBC and CBN were detected at low levels in 2SN and 4SN.
Among “OG Kush”, the outlier shares a similar THC profile with 4SN (Figure 5.10D).
Examination of the minor cannabinoids reveals the “OG Kush” samples are vastly
different in CBGA content, and CBG is higher in 2SN (Figure 5.11D). Only CBG,
CBGA, and CBN were detected in 1SN*, while CBD was detected in the three consensus
samples. 2SN and 4SN both contained CBN and CBC. Hierarchical clustering analysis
using data from eight cannabinoids produced two large clusters, with assignment of the
genetic outlier to one cluster, while the consensus sample were assigned to the other
cluster (Figure 5.14). Clustering analysis containing only “OG Kush” samples placed the
genetic outlier with two consensus samples and assigned 2SN to the other cluster (Figure
5.15D). Hierarchical clustering analysis of the minor cannabinoids assigned 4SN, and
3SN and 2SN were assigned to the other cluster (Figure 5.16). Clustering analysis of “OG
Kush” assigned 1SN*, 4SN and 3SN to one cluster and 2SN to the other (Figure 5.17D).
Principal Components Analysis generated plots for eight cannabinoids which
represented 99.9% of the variation in the data and is explained almost entirely by THCA
concentrations. The PCA scaled by THCA (Axis 1; 99.002 % of variation; r = 1.00, tau =
0.981) (Figure 5.18) confirms that THCA is the overwhelming source of variation. A
PCA was conducted on the minor cannabinoids (CBDA, CBG, CBGA, CBC, CBN,
THCV) to determine if any minor cannabinoids are driving variation (Figure 5.19). The
PCA scaled by CBGA (Axis 1, 99.2% of variation; r = -1.00, tau = -1.00) confirms that
CBGA is the overwhelming source of variation.
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PCA of THCA

Figure 5.18. Principal Components Analysis of scaled by THCA on Axis 1 (99.002% of variation) and remaining variation on
Axes 2 and 3 (0.900% and 0.079% of variation).
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PCA of CBGA

Figure 5.19. Principal Components Analysis of scaled by CBGA on Axis 1 (99.925% of variation) and the remaining variation
on Axis 2 (0.075% of variation).
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Given that THCA and CBGA were found to be driving variation, a linear
regression analysis of THCA and CBGA was conducted to determine if there is a
relationship between these two cannabinoids (Figure 5.20). There is a weak positive
correlation (R2 = 0.1749) between THCA and CBGA, and samples within strains do not
cluster, although all ‘Blue Dream’ samples were low in CBGA.

Figure 5.20. Linear regression analysis of THCA level (% dry weight) against
CBGA (% dry weight). Samples are color coded and labeled with the abbreviated
identification (Table 5.4).
Terpenes
A panel of 21 terpenes were analyzed in seven strains of commercially-available
Cannabis (Table 5.9). Nineteen cannabis samples drawn from seven strains were
analyzed: “Durban Poison” (3), “Blue Dream” (5), “Mob Boss” (3), “OG Kush” (4),
“White Widow” (1), “White Urkle” (2), and “Tangerine Haze” (1). The analyses included
samples of the same strain acquired from different dispensaries, clones from the same
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dispensary (“White Urkle”), and a single-representatives of two strains (“White Widow”
and “Tangerine Haze.
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Table 5.9. Average terpene percent distribution by mass (mg) calculated as normalized area percentages of each of the terpenes present in the
samples. The general molecular class is denoted as monoterpene (m) or sesquiterpene (s).

Blue Dream

Mob Boss

OG Kush

-pinene
(m)

camphene
(m)

myrcene
(m)

-pinene
(m)

3-carene
(m)

-terpinene
(m)

limonene
(m)

1SN

11.29 (0.25)

3.66 (0.17)

9.03 (0.20)

6.66 (0.33)

3.24 (NA)

3.46 (NA)

1.80 (2.54)

4SN

11.87 (0.26)

4.64 (0.13)

6.93 (0.15)

6.13 (0.23)

4.60 (NA)

4.53 (0.13)

5.57 (NA)

5SN

11.14 (0.14)

3.34 (0.39)

7.82 (0.09)

5.68 (0.26)

3.14 (0.25)

2.96 (NA)

3.19 (NA)

6SN

12.65 (0.50)

3.58 (0.08)

8.65 (0.58)

6.36 (0.22)

3.51 (0.01)

3.47 (0.06)

3.29 (NA)

Consensus

11.71 (0.69)

3.81 (0.58)

8.11 (0.93)

6.21 (0.41)

3.67 (0.64)

3.61 (0.66)

3.46 (1.56)

3SN*

7.67 (0.22)

3.02 (0.11)

6.26 (0.20)

4.54 (0.04)

2.98 (0.11)

2.81 (0.11)

4.54 (1.09)

1SN

7.10 (0.34)

3.06 (0.46)

3.64 (0.44)

3.50 (0.43)

2.87 (0.32)

2.89 (0.31)

2.01 (2.84)

3SN

12.86 (0.61)

2.81 (0.37)

3.72 (0.39)

3.33 (0.47)

2.84 (NA)

2.14 (NA)

2.90 (NA)

Consensus

9.98 (4.08)

2.93 (0.17)

3.68 (0.06)

3.42 (0.12)

2.85 (0.02)

4.09 (0.53)

2.46 (0.63)

5SN*

7.95 (0.18)

4.50 (0.45)

7.15 (0.27)

5.26 (0.77)

0.00

4.09 (0.33)

7.42 (0.30)

2SN

2.13 (0.03)

1.26 (0.02)

3.21 (0.07)

2.04 (0.02)

0.93 (0.05)

0.49 (0.69)

12.79 (0.15)

3SN

2.19 (0.28)

1.53 (0.24)

7.57 (0.34)

4.30 (0.01)

0.53 (0.75)

0.57 (0.80)

3.34 (1.34)

4SN

3.40 (0.15)

2.63 (NA)

9.89 (0.52)

6.35 (0.07)

2.63 (0.19)

2.56 (0.19)

0.00

Consensus

2.57 (0.72)

1.81 (0.72)

6.98 (3.39)

4.23 (2.15)

1.36 (1.11)

1.21 (1.18)

5.44 (6.74)

1SN*

3.05 (0.19)

2.70 (0.31)

8.32 (0.50)

5.63 (0.02)

2.89 (NA)

2.42 (NA)

2.74 (0.53)

1SN

4.64 (0.31)

3.26 (0.09)

3.94 (0.22)

3.67 (0.10)

2.96 (0.21)

2.84 (NA)

3.67 (NA)

4SN

5.28 (0.18)

3.47 (0.11)

3.43 (0.00)

4.68 (0.15)

4.01 (0.12)

3.81 (0.15)

0.00

5SN

4.61 (0.26)

2.62 (0.12)

4.78 (0.21)

3.71 (0.25)

3.52 (0.06)

3.34 (0.09)

3.46 (158)

Consensus

4.85 (0.38)

3.12 (0.44)

4.05 (0.68)

4.02 (0.57)

3.50 (0.52)

3.33 (0.49)

2.38 (2.06)

White Widow

WW1

5.02 (0.33)

4.33 (0.39)

9.32 (0.81)

7.68 (0.98)

0.00

4.18 (NA)

0.00

White Urkle

WE

11.42 (1.89)

1.89 (0.44)

5.78 (2.22)

3.20 (0.45)

1.68 (0.32)

1.75 (0.40)

1.15 (1.62)

Tang. Haze

TANG1

3.51

2.14

2.6

2.41

2.11

2.09

0.00

Durban Poison
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Table 5.9 continued

Blue Dream

Mob Boss

p-cymene
(m)

ocimene
(m)

g-terpinene
(m)

terpinolene
(m)

linalool
(m)

isopulegol
(m)

geraniol
(m)

1SN

0.00

3.46 (0.28)

2.94 (NA)

3.26 (0.19)

6.50 (0.10)

2.51 (0.03)

2.57 (0.16)

4SN

0.00

4.93 (0.02)

3.92 (NA)

0.00

4.86 (0.19)

3.23 (NA)

3.60 (0.21)

5SN

0.00

3.05 (0.28)

3.04 (NA)

4.18 (1.33)

3.45 (2.04)

2.20 (NA)

2.75 (NA)

6SN

0.00

3.47 (0.03)

3.02 (NA)

3.30 (0.06)

6.94 (0.12)

2.46 (0.15)

2.54 (NA)

Consensus

0.00

3.59 (0.57)

3.23 (0.46)

2.68 (1.84)

5.44 (1.60)

2.60 (0.44)

2.87 (0.50)

3SN*

0.00

3.47 (0.02)

2.58 (0.17)

4.91 (0.06)

5.02 (0.10)

1.97 (0.01)

2.25 (0.00)

1SN

0.00

3.09 (0.40)

1.15 (1.62)

2.74 (0.21)

4.11 (0.26)

2.74 (0.20)

2.52 (0.25)

3SN

0.00

3.02 (0.34)

2.18 (0.47)

2.64 (0.36)

3.71 (0.30)

1.88 (0.05)

1.90 (0.35)

Consensus

0.00

3.06 (0.05)

1.67 (0.73)

2.69 (0.07)

3.91 (0.28)

2.17 (0.42)

2.21 (0.44)

5SN*

0.00

3.82 (0.30)

3.54 (0.20)

3.72 (0.06)

5.45 (0.29)

2.92 (0.17)

3.45 (0.67)

2SN

0.00

0.94 (0.10)

0.80 (0.04)

1.16 (0.09)

9.73 (0.34)

1.13 (0.02)

0.91 (0.01)

3SN

0.00

1.20 (0.09)

0.57 (0.81)

1.38 (0.14)

10.18 (0.45)

1.15 (0.07)

1.13 (0.17)

4SN

0.00

2.81 (0.11)

2.33 (NA)

2.69 (0.20)

6.57 (0.15)

1.84 (0.19)

2.13 (0.03)

Consensus

0.00

1.65 (1.01)

1.23 (0.96)

1.75 (0.83)

8.83 (1.97)

1.37 (0.41)

1.39 (0.65)

1SN*

0.00

3.05 (0.11)

2.48 (NA)

2.78 (0.19)

6.19 (0.04)

1.79 (0.22)

2.09 (0.06)

1SN

0.00

3.11 (0.34)

2.59 (NA)

2.81 (0.11)

6.08 (0.09)

2.33 (0.34)

2.42 (0.13)

4SN

4.39 (0.18)

6.95 (0.19)

3.66 (0.21)

12.37 (0.19)

3.95 (0.06)

2.38 (0.06)

2.94 (0.37)

5SN

1.53 (2.17)

8.08 (0.16)

3.04 (0.03)

16.89 (0.97)

2.65 (0.15)

1.92 (0.01)

2.49 (0.02)

Consensus

1.97 (2.23)

6.05 (2.60)

3.09 (0.54)

10.69 (7.19)

4.23 (1.73)

2.21 (0.25)

2.62 (0.28)

White Widow

WW1

6.12 (0.83)

3.59 (0.33)

3.47 (0.41)

1.60 (2.26)

4.48 (0.52)

2.77 (0.24)

2.94 (0.38)

White Urkle

WE

1.24 (1.75)

3.23 (1.02)

1.44 (0.24)

0.69 (0.97)

1.51 (0.34)

1.19 (0.22)

1.30 (0.34)

Tang. Haze

TANG1

3.26

2.28

1.81

1.89

4.83

1.81

1.55

OG Kush

Durban Poison
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Table 5.9 continued

Blue Dream

Mob Boss

OG Kush

-caryophyllene
(s)

-caryophyllene
(s)

nerolidol-1
(s)

-gurjunene
(s)

nerolidol-2
(s)

guaiol
(s)

-bisabolol
(s)

1SN

16.03 (0.99)

7.08 (0.33)

4.21 (0.30)

4.82 (0.46)

4.87 (0.36)

2.50 (0.09)

4.85 (0.17)

4SN

16.67 (2.07)

7.62 (0.33)

4.10 (NA)

5.18 (0.06)

4.60 (0.32)

3.10 (0.01)

4.45 (0.23)

5SN

19.07 (NA)

6.67 (2.32)

5.84 (NA)

6.39 (1.62)

4.20 (2.78)

4.57 (2.98)

5.01 (NA)

6SN

14.98 (0.75)

6.80 (0.38)

2.50 (1.63)

4.74 (0.02)

5.02 (0.19)

2.68 (0.14)

4.48 (0.68)

Consensus

16.69 (1.73)

7.04 (0.42)

4.16 (1.36)

5.28 (0.76)

4.67 (0.36)

3.21 (0.94)

4.70 (0.28)

3SN*

14.00 (0.18)

5.91 (0.00)

3.46 (0.03)

3.90 (0.07)

5.75 (0.07)

8.73 (0.11)

7.47 (0.01)

1SN

15.01 (0.04)

7.12 (0.08

6.12 (0.03)

6.28 (0.33)

13.35 (0.18)

2.30 (0.23)

8.86 (0.37)

3SN

18.90 (0.05)

8.46 (0.29)

3.94 (3.39)

6.15 (0.32)

12.71 (0.08)

1.83 (0.40)

6.02 (0.25)

Consensus

16.95 (2.75

7.79 (0.95)

5.03 (1.54)

6.21 (0.10)

13.03 (0.45)

2.07 (0.33)

7.35 (1.89)

5SN*

10.01 (0.97)

6.18 (0.08)

1.31 (0.09)

6.00 (0.09)

9.87 (0.68)

3.04 (0.37)

4.33 (0.05)

2SN

15.81 (0.03)

7.83 (0.04)

2.43 (0.12)

10.54 (0.10)

24.10 (0.10)

0.67 (0.07)

0.92 (0.37)

3SN

27.77 (0.09)

10.04 (0.14)

2.86 (2.55)

5.40 (0.09)

10.80 (0.22)

7.49 (0.12)

0.00

4SN

22.63 (0.27)

7.57 (0.09)

0.95 (0.08)

5.04 (0.15)

7.94 (0.16)

6.88 (0.09)

5.54 (0.16)

Consensus

22.07 (6.00)

8.51 (1.32)

2.08 (1.00)

6.99 (3.08)

14.28 (8.62)

5.01 (3.77)

2.15 (2.97)

1SN*

23.13 (1.42)

8.05 (0.39)

1.00 (0.01)

4.95 (0.09)

7.88 (0.65)

7.22 (0.56)

5.54 (0.18)

1SN

13.13 (0.32)

5.63 (0.05)

4.60 (NA)

5.18 (0.03)

10.77 (0.54)

10.44 (0.21)

12.19 (0.38)

4SN

11.53 (0.54)

4.39 (1.43)

5.11 (2.63)

4.73 (0.07)

7.49 (0.62)

5.42 (0.09)

0.00

5SN

9.21 (1.18)

4.26 (0.41)

8.36 (1.56)

3.63 (0.34)

5.84 (1.02)

4.97 (0.47)

1.08 (1.53)

Consensus

11.29 (1.97)

4.76 (0.75)

6.02 (2.04)

4.51 (0.80)

8.04 (2.51)

6.94 (3.03)

4.43 (6.75)

White Widow

WW1

16.84 (NA)

6.64 (2.68)

10.01 (1.66)

4.80 (0.57)

7.03 (1.09)

6.61 (1.12)

0.00

White Urkle

WE

34.12 (0.98)

699 (6.10)

6.29 (0.96)

4.20 (4.20)

4.72 (5.04)

1.26 (0.37)

4.95 (4.07)

Tang. Haze

TANG1

28.31

2.49

5.14

4.35

9.21

6.78

11.43

Durban Poison
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Histograms of 21 terpenes were generated to compare terpene composition among
samples within strains (Figure 5.21). The level of terpenes varied within strains as well as
across the four strains. “Durban Poison” samples were genetically identical, and yet the
terpene levels varied among the samples (Figure 5.21A). Although many terpenes were
similar among the samples, limonene, p-cymene, ocimene, terpinolene, nerolidol-1,
nerolidol-2, guialol and -bisabolol had at least one sample that was markedly different.
In the PCA of terpenes “Durban Poison” showed a wide distribution across Coordinate 1
(Figure 5.23).
Four “Blue Dream” samples were genetically identical (1SN, 4SN, 5SN and 6SN)
and 3SN* was a genetic outlier. Although many of the terpenes had similar levels, pinene, terpinolene, nerolidol-1, guialol, and -bisabolol had at least one sample that was
markedly different (Figure 5.21B). Seventeen of 21 terpene levels in the genetic outlier
fell outside the standard deviation of the genetic consensus (Figure 5.22A). Of the five
highest levels of terpenes pooled within each strain, eight of 12 terpenes in the genetic
outlier fell outside the standard deviation of the genetic consensus average (Figure
5.23A). In the PCA of terpenes “Blue Dream” samples cluster, indicating shared terpene
characteristics (Figure 5.24).
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Figure 5.21. cont. next page
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Figure 5.21. Terpene variation within each accession of four strains (% distribution) for (A) “Durban Poison”, (B) “Blue
Dream”, (C) “Mob Boss”, and (D) “OG Kush”. The genetic outlier is indicated with an asterisk.
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C
Figure 5.22. Twenty-one terpenes (A) “Blue Dream”, (B) “Mob Boss”, and (C) “OG
Kush”, with the average for the genetic consensus samples and the genetic outlier.
Error bars represent the standard deviation.
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Two “Mob Boss” samples were genetically identical (1SN and 3SN) and 5SN*
was a genetic outlier. Although terpenes such as ocimene, terpinolene, isopulegol, and gurjunene had similar levels, almost all terpenes had at least one sample that was
markedly different, and in many cases the sample with the different level was the genetic
outlier 5SN* (Figure 5.21C). Nineteen of 21 terpene levels in the genetic outlier fell
outside the standard deviation of the genetic consensus (Figure 5.22B). Of the five
highest levels of terpenes pooled within each strain, 10 of 12 terpene levels in the genetic
outlier fell outside the standard deviation of the genetic consensus (Figure 5.23B). In the
PCA of terpenes “Mob Boss” samples cluster, indicating shared terpene characteristics
(Figure 5.24).
Three “OG Kush” samples were genetically similar (2SN, 3SN and 4SN) and
1SN* was a genetic outlier. Although terpenes such as isopulegol, and geraniol had
similar levels, almost all terpenes had at least one sample that was markedly different,
although there does not seem to be a sample that is consistently different across terpenes
(Figure 5.21D). However, samples 1SN* and 4SN have highly similar levels in almost
every terpene. This was supported in the average terpene level of the genetic consensus
samples compared to the genetic outlier, where only thirteen of 21 terpenes fell outside
the standard deviation of the genetic consensus (Figure 5.22C). Of the five highest levels
of terpenes pooled within each strain, and only one of 10 terpene levels in the genetic
outlier fell outside the standard deviation of the genetic consensus average (Figure
5.23C). The PCA of “OG Kush” samples do not form a tight cluster, indicating minimal
shared terpene characteristics (Figure 5.24).
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A

Figure 5.23. Top five terpenes with the highest levels pooled for (A) “Blue Dream”,
(B) “Mob Boss”, and (C) “OG Kush”, with the average for the genetic consensus
samples and the genetic outlier. Error bars represent the standard deviation.

Histograms of the average terpene levels for seven strains was generated to
examine terpene variation of different strains to explore the possibility that strains may
have unique terpene composition (Figure 5.24). From this analysis, it is clear that strains
have varying terpene profiles. For example, “White Widow” had no detectable levels of
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-bisabolol and “Durban Poison” has a much higher level of terpinolene than the other
strains.

Figure 5.24. PCA clustering analysis. Genetic outlier labels are underlined.

In order to determine if specific terpenes contribute to variation among strains,
standard deviations across all samples were calculated and terpenes with the highest
deviation were graphed by strain (Figure 5.25). “OG Kush” has relatively high levels of
-caryophyllene and neridiol-2 compared to -pinene, -bisabolol and terpinolene.
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Figure 5.25. Average terpene levels in seven strains (% distribution by terpene). “Blue Dream”, “Mob Boss” and “OG Kush”
averages only include the genetic consensus samples. The molecular structure for each terpene is displayed above the graph.
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Figure 5.26 Terpene profiles for seven strains. These five terpenes had the five highest average % distributions across samples and
are arranged by highest average terpene level. “Blue Dream”, “Mob Boss” and “OG Kush” averages only include the genetic
consensus samples.
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Discussion
Cannabis diversity is reflected in a wide range of phenotypes. Over the last
several decades of prohibition, underground breeders have created new strains with
variable and unique characters that are desirable to consumers. Now that Cannabis is a
growing legal market in the majority of the United States, variation is problematic as
medical and recreational consumers and industry look for consistency in products.
Consumers accept slight variation in plants of the same variety, but there is also an
expected level of consistency when looking for a particular product. A ‘Granny Smith’
apple is not an acceptable substitute for a ‘Honey Crisp’ apple, while there may be some
variability within either type sourced from different producers or regions. Variation in
any plant variety (including Cannabis) can come from several sources, such as growth
conditions (soil, light, temperature, water, air flow, etc.), harvest time (early, mid or late),
storage conditions, and shelf life (time until deterioration), but no matter the
environmental variation affecting the quality of the harvest, the genetic integrity is
maintained. Moreover, cannabinoid concentrations can differ significantly not only at
different times during flower maturation, but also in flowers from different locations
(high or low) on the same plant (Aizpurua-Olaizola et al. 2016; Richins et al. 2018).
Previous work has uncovered genetic variation within Cannabis strains (Chapter II),
which we consider in some cases to be an initial source of variation; if there is genetic
variation within a strain, the potential to grow a consistent product among facilities is
more difficult.
Public interest in Cannabis is increasing, and breeders continue to produce strains
with unique chemical compositions. Interest in medical applications of Cannabis is
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expanding, and clinicians are seeking information on the benefits of particular
phytochemical constituents, or combinations thereof, that contribute to alleviating certain
symptoms of a variety of medical conditions. Evidence suggests Cannabis
phytochemicals work synergistically (Ben-Shabat et al. 1998), and the unique
combination of cannabinoids and terpenes in different strains is a centerpiece of interest
in the industry. Recently, the potential of using a chemical fingerprint to identify specific
strains and provide consistent products to consumers has been suggested (Hazekamp and
Fischedick 2012; Hillig and Mahlberg 2004; Jikomes and Zoorob 2018).
The purpose of this study was to determine if genetic differences are mirrored as
differences in chemical profiles within the same strain. Four strains, three of which
included samples that were genotyped as identical (“Durban Poison”, “Blue Dream” and
“Mob Boss”), and one which had samples differing at only one locus (“OG Kush”), were
analyzed. Three of the strains included a previously determined genetic outlier (“Blue
Dream”, “Mob Boss” and “OG Kush” (Chapter IV). Cannabinoid and terpene levels of
genetic consensus samples were compared to levels in the genetic outlier to determine if
phytochemicals vary (1) among samples that are genetically identical (2) within strains,
and (3) among different strains. Cannabis research has shown some strains have limited
variability and may be distinguishable by chemotype (Hazekamp and Fischedick 2012;
Jikomes and Zoorob 2018). However, data are limited describing chemical composition
and quality within strains resulting from variation in the genotype and/or varying
environmental conditions (Richins et al. 2018).
Cannabinoids produced in the trichomes of the female flower are phytochemicals
that elicit physiological effects and are known to vary in potency due to environmental
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and genetic differences. Our cannabinoid analyses demonstrate that not only is there
variation in levels of phytochemicals, but also in the relative ratios of cannabinoids
(THC, CBD, and CBG) among plants with identical genotypes (Figure 5.9). THCA/THC
varied among samples within the four strains (Figure 5.14), and the levels in the genetic
outlier fell within one standard deviation for “Blue Dream” and “Mob Boss”, but not for
“OG Kush”. Given that THCA is one of the main phenotypic traits breeders are selecting,
it is possible that the minor cannabinoids paint a more accurate picture of how genetic
differences are reflected in chemotype. The minor cannabinoids varied among samples
within the four strains (Figure 5.13). Genetic outliers varied in cannabinoid levels in
“Blue Dream” (CBC) “Mob Boss” (THCV and CBN), and “OG Kush” (CBDA).
Clustering analysis scaled to THCA and CBGA indicated these two cannabinoids are
driving variation in all samples (Figures 5.18 and 5.19).
Terpenes produced in the trichomes of the female flower are phytochemicals that
contribute to aromas and flavors in Cannabis and are known to vary in potency due to
environmental and genetic differences. Our terpene analyses demonstrate there is
variation among plants with identical genotypes (5.21). Terpenes varied among samples
within the four strains (Figure 5.21), and the levels in the genetic outlier fell within one
standard deviation for four of 21 terpenes for “Blue Dream”, two of 21 terpenes for “Mob
Boss”, and eight of 21 terpenes for “OG Kush” (Figure 5.18). Therefore the terpenes
measured in the genetic outlier of “Blue Dream” differed by 80%, “Mob Boss” differed
by 90%, “OG Kush” differed by 61%. Although variation in terpenes is expected due to
differences in cultivation and storage practices, these results suggest that the genetic
outlier is not only genetically different, but also chemotypically different. This analysis
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gives more evidence to mislabeling and also indicate the need for further examination of
genetic differences in strains and how they may be driving variability in chemotypes.
The variation assessment of cannabinoids among strains show THCA, THC, and
CBGA are the largest constituents in the profile with variable levels within strains
(Figure 5.10 and 5.11). In the light of recent work highlighting genetic variation within
strains (Schwabe and McGlaughlin 2018), it is possible that genetic variability would
result in deviations from chemotype expectations. Fischedick et al. (2010) collected
samples of “White Widow” and “Amnesia” from 10 coffee shops in the Netherlands and
found chemical deviants in both strains, which coincidently aligned with the chemotype
of the alternate strain, possibly indicating a mix-up at the coffee shop or the supplier.
However, without examining the genetic identity of the samples, it is unclear if the
chemical deviation from the other samples in the set were due to genetic differences, or
differences in flower maturity, or post-harvest processing and storage. As there are no
standard growing or harvesting protocols, variation in abundance of phytochemicals is
expected among facilities. Previous work has shown chemical composition and
THCTOTAL can be highly variable within strains and has suggested that strain names are
an unreliable indicator of potency, and therefore strain names should be eliminated and
Cannabis types should be based on chemotype (Hazekamp and Fischedick 2012; Elzinga
et. al 2015). However, strain names are not potency specific, but rather a name given to a
cultivar with a unique profile of hundreds of compounds. Although, accurate reporting of
a wider scope of phytochemicals in products would be beneficial, the unique cultivars
and varieties should have names as they allow consumers and growers to communicate
and identify characteristics associated with a certain cultivar. Consistency in cultivars is
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achievable through genotyping, stabilizing genetic lines, and standardizing protocols in
the Cannabis industry. Without standard conditions, and a confirmed genotype, variation
is not only expected but will continue to proliferate.
Chemotypes of “Blue Dream” and “OG Kush” were previously analyzed in a
large study which included 35 strains with > seven samples in each (N = 494) (Elzinga et
al. 2015). It was found that most replicates within strains did not cluster and showed
highly variable chemotypes, but some strains, including “Blue Dream”, formed clear
clusters indicating a distinct chemical profile. In the current study, we also found that
“Blue Dream” forms a distinct cluster, even with the genetic outlier (Figures 5.19 and
5.24). Fischedick et al. (2010) found that Cannabis clones of several strains could be
distinguished from one another based on their cannabinoid and terpene content. Cannabis
varieties are generally divided into three chemotype groups based on THC:CBD ratios
(Hazekamp and Fischedick 2012; Hillig and Mahlberg 2004; Jikomes and Zoorob 2018).
Most drug-type, and all the strains included in this study, are included in the chemotype I
group, which is categorized as high THC and low CBD (Jikomes and Zoorob 2018).
Given that there has been a relationship found between THC/CBD in different
chemotypes, we thought perhaps there might also be a relationship between CBGA and
THCA. Linear regression on the samples here indicate there is a weak relationship (R2 =
0.174) between CBGA and THCA (Figure 5.20), but because there is so much variation,
more sampling is needed to examine this further. Elzinga et al. (2015) proposed that
strains with distinct chemical profiles might be more easily identified by their smell due
to relatively high concentrations of specific terpenes. However, our analysis indicates
“Blue Dream” does not have relatively high levels of any specific measured terpenes. The
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highest terpene found in “Blue Dream” samples was -caryophyllene, but levels were
much higher in “OG Kush”, “White Urkle” and “Tangerine Haze” (Figure 5.25 & 5.26).
The most abundant terpene in the seven strains we examined was -caryophyllene,
(Figure 5.25) although other terpene studies have found myrcene to be the most abundant
terpene in Cannabis (Casano et al. 2011). It is not clear why there would be such a clear
descrepancy between these two studies. Strain names were not provided in the Casano et
al. (2011) study, but they categorized their samples as ‘mostly indica’ or ‘mostly sativa’,
and the ‘mostly sativa’ had much lower levels of myrcene than the ‘mostly indica’
samples. All of the strains in our data set are Hybrid types with the exception of “Durban
Poison”, which is a Sativa type strain.
Since this was an investigation of sources of variation within Cannabis, we
thought it would be interesting to compare THC levels reported on the dispensary
packaging to the total THC equivalent levels measured at Mile High Labs. Jikomes and
Zoorob (2018) analyzed Washington state’s seed-to-sale tracabililty data set and found
principle cannabinoid variation among state-certified testing laboratories. The 15 samples
we used for this study had striking discrepancies in the reported levels of major
cannabinoids (THCA and THC) between dispensary packaging labels and levels
measured by Mile High Labs (Table 5.10). Every sample tested had lower THCTOTAL
content than was reported on packaging labels, with reported levels of THCTOTAL by
dispensaries being 23.5% – 61.48%. higher than what was measure at Mile High Labs.
This discrepancy could be the result of several variables such as lab testing protocols,
storage conditions, or age, but there is not enough information provided by distributors to
determine the source of the discrepancy. However, this should be considered a major
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issue in the industry, since the high potency strains that have been receiving attention in
that last few years may not actually have the THC levels reported by the testing lab and
claimed on the packaging. For example, “Mob Boss” 5SN had one of the highest reported
THC levels (25.2 – 28.9 %), but tested at 10.42% at Mile High Labs, an average
difference of 61.48%. The highest total THC equivalent measured at Mile High Labs was
“OG Kush” 2SN, and although the packaging report was over-represented, this sample
had the least discrepancy of only 23.5% more total THC equivalent than was determined
by Mile High Labs.
Table 5.10. THCTOTAL determined by mile high labs compared to THC reported
on retail packaging. Fifteen samples from four strains with the THCTOTAL (total % dry
weight) measured by Mile High Labs (MHL). The THC levels reported by the
dispensary, the discrepancy difference in average reported THC and the THC (total)
measured by MHL, and the % of THC that was over-reported by the dispensary label
vs. what MHL measured.
Strain

Sample ID

MHL
THC
(TOTAL)

Reported
Range

Reported
Average

THC
Discrepancy

% THC
overreporte
d

Durban Poison

DuPo 1SN

11.58

NA

17.40

5.82

33.45

DuPo 4SN

10.81

NA

20.14

9.33

46.33

DuPo 5SN

15.63

NA

21.50

5.87

27.30

BlDr 1SN

12.80

NA

17.33

4.53

26.14

BlDr 3SN

13.37

NA

17.87

4.50

25.18

BlDr 4SN

7.970

14.41-25.18

19.80

11.82

59.74

BlDr 5SN

11.35

NA

16.64

5.29

31.79

BlDr 6SN

15.26

NA

NA

NA

NA

MoBo1SN

10.66

19.00-31.00

25.00*

14.34

57.36

MoBo 3SN

13.47

22.12-24.87

23.50*

10.02

42.67

MoBo 5SN

10.42

25.20-28.90

27.05*

16.63

61.48

OGKu 1SN

11.23

15.20-26.14

20.67*

9.44

45.67

OGKu 2SN

22.70

28.07-31.28

29.68*

6.98

23.50

OGKu 3SN

18.06

NA

24.10

6.04

25.06

13.60

NA

25.93

12.33

47.55

Blue Dream

Mob Boss

OG Kush

OGKu 4SN




Asterisk indicates samples identified as the same grow facility and batch
*Average calculated based on the THC% range reported on the packaging

192
Although these results show variation among genetically identical samples,
challenges and limitations need to be addressed. The samples were purchased three
months prior to chemotype testing and had been moved in and out of -2 C storage during
the sensory study (Chapter IV). During this process, care was taken to limit the
degradation of phytochemicals by storing at low temperatures (-2 C) in amber glass jars
with screw-top lids. Moreover, CBN, the degradation product of THCA, was not present
in levels indicative of incorrect storage. It is possible, however, that phytochemical levels
were affected. There may also be differences in lab testing protocols. Although there are
standard protocols for testing in Colorado, labs are not restricted to either HPLC or GC,
and it is possible these two tests may produce different results. Dispensaries and
consumers often choose products with higher THC content, and for this reason, some labs
may have protocols maximizing THC measures. Mile High Labs is traditionally a facility
that caters to the Hemp industry and therefore not looking to maximize the measurement
of THCA. Mile High Labs has a duty to accurately measure THCA and CBDA content
following the same protocols as the DEA and USDA, as Hemp is defined by THCTOTAL <
0.3%, and crops that measure over that threshold are destroyed. However, because Mile
High Labs is a Hemp testing facility, the protocol may not be calibrated to measure high
amounts of THC, which we recognize as a limitation and therefore further investigation
of the discrepancy is needed.
This study demonstrated significant variation in cannabinoids and terpenes even
when samples are genetically identical, which could be annoying for recreational
consumers expecting certain effects but is more problematic for those consuming to
alleviate medical symptoms. This study included a relatively small sampling of Cannabis
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strains, but nevertheless demonstrated genotype is not necessarily reflected as a
predictable chemotype. In order to determine what is a reasonable amount of variation in
chemotypes, more in-depth studies examining other environmental factors known to
influence cannabinoid and terpene production such as growing conditions, harvest time,
curing procedure and storage conditions, are needed.
Conclusion
The purpose of this study was to determine if genetic differences are mirrored as
differences in chemical profiles of cannabinoids and terpenes within the same Cannabis
strain. Based on these results, cannabinoids and terpene levels vary (1) among samples
that are genetically identical, (2) within strains, and (3) among strains. The samples used
in this study had variable chemotypes, but the variation did not seem to be linked to
genetic identity. Given that chemotype is a phenotypic expression, and phenotype is the
result of genotype and environment, the variation observed in cannabinoids and terpenes
are most certainly the result of a combination of several variables. The Cannabis industry
should aim to produce consistent products, especially for medicinal patients. There have
been suggestions that focusing on chemotyping rather than using strain names for
consistency would be a viable option. Minimizing phenotypic variation, including
chemotype, would require standard growing conditions, harvesting protocols, curing
techniques and storage conditions. However, the Cannabis industry currently has no such
accepted standards for growing facilities and/or dispensaries, and therefore
phytochemical variation within strains is inevitable, even if plants are genetically
identical. Chemotyping for identity would be relatively easy if it were able to accurately
identify and distinguish strains from one another. These results suggest that this is not the
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case. Before chemotyping for identity can be utilized, it is crucial that industry standards
are set and adhered to by every grower and producer. Until that happens, the only way to
accurately identify Cannabis strains is through genotyping.
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CHAPTER VI
CONCLUSION
Conclusion
Cannabis sativa is a highly versatile plant with variable phenotypes in fiber
production, flower production, and phytochemical production (Clarke and Merlin 2013,
2016; Small 2015a; Small 2016). Artificial selection for desirable phenotypic characters
throughout the history of the human relationship with Cannabis has led to genetic
divergence between hemp and drug-types (Dufresnes et al. 2017; Henry 2015; Houston et
al. 2017; Lynch et al. 2016; Sawler et al. 2015; Soler et al. 2017). Cannabis has largely
been prohibited in the U.S. since the 1930’s, but recent legalization in many states
following growing public acceptance has led to a wave of new legislation allowing
medical and adult recreational marijuana as well as hemp production. The Cannabis
industry is growing at an unprecedented rate, but due to a tumultuous history, basic
scientific knowledge and research on the plant is lacking. Not only that, but protections
afforded to other plant varietals are not applicable to Cannabis and therefore stable
genetic lines are relatively rare. Without taking the time and resources to stabilize the
genetics through inbreeding, cloning is the preferred method for many growers to
reproduce plants with desirable phenotypes. However, variation among plants that should
be essentially identical has been identified as a problem (Chapter 2; Schwabe and
McGlaughlin 2018) for the industry as they seek to provide customers with the quality
and consistency they deserve. Variation within strains is of particular concern as
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practitioners worldwide turn to Cannabis to treat a growing number of medical
conditions.
The genetic, olfactory, and phytochemical research presented in this dissertation
provides considerable evidence of both genotypic and phenotypic variation in Cannabis
sativa (Chapters II-V). This investigation found variation is not limited to one source, but
rather several possible sources. Potential origins for the genetic variation observed are
numerous, but within strain variation was greater than expected (Chapter II), which is of
particular concern for medical marijuana patients. Additionally, genotypic variation was
not necessarily reflected in phenotypic variation, and genotypic cohesiveness among
samples did not result in a consistent phenotype (Chapters IV and V). Although these
studies were conducted using relatively small sample sizes, the results clearly
demonstrate the need for regulatory systems.
Cannabis can be subdivided into two main categories: Hemp (<0.3% THC) and
drug-types (>0.3% THC). The drug-type categories are further sub-divided into the
commonly referenced Sativa, Indica, and Hybrid types, as well as the High CBD type
which has lower THC levels but has >0.3% THC and is therefore assigned to the drugtype category. The commonly referenced Sativa, Indica and Hybrid types used to
describe differences in psychoactive effects were not clearly resolved using genetic
analysis (Chapter II and III), and this is probably due to extensive hybridizing of strains
to create novel combinations with characteristics of both Sativa and Indica types. The
genetic investigation had representative samples ranging from 100% Sativa to 100%
Indica (Chapter II and III). However, the phytochemical portion of the study only
included hybrids (“Blue Dream” 50:50, “Mob Boss” 50:50, “OG Kush” 55:45, “White
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Widow” 60:40, “Tangerine Haze” 60:40, and “White Urkle” 50:50) and “Durban
Poison”, which is 100% Sativa. Therefore, investigating category assignment based on
scent profile or phytochemical content was not possible in this study (Chapter IV and V).
Hemp is genetically divergent from drug-types, although there are some drug-types that
share a high degree of ancestry with Hemp types (Chapter III). The High CBD samples
bridge the genetic division between Hemp and drug-types (Chapter III). One of the most
important discoveries was that “research grade marijuana” supplied for medical studies in
the U.S. is substantially different from drug-type samples purchased through the legal
market (Chapter III). This has serious implications because medical studies researching
medical applications using federally supplied marijuana are inherently flawed as medical
patients do not have access to and are not consuming similar products.
Cannabis phytochemicals are abundant and 120 terpenes to date have been
identified (ElSohly et al. 2017) which contribute to the diverse aromas found in
Cannabis. The discovery of genetic inconsistencies within strains led us to investigate if
genetic differences were expressed through detectable aromatic differences (Chapter IV).
We purposefully chose four strains based on availability and previously determined
unique aromatic profiles (Gilbert and DiVerdi 2018). There was considerable variation in
the aromatic profiles within samples of the same strain and with identical genotypes but
purchased from different locations (Chapter IV). However, analyses revealed the
aromatic profile of the genetic outliers not only differed substantially from those with the
same genotype, but also the aromatic profile of the outliers were uncharacteristic of
previously described profiles (Gilbert and DiVerdi 2018; Leafly 2018b). Detectable
differences in aromatic profiles of a genetic imposter suggest that genetic inconsistencies

198
observed within strains may not be simply a case of mistaken identity, but perhaps an
indication of mislabeling or relabeling.
In addition to terpenes, Cannabis also has 120 known cannabinoids (ElSohly et al.
2017) which are responsible for physiological and psychoactive effects (Andre et al.
2016). Laws on potency testing for several cannabinoids vary from state to state, but
THCA/THC and CBDA/CBD are a standard requirement (e.g.: Colorado Department of
Revenue 2017). In order to further examine the relationship between genetic variation
and chemotype, we analyzed eight cannabinoids and found variation in levels of
phytochemicals, as well as the relative ratios of cannabinoids among plants with identical
genotypes (Chapter V). Also, it appears that two cannabinoids, THCA and CBGA are the
contributing to the majority of the variation (Chapter V). Variation in cannabinoids did
not appear to align with genetic variation (or lack of variation). These results indicate that
cannabinoid levels are likely substantially influenced by environmental conditions that
vary among different growing facilities.
Sensory perception of the various aromas found in Cannabis is attributed to levels
and combinations of terpenes produced in the flower trichomes. Olfaction and
perceptions of smell are personal and subjective, and the subjects who participated in this
research were not sensory experts. However, additional scientific examination was
possible by analyzing the terpene profiles of the samples in the olfactory study. A
pairwise analysis between sensory perception and terpene levels found 33 significant
correlations (Table 6.1). This analysis shows perceived scents produced by the terpenes
can be categorized: a-caryophyllene and b-caryophyllene are contributing to “Earthy”
smells including soil, buttery, nutty or roasted aromas; guaiol and isopulegol contribute to
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the “Spicy” including spices and dried leafy scents; neridiol-1, ocimene, p-cymene and
terpinolene contribute to “Floral” scents such as fresh plants/flowers; neridiol-2 is the
main contributor to “Pungent” scents including diesel, ammonia and chemical smells.
Table 6.1. Significant pairwise Pearson correlation coefficients (R2) between
terpene levels (Chapter V) and scents detected in the olfactory study (Chapter
IV).
Smell
Terpene
R2
P
Butter
a-caryophyllene
0.648
0.0226
Cheese
a-caryophyllene
0.632
0.0274
Coffee
a-caryophyllene
0.623
0.0304
Earthy
a-caryophyllene
0.623
0.0304
Menthol
a-gurjunene
0.584
0.0461
Butter
b-caryophyllene
0.741
0.0059
Coffee
b-caryophyllene
0.638
0.0257
Nutty
b-caryophyllene
0.583
0.0468
Sage
guaiol
0.740
0.0059
Pepper
isopulegol
0.582
0.0472
Menthol
limonene
0.584
0.0460
Coffee
linalool
0.794
0.0021
Butter
myrcene
0.673
0.0165
Flowery
nerolidol-1
0.632
0.0304
Mint
nerolidol-1
0.678
0.0154
Rose
nerolidol-1
0.721
0.0082
Sweet
nerolidol-1
0.607
0.0363
Violet
nerolidol-1
0.735
0.0065
Ammonia
nerolidol-2
0.694
0.0123
Chemical
nerolidol-2
0.640
0.0250
Diesel
nerolidol-2
0.620
0.0316
Pungent
nerolidol-2
0.602
0.0385
Flowery
ocimene
0.617
0.0326
Mint
ocimene
0.925
< 0.0001
Flowery
p-cymene
0.732
0.0068
Lemon
p-cymene
0.629
0.0285
Mint
p-cymene
0.848
0.0005
Tropical fruit
p-cymene
0.600
0.0392
Flowery
terpinolene
0.753
0.0047
Mint
terpinolene
0.821
0.0011
Rose
terpinolene
0.721
0.0082
Tropical fruit
terpinolene
0.641
0.0247
Violet
terpinolene
0.605
0.0373
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The abundance of phytochemicals present in Cannabis is impressive and are one
of the main drivers of the artificial selection process for desirable aromas and
physiological effects. There is an expected amount of variation among organisms of the
same genetic lineage, as phenotypic variation is the product of genotype and
environment. Therefore, individuals with identical genotypes are expected to have highly
similar phenotypes. However, the extent to which environmental variation impacts
phenotype is largely unknown. Analyses of both terpene and cannabinoid profiles among
individuals with identical genotypes acquired from different sources indicate
environmental variation has a substantial impact on phenotype in Cannabis. Considering
these results, medical marijuana patients are unlikely to have access to consistent
products, even if the genotype has been verified. Not only are potency levels variable, but
variation in phytochemical constituents detected in the samples is evident.
The Cannabis industry needs a system to verify products to ensure consumers are
provided the product as indicated by the name provided. There have been suggestions
that due to strain name unreliability, describing products based on chemotype may be a
solution. However, I would caution against this approach as there are 560 chemical
constituents in Cannabis and analytical labs only test a small portion of cannabinoids and
terpenes, ignoring the vast majority of the micro-chemotype which likely contribute to
differences in aromatic profiles and effects (Amirault and Boyar 2019). Additionally, the
variation in samples with identical genotypes indicates varying environmental conditions
are influencing chemical profiles. Cannabis consumers, practitioners, breeders, and
growers need to be able to communicate about varietals, and the most familiar method to
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do this is to give varietals a name. It would be counter intuitive and incredibly difficult to
discuss Cannabis flowers based on a partial chemotype that changes over time.
Future Directions
The Cannabis industry exists to produce products for a variety of markets. The
industrial hemp industry grows crops for fiber, oils, and seeds which can be transformed
into thousands of products. Because many industrial hemp products are produced from
processed plant material, consistency among plants is not imperative. The marijuana
Cannabis industry grows plants for human consumption, some of which are processed,
such as isolates, tinctures and edibles. However, there is a large proportion of products on
dispensary shelves that are sold under specific names and are non-processed flowers.
These products are intended to be smoked and will have some effect on the consumer.
Recreational adult use is associated with the psychotropic responses to partaking in
smoking marijuana. Medicinal use may include psychotropic responses, but more
importantly, the medical consumer is seeking to alleviate symptoms related to particular
medical conditions. Medicine needs to be reliable and consistent, and current Cannabis
products sampled in this study are not reliable or consistent. Producers strive to produce a
consistent phenotype through cloning, but it is apparent that environmental influences
have a large effect. A standard genotyping procedure is needed to confirm identity in
addition to the chemotype tests currently in place that determine potency. Also, a set of
standard growing conditions needs to be established, as well as standard harvesting and
curing procedures.
Studies have shown that environmental stresses can lead to phenotypic changes in
plants. I am unaware of any published work investigating how environmental stress
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effects the epigenome and the phenotypic consequences of those changes in clonal plants.
It is possible that the stress of the cloning process, on both the plant from which clones
are cut as well as the resulting progeny, will result in phenotypic changes due to
epigenetic changes. This is certainly a possible source for variation in Cannabis and
warrants investigation. Additionally, a system to protect intellectual property of breeders
who develop genetically stable lines (varietals) would limit variation from cloning and
allow desirable lineages to persist into the future.
The results of these studies suggest the industry should implement regulatory
checks in the form of genetic testing in order to provide consistency, especially for
medical applications. Current required testing includes pesticide and potency analysis and
reporting, and genetic tests could be implemented to verify products. In order to provide
consumers consistent products, it is imperative to understand sources of variation.
Phenotypic variation is unavoidable when genotype has not been verified. Following
genotypic confirmation, it is possible to create phenotypic consistency if standard
growing conditions can be established. This would not stifle the ability for growers to
develop alternative conditions to produce different desirable characters such as larger
flowers or higher terpene content, but it would allow for the production of consistent
products if standard conditions are met. Following verification and established standards
in protocols, deviations resulting in phenotypic changes should be disclosed to consumers
so they are aware that there may be deviations from expected effects. Consumers deserve
to be provided with quality consistent products as the industry continues to thrive on a
global scale.
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